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Abstract 
Bone healing following trauma is known to be associated with an early increase in serum 
concentrations of several pro-inflammatory and angiogenic growth factors. However, the temporal 
pattern of growth factors (GFs) involved in bone formation and their relationship with trauma 
severity has not been explored. Furthermore, to what extent osteogenic progenitors, including 
mesenchymal stem cells (MSCs) are ‘mobilized’ following trauma is unknown.  
This study investigated the systemic levels of four GFs (PDGF-AA, TGF-β2, follistatin and angiogenin) 
over the first two weeks following trauma in three groups of patients with increasing severity 
(Isolated trauma (n=15), Polytrauma (n=15), and  Head injury (n=14)) and compared to Healthy 
Controls (n=9). The dynamics of GF release measured by ELISA was correlated with clinical and 
biochemical inflammatory parameters and the healing outcome assessed by clinical and radiological 
parameters as well as requirement of surgical re-interventions. Potential MSC mobilization from 
their iliac crest bone marrow (ICBMA) niches into peripheral circulation was measured by standard 
colony-forming assay-fibroblast, at least twice following trauma. Further correlations were sought 
with circulating levels of platelets, PDFG-BB and PDGF-AA. 
Growth factors described as anabolic for bone (PDGF-AA and angiogenin) had an initial suppression 
following trauma (50% and 80% by day 1, respectively), whereas inhibitory GF follistatin was 
upregulated compared to control (1.5-fold by day 1). This effect was more pronounced with 
increasing trauma severity. The variability of TGF-β2 was too high to allow differences between 
trauma groups to be detected. The dynamics of all GFs were not correlated with the inflammatory 
state of the patients, assessed both clinically (Systemic Inflammatory Response Syndrome score) and 
biochemically (total white cell count, C-reactive protein and platelet levels). However, there was a 
significant correlation between levels of time-matched PDGF-AA and platelets (p<0.01, r=+0.61), 
independent of trauma severity. A marked suppression of TGF-β2 throughout the time course which 
reached statistical significance in the first week following trauma (5-fold, p<0.05) was observed in 
patients identified as ‘poor healers’; the same group additionally displayed an altered dynamics of 
follistatin release compared to patients who healed normally. 
The numbers of ICBMA MSCs were dynamic over time in the same patient, but did not correlate with 
trauma severity or patients’ inflammatory state. Instead, significant correlations were observed 
between the changes in ICBMA MSC numbers and changes the levels of PDGF-AA (p<0.01, r=+0.55), 
and PDGF-BB (p=0.03, r=+0.38) and circulating platelets (p=0.02, r=+0.44). No MSCs were found in 
patients’ peripheral blood at any time point studied. 
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These data indicated that measuring GFs implicated in BMP signalling pathway may lead to the 
discovery of novel biomarkers of fracture non union. Measuring patient’s inflammatory response 
following fracture did not correlate with the release of growth factors studied suggesting that these 
phenomena were independent. Limited MSC mobilization in the bone marrow (but not into PB) did 
take place but appeared to be related to platelet counts and a possible release of PDGF-AA and 
PDGF-BB GFs, which are known to be mitogenic for MSCs. It was not linked to trauma severity or 
predictive of the healing outcome. Further research is needed to investigate the predictive value of 
TGF-β2 and follistatin in a larger cohort of patients. Whilst this is the first study showing a ‘dynamic’ 
nature of the MSC pool in human BM, further work should determine whether the influence of 
platelets is due to enhanced MSC migration or their proliferation in situ. 
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1. General Introduction 
1.1. Fracture healing 
Fracture healing represents a physiological process regulated by a variety of mediators and cells. It 
was initially described as consisting of three stages: an initial inflammatory response followed by the 
development of osteogenic repair tissue and finally bone remodelling (McKibbin 1978). This 
progression of events is dependent on factors such as mechanical stability/rigidity and the local 
biological cell environment.  However, currently the fracture healing process is understood to 
comprise 2 modes of healing; direct (no callus formation) and indirect or secondary (callus 
formation, with or without formation of cartilage first) (Einhorn 1998), as represented in Figure 
1.1-1.The mechanism of fracture repair in vivo is reasonably well understood. This involves 
coordinated action of the inflammatory response and mesenchymal stem cells (MSCs) that lead to 
an ordered sequence of events including inflammatory removal of debris from the fracture site, 
angiogenesis and subsequently bone re-modelling leading to repair with various cytokines being 
involved at different stages (Dimitriou, Tsiridis et al. 2005). 
 
 
Figure 1.1-1 Schematic representation of Direct and Indirect (Secondary) Bone Healing. (From (McKinley 2003) 
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1.1.1. Direct bone healing 
The process of direct or primary bone healing can only occur in the presence of absolute fracture 
stability (by rigid internal fixation), with fracture defects of less than 0.01mm (Shapiro 1988) and 
interfragmentary strain less 2% (Mann and Payne 1989). 
This process is initiated by osteoclast bone resorbing cells, which creates tunnels (cutting cones) 
(McKibbin 1978) across fracture sites. The resultant pathways allow for neo-vascularisation, 
accompanied by endothelial cells, and perivascular MSCs, which eventually differentiate to 
osteoblasts (Kaderly 1991). These cutting cones advance across the fracture site at a rate of 50-
100µm/day (Marsell and Einhorn 2011). This process concurrently generates new bone and re-
establishes the Haversian system. These bridging bony tissues directly remodel into lamellar bone; 
allowing for fracture healing without callus formation (Marsell and Einhorn 2011). 
 
1.1.2. Indirect (secondary) bone healing 
Most fractures however, heal by the indirect process, consisting of endochondral and 
intramembranous bone healing components (Gerstenfeld, Alkhiary et al. 2006). Endochondral 
healing occurs outside the periosteum but within proximity of the fracture site (forming soft callus), 
whereas intramembranous healing occurs within the periosteum (forming hard callus) (Gerstenfeld, 
Alkhiary et al. 2006). This secondary bone healing undergoes the classically described overlapping 
stages of an initial inflammatory phase, followed by repair and finally bone remodelling(McKibbin 
1978). 
Following fracture, a haematoma clot forms on the fracture site. This clot not only functions to limit 
the amount of blood loss (bleeding), but is a rich source of growth factors and cytokines which 
function to initiate the cascades of cellular processes involved in fracture healing. Degranulating 
platelets within the clot release among others, platelet derived growth factors and transforming 
growth factor-1, both of which are pro-osteogenic growth factors (Lieberman, Daluiski et al. 2002).   
The accompanying acute inflammatory process, also results in the release of cytokines such as 
tumour necrosis factor-α (TNF-α), interleukin-1 (IL-1), IL-6, IL-11 and IL-18 (Gerstenfeld, Cullinane et 
al. 2003). These cytokines are produced at the local fracture site by the invading macrophages, 
polymorphonuclear leucocytes and lymphocytes, and incite further downstream response through 
the recruitment of more inflammatory cells, stimulating vascularisation and extracellular matrix 
formation (Kon, Cho et al. 2001). Recruited macrophages aid in the resorption and removal of 
necrotic bone and help the creation of callus. Additionally, TNF-α acts as a chemotactic agent to 
recruit cells and is involved in the induction of osteogenic differentiation of MSCs (Cho, Kyoung et al. 
Page 3 
 
2006).  Among the interleukins, it is believed that IL-1 and IL-6 exert the most influence in the 
fracture healing process (Kon, Cho et al. 2001). IL-1, which is secreted by macrophages, induces IL-6 
production by osteoblasts, initiates the cartilaginous soft callus production and fracture site 
angiogenesis (Kon, Cho et al. 2001). On the other hand, IL-6 stimulates angiogenesis via the 
production of vascular endothelial growth factor as well as the differentiation of cells of osteoblastic 
and osteclastic lineages (Yang, Ricciardi et al. 2007).  Overall the inflammatory phase occurs 
immediately upon fracture, lasting for up to a week, and leading on to the repair phase. 
The fracture healing repair phase involves the formation of a cartilaginous tissue within the fracture 
haematoma, external to the periosteum (Marsell and Einhorn 2011).  At the same time, a more 
direct bony tissue formation occurs through the process of intramembranous ossification, internal to 
the periosteum (Marsell and Einhorn 2011). These processes occur via recruitment of MSCs from 
adjacent soft tissues, periosteum, cortical bone and bone marrow. Key roles are played by 
transforming growth factor-beta 2 and 3, growth differentiation factor 5 in the differentiation into 
chondrocytes and subsequent process of endochondral ossification of the soft callus (Cho, 
Gerstenfeld et al. 2002). Similarly, bone morphogenic proteins 5 and 6 have been suggested to be 
involved in cellular proliferation of the intramembranous ossification process (Cho, Gerstenfeld et al. 
2002). 
The chondrocytes within the cartilaginous soft tissue progressively become hypertrophied, and 
begin forming matrix vesicles which migrate to the surrounding matrix and participate in its 
calcification (Einhorn 2005). Following this process, this calcified cartilage tissue itself becomes 
replaced with woven bone. The chondrocytes replacement occurs via an ordered process of 
programmed cellular death (apoptosis) (Lee, Choi et al. 1998), prior to removal by multinucleated 
cells called chondroclasts. The degradation of the chondrocytes and surrounding calcified matrix 
enables neo-vascularisation of the callus tissue with concomitant invasion by perivascular MSCs 
which ultimately differentiate into bone forming osteoblasts (Einhorn 2005). This process occurs 
between 4 and 6 weeks following fracture. 
The final process of remodelling involves the co-ordination of hard callus removal by osteoclasts 
(mediated by IL-1 and TNF-α (Ai-Aql, Alagl et al. 2008)) and lamellar bone formation by osteoblasts 
(mediated by molecules from the bone morphogenic protein families (Marsell and Einhorn 2009)). 
This process may take years to be completed. 
Most of the knowledge described above was based on data derived from experiments on animal 
models, and extrapolated to human. Replication of the animal model studies in humans by serial 
sampling of tissues from fracture sites would be unethical and unlikely to obtain regulatory approval. 
Additionally, the effect of different types of fracture location, severity and concomitant injuries on 
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the fracture healing process has yet to be fully explored. Hence, a method of understanding the 
dynamics of fracture healing in human would be serial measurements over time of levels of growth 
factors known to participate in the fracture healing process. 
 
1.2. Growth Factors and Fracture Healing 
Various signalling molecules are involved in the process of bone healing. Broadly, they are divided 
into pro-inflammatory cytokines [(as Interleukin-1β (IL-1β), IL-6, IL-8, IL-12, tumour necrosis factor 
(TNF) and interferon gamma (IFN-γ)], growth and differentiation factors [(transforming growth 
factor-β (TGF-β), platelet-derived growth factor (PDGF), bone morphogenic proteins (BMPs), 
fibroblast growth factors (FGFs), insulin-like growth factors (IGFs)], matrix metalloproteinases (MMP-
9, MMP-14) and angiogenic factors [(vascular endothelial growth factor (VEGF), angiopoietin)]. In 
addition there are also inhibitory molecules (noggin, follistatin, chordin, BAMBI, Smad) which are 
believed to play an essential role in regulating the signalling molecules. Each factor exerts its 
influence at different time points between day 0 and 21 following fracture (Dimitriou, Tsiridis et al. 
2005). Table 1.2-1 illustrates the stages of fracture healing discussed earlier (Section 1.1) and the 
associated expression of signalling molecules.  
 
Table 1.2-1 Stages of Fracture healing and expression of signalling molecules (Adapted from (Ai-Aql, Alagl et al. 2008), 
(Dimitriou, Tsiridis et al. 2005) and (Phillips 2005))  
Stage of Fracture 
Repair 
Biological Processes 
Expression of Signaling Molecules and their 
Proposed Functions 
Inflammation (First 
hours to day 7)  
Hematoma 
IL-1, IL-6, and TNF-α play a role in initiating 
the repair cascade. 
 Inflammation 
TGF-β, PDGF, and BMP-2 expression increases 
to initiate callus formation. 
 Recruitment of MSCs 
GDF-8 is restricted to day 1, suggesting its role 
in controlling cellular proliferation. 
Cartilage Formation 
and Periosteal 
Chondrogenesis and 
endochondral 
TGF-β2, -β3, and GDF-5 peak due to their 
involvement in chondrogenesis and 
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Response (Days 6-10) ossification begins endochondral bone formation. 
 
Cell proliferation in 
intramembranous 
ossification 
BMP-5 and BMP-6 rise 
 
Vascular in-growth/Neo-
angiogenesis 
Angiopoietins and VEGFs are induced to 
stimulate vascular in growth from vessels in 
the periosteum. 
   
Cartilage Resorption 
and Primary Bone 
Formation (Days 11-20) 
Phase of most active 
osteogenesis 
TNF-α rises in association with mineralized 
cartilage resorption. This promotes the 
recruitment of MSCs and induces apoptosis of 
hypertrophic chondrocytes. 
 
Bone cell recruitment 
and woven bone 
formation 
RANKL and M-CSF rise in association with 
mineralized cartilage resorption. 
 
Chondrocyte apoptosis 
and matrix proteolysis 
 
 
Osteoclast recruitment 
and cartilage resorption 
BMP-3, -4, -7, and -8 rises in association with 
the resorption of calcified cartilage. They 
promote recruitment of cells of the 
osteoblastic lineage. 
 Neo-angiogenesis 
BMP-5 and -6 remain high during this stage, 
suggesting a regulatory effect on both 
intramembranous and endochondral 
ossification. 
  
VEGFs are up-regulated to stimulate neo-
angiogenesis. 
Secondary Bone 
Formation and 
Remodeling (Day 21 
onwards) 
Bone remodeling 
coupled with osteoblast 
activity 
IL-1 and IL-6 rise again in association with 
bone remodeling, whereas RANKL and M-CSF 
display diminished levels. 
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As can be seen in the summary table above (Table 1.2-1), growth factors such as PDGF and TGF-β, 
together with pro-angiogenic factors predominate in the first 10 days following fracture. Molecules 
from the BMP families would become the prevailing growth factors at a later stage (2nd to 3rd week 
onwards). Were the BMP molecules initially suppressed by the presence of inhibitory molecules (to 
BMPs) such as noggin and follistatin? The effect of additional fractures and other injuries (such as 
traumatic brain injury) to the early dynamics (first 2 weeks) of these molecules remain obscure. 
 
1.3. Cellular component of Fracture Healing 
MSCs are multipotent cells capable of differentiating and giving rise to diverse cells such as 
osteoblasts, chrondrocytes, and adipocytes (Bianco, Cao et al. 2013). As discussed previously, MSCs 
contribute a significant role in this process through their osteogenic differentiation capacities, 
supported by a plethora of other cellular phenotypes throughout the different stages of fracture 
healing. Further details regarding MSCs will be discussed in Chapter 6.  Table 1.3-1 summarises the 
roles played by the key cellular phenotypes found within the fracture site. 
 
Table 1.3-1 Cellular phenotypes involved in the fracture healing process 
Cellular phenotypes Roles 
Mesenchymal stem 
cell 
Differentiates into: 
 
Chondrocytes: Formation of cartilaginous soft callus as part of the 
endochondral fracture healing process 
 
Osteoblasts: Bone forming cells 
Neutrophils Dominant leucocytes at fracture site within first 24 hours of fracture (Chung, 
Cool et al. 2006). Secrete several macrophage chemoattractants, such as 
MCP-1, also known as CCL2, and IL-6 (Kasama, Strieter et al. 1993; Hurst, 
Wilkinson et al. 2001) 
Monocytes Differentiates into: 
 
Macrophages: resorption and removal of necrotic bone and help in the 
creation of callus. Secrete pro-inflammatory cytokines such as TNF-α, IL-1, IL-
6, IL-11 and IL-18 (Gerstenfeld, Cullinane et al. 2003), and growth factors 
such as fibroblast growth factor, PDGF (Lieberman, Daluiski et al. 2002) 
 
Multi-nucleated chondroblasts: resorption and removal of hypertrophied 
chondrocytes, degradation of its calcified matrix and induction of neo-
 Establishment of marrow 
Diminished expression of members of the 
TGF-β superfamily. 
Page 7 
 
vascularisation (Lee, Choi et al. 1998) 
 
Multi-nucleated osteoclasts: resorption of woven bone during remodelling 
process 
Lymphocytes B-lymphocytes:  not found in any stages of fracture healing (Andrew, Andrew 
et al. 1994) 
 
T-lymphocytes: selectively recruited into fracture haematoma and 
subsequent granulation tissue/soft callus (Andrew, Andrew et al. 1994). 
Enables osteoblast maturation during early phase of fracture repair (Nam, 
Mau et al. 2012). 
Platelets Involved in the formation of the fracture haematoma through the clotting 
cascade. Degranulating platelets are a rich source of cytokines such as PDGF 
and TGF-β (Lieberman, Daluiski et al. 2002) 
 
The roles of the different cellular phenotypes described above during the fracture healing process 
occur around the fracture site. What remains unclear is whether the local injury (fracture) exerts a 
more generalized systemic effect away from site of injury. Particularly, do the cells in similar 
environments (bone marrow) away from fracture site, get stimulated and up-regulated following a 
fracture? 
 
1.4. Measurement of Trauma Severity 
Efforts have been made previously to quantify the severity of trauma as a tool to predict prognosis 
and subsequently to improve survival. There are two main groups of trauma scoring systems. The 
first is developed from the Abbreviated Injury Scale(American Association for Automotive Medicine. 
Committee on Injury and States 1980) while the second is a disease based database classification 
system (ICD-9)(1980). Different scoring systems have been suggested such as Injury Severity Score 
(ISS)(Baker, O'Neill et al. 1974), New Injury Severity Score (Osler, Baker et al. 1997), Trauma Injury 
Severity Score (Boyd, Tolson et al. 1987), Acute Physiology and Chronic Health Evaluation (Waters, 
Nightingale et al. 1990) and the International Classification of Diseases (Kim, Jung et al. 2000) based 
systems. All have been shown to be useful and beneficial. However, most of these systems are 
complex, not robust enough or inaccurate in the assessment of trauma patients (McAnena, Moore 
et al. 1992). Table 1.4-1 summarises the main trauma scoring systems that have been previously 
proposed. 
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Table 1.4-1 Comparison of Trauma Scoring Systems 
Scoring System Brief description Strengths Limitations 
Abbreviated Injury 
Scale (American 
Association for 
Automotive Medicine. 
Committee on Injury 
and States 1980) 
Score of one (minor) to 
six, one being a minor 
injury and six being 
life-threatening  
Regarded as “industry 
standard” for its ability 
in injury-specific 
descriptions 
Severity scale non-
linear, and provides no 
mechanism to 
summarize a single 
patient’s multiple 
injuries into a single 
score 
Injury Severity Score 
(Baker, O'Neill et al. 
1974) 
Sum of the squares of 
the largest AIS values 
assigned to the three 
most severe injuries in 
different body regions. 
Taking age into 
account, it correlates 
well with mortality and 
length of stay. 
Relatively easily to 
calculate 
Requires AIS codes to 
be available. Does not 
take into account 
multiple injuries in 
same body region 
New Injury Severity 
Score (Osler, Baker et 
al. 1997) 
Sum of the squares of 
the AIS scores a 
patient’s three most 
severe injuries. 
Takes into account 
multiple injuries in the 
same region 
Does not discriminate 
between injury 
severities in different 
body regions 
Revised Trauma Score 
(Champion, Sacco et 
al. 1989) 
Physiologic injury 
severity score based 
on Glasgow Coma 
Scale, systolic blood 
pressure and 
respiratory rate 
Numerically 
summarizes 
physiologic injury 
severity, and have high 
inter-rater reliability 
and predict 
survival/death 
outcome(Champion, 
Sacco et al. 1989) 
The inclusion of 
Glasgow Coma Scale, 
limits application on 
patients who are 
intubated/mechanically 
ventilated, sedated or 
under influence of 
alcohol/drugs 
Trauma Score and 
Injury Severity Score 
(TRISS) (Boyd, Tolson 
et al. 1987) 
Probability of survival 
score based on Injury 
Severity Score, Revised 
Trauma Score and 
patient’s age 
Widely used, and is the 
scoring system 
adopted by the 
Trauma Audit and 
Research Network 
(TARN) 
Weaknesses inherent 
in its component 
scores, may over-
estimate potentially 
avoidable death, 
especially in patients 
with severe head 
injury(Hill, Lennox et al. 
1992) 
Anatomic Profile Score 
(Copes, Champion et 
al. 1990) 
An anatomy based 
scoring system, divided 
into four components: 
Head/spinal cord, 
Thorax/anterior neck, 
other serious injuries, 
non-serious injuries  
Better than ISS in 
discriminating trauma 
survivors from non-
survivors 
Complex to calculate 
A Severity 
Characterization of 
Trauma (ASCOT) 
(Champion, Copes et 
al. 1990) 
Probability of survival 
model based on 
Anatomic Profile 
Score, age and Revised 
Trauma Score 
Improved survival 
prediction over the 
TRISS model 
Not widely used due to 
complexity of 
calculation of the 
Anatomic Profile Score 
International 
Classification of 
World Health 
Organization 
Wide availability, as 
commonly used by 
Needs to be 
converted/adapted to 
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Disease (ICD) (1980) sponsored system of 
diagnostic codes for 
classifying diseases 
hospitals to codify 
clinical diagnoses 
generate injury scores 
ICD-9-based Injury 
Severity Score (ICISS) 
(Osler, Rutledge et al. 
1996) 
The product of all the 
Survival Risk Ratio for 
each of the individual 
patient’s injuries. The 
Survival Risk Ratio is 
calculated from 
trauma registries; ratio 
of survivors to total 
occurrence per ICD-9 
code 
Data already collected 
in hospital discharge 
summaries; does not 
require separate 
potentially time and 
expense consuming 
AIS-based data 
collection. Often 
outperforms other 
scoring systems on 
discriminatory 
ability(Meredith, Evans 
et al. 2002; 
Stephenson, Langley et 
al. 2002) 
Relies on robustness of 
locally collected data. 
The Survival Risk Ratio 
calculated for a region 
may not be 
representative of 
another region, and 
may require derivation 
of local Survival Risk 
Ratio databases 
Acute Physiology and 
Chronic Health 
Evaluation (APACHE) 
(Waters, Nightingale et 
al. 1990)  
Physiological score 
designed to measure 
severity of disease for 
adult patients 
admitted to intensive 
care units (ICU). 
Calculated based on 
values on the first ICU 
admission day 
Provides estimated risk 
of mortality in ICU 
patients 
Not specifically 
designed for trauma 
patients, scoring 
system is 
computationally 
complex, and may 
underestimate 
mortality risk of trauma  
patients  previously 
stabilized prior to 
transfer to ICU 
 
Despite the various trauma scoring system proposed, the ISS is still currently the most widely used 
and adopted system(Sacco, MacKenzie et al. 1999) and is the system adopted by the national 
trauma registry (UK TARN). Hence, it is most easily recognisable in communications with colleagues 
and comparison of data derived from this study based on injury severity is most easily compared 
using the ISS score.  
Within this study, the purpose of a trauma scoring system is to discriminate between patients who 
are considered to be multiply injured polytrauma patients and those who have sustained isolated 
trauma only. Currently, the consensus for the definition of polytrauma is an ISS score of 16 or more 
(Copes, Champion et al. 1988; Keel and Trentz 2005) as patients with such scores have a mortality 
risk of 10% (Baker, O'Neill et al. 1974). This study will follow the most universally accepted 
conventions, and similarly define polytrauma patients as those with ISS≥16.  Detailed calculation to 
derive ISS for each patient is detailed in Figure 1.4-1. 
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Each injury is assigned an Abbreviated Injury Scale (AIS) score and is allocated to one of six 
body regions (Head, Face, Chest, Abdomen, Extremities (including Pelvis), and External). 
 
AIS score is on a scale of one to six, one being a minor injury and six being life-threatening. 
 
Injury Severity Score (ISS) 
The sum of the squares of the largest AIS values assigned to the three most severe injuries in 
different body regions. Unless the patient has AIS value of 6, regardless of other injuries 
sustained, they are assigned an ISS of 75 
Figure 1.4-1 Calculation of the Injury Severity Scale (Adapted from (Baker, O'Neill et al. 1974) 
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1.5. Traumatic Head Injury and Fracture Healing 
For the past few decades, there has been increasing belief that the additional presence of traumatic 
brain injury (TBI) in patients with extremity fractures is associated with enhanced rate of fracture 
healing (Newman, Stone et al. 1987; Perkins and Skirving 1987; Spencer 1987). Early evidence 
originated from observations that patients with TBI are significantly at risk of developing 
periarticular heterotopic ossification (Garland, Blum et al. 1980; Mital, Garber et al. 1987; Hendricks, 
Geurts et al. 2007; Simonsen, Sonne-Holm et al. 2007). There was initial scepticism of the validity of 
this phenomenon of accelerated fracture healing following TBI when Garland et al observed no 
significant enhancement of fracture healing in femur (Garland, Rothi et al. 1982) and tibial (Garland 
and Toder 1980) fractures in association with TBI. However, these studies were single group only 
(TBI and fracture) observations. Further studies comparing patients with similar fractures 
demonstrated significantly faster healing rate for long bone fractures such as femur (Perkins and 
Skirving 1987), tibia (Newman, Stone et al. 1987) and humerus (Spencer 1987) in patients with TBI 
compared to patients with similar injuries but without TBI. 
The clinical observations of enhanced osteogenesis in post-TBI patients have led to further studies to 
try to elucidate the patho-mechanism of this phenomenon. Cerebrospinal fluids derived from post-
TBI patients have demonstrated a significant proliferative effect on osteoblastic type cells (Gautschi, 
Toffoli et al. 2007). However, the fact that this effect is seen away from the site of injury (for 
example, tibia and femur) has led to a postulate that the mediator(s) responsible might be found 
within the peripheral circulation. Several studies in human patients as well as animal models have 
shown that serum derived post-TBI enhances the in vitro proliferation of human fetal osteoblastic 
cell lines, primary human osteoblasts and MSCs (Bidner, Rubins et al. 1990; Boes, Kain et al. 2006; 
Cadosch, Gautschi et al. 2009; Gautschi, Cadosch et al. 2009).  Further evidence to support these in 
vitro observations were seen when RNA expression of osteoblastic markers were enhanced in cells 
co-cultured with serum from post-TBI patients (Cadosch, Gautschi et al. 2009; Gautschi, Cadosch et 
al. 2009). Additionally, serum from patients with the addition of TBI (compared to fracture alone), 
has been shown to induce an up to 2.5-fold increase in release by T-lymphocytes of pro-fracture 
healing growth factors such as IL-10, IL-4 and TGF-β (Cadosch, Al-Mushaiqri et al. 2010). Indeed, 
biomechanical testing (in animal models) showed significantly increased stiffness (Boes, Kain et al. 
2006) as well as maximum fracture load and strain values (Ozan, Yildiz et al. 2010) in the post-TBI 
group compared to fracture alone (Boes, Kain et al. 2006).   
Various studies have attempted to elucidate the molecule responsible for this observation. Table 
1.5-1 summarises the target molecules studied to date, which attempted to examine the effect that 
traumatic brain injury exerts on these molecules. Broadly, the molecules studied could be anabolic 
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growth factors (to fracture healing), bone turnover markers and molecular breakdown of tissue of 
nervous origin (such as brain). Overall, despite some evidence, the mechanism linking the molecules 
to the phenomenon of accelerated fracture healing remains inconclusive. 
 
Table 1.5-1 Potential molecular candidates responsible for accelerated fracture healing post traumatic brain injury 
 Candidate molecule Source Message 
G
ro
w
th
 F
ac
to
rs
 
Bone morphogenetic protein-2 (BMP-2) 
(Wang, Sun et al. 2011) 
Serum  
Patients with traumatic brain 
injury (TBI), with consequent 
heterotopic ossification (HO) 
had significantly higher levels in 
first post-injury month 
compared to those with TBI but 
no HO 
Basic fibroblast growth factor (bFGF) 
(Wildburger, Zarkovic et al. 1994; 
Wildburger, Zarkovic et al. 1995; 
Andermahr, Elsner et al. 2006) 
Plasma 
(Andermahr, 
Elsner et al. 2006) 
Serum 
(Wildburger, 
Zarkovic et al. 
1994; 
Wildburger, 
Zarkovic et al. 
1995) 
TBI associated with increased 
circulating levels, but additional 
presence of long bone fracture 
did not cause additional 
elevation of levels (Andermahr, 
Elsner et al. 2006). 
Serum levels in patients with 
TBI and enhanced osteogenesis 
were not significantly different 
to ones with normal healing 
(Wildburger, Zarkovic et al. 
1995). 
Interleukin-6 (Beeton, Chatfield et al. 
2004) 
Serum 
TBI and fracture patients had 
significantly elevated levels of 
IL-6 compared to fractures only 
(Beeton, Chatfield et al. 2004). 
Intact parathyroid hormone (Trentz, 
Handschin et al. 2005) 
Serum 
Levels significantly higher on 
days 0 and 1 in combined TBI 
and fracture patients (Trentz, 
Handschin et al. 2005) 
Activin A (Phillips, Nguyen et al. 2006) Serum and CSF 
Levels significantly higher in 
patients with TBI (with or 
without fracture) compared to 
healthy controls 
Levels correlate with surrogate 
markers of TBI severity (NSE, S-
100β)  
Calcitonin (Trentz, Handschin et al. 
2005) 
Serum 
Levels lower in first week post 
fracture in presence of TBI 
(Trentz, Handschin et al. 2005) 
Vascular endothelial growth factor 
(Gong, Hao et al. 2012) 
Serum 
Serum VEGF of patients with 
TBI significantly raised in the 
first 3 weeks post injury 
compared to healthy control 
(Gong, Hao et al. 2012) 
Matrix metalloproteinase-9 (Gong, Hao Serum Serum MMP-9 of patients with 
Page 13 
 
et al. 2012) TBI significantly raised in the 
first 3 weeks post injury 
compared to healthy control 
(Gong, Hao et al. 2012) 
B
o
n
e 
tu
rn
o
ve
r 
m
ar
ke
rs
 
Bone specific alkaline phosphatase (B-
ALP) (Wildburger, Zarkovic et al. 1994; 
Trentz, Handschin et al. 2005) 
Serum 
Combination of TBI and 
fracture led to significantly 
elevated serum levels 
compared to TBI or fracture 
only (Trentz, Handschin et al. 
2005) 
Levels rose significantly in 2nd 
week after injury (Wildburger, 
Zarkovic et al. 1994) 
1-CTP (Trentz, Handschin et al. 2005) 
(pyridinoline cross-linked telopeptide 
parts of type-I collagen) 
Serum 
Levels significantly lower with 
TBI (Trentz, Handschin et al. 
2005), reflecting lower 
osteoclastic activity 
PICP (Wildburger, Zarkovic et al. 1994; 
Trentz, Handschin et al. 2005) (Carboxy-
terminal propeptide of procollagen type 
I) 
Serum 
Levels significantly lower with 
TBI (Trentz, Handschin et al. 
2005) 
Significantly increased level 
found in 1st week after injury 
(Wildburger, Zarkovic et al. 
1994) 
Osteocalcin (Trentz, Handschin et al. 
2005) 
Serum 
Osteocalcin levels significantly 
lower in the presence of TBI 
(Trentz, Handschin et al. 2005). 
C
N
S 
B
re
ak
d
o
w
n
 p
ro
d
u
ct
 
PACAP (van Landeghem, Weiss et al. 
2007) (pituitary adenylate cyclase 
activating polypeptide) 
Brain tissue 
Increased expression of PACAP 
by neurons and glial cells in 
pericontusional cortex area. 
Brain derived neurotrophic factor 
(BDNF) (Chiaretti, Piastra et al. 2003) 
Plasma and CSF 
Significant increase in CSF 
levels in children following TBI 
(Chiaretti, Piastra et al. 2003)  
Substance P (Zacest, Vink et al. 2010) Brain tissue 
Increased immunoreactivity to 
substance P in cerebral cortex 
following TBI (Zacest, Vink et al. 
2010) 
Protein S-100B (Raabe and Seifert 2000; 
Romner, Ingebrigtsen et al. 2000; 
Pelinka, Kroepfl et al. 2004; Stranjalis, 
Korfias et al. 2004; Gautschi, Toffoli et 
al. 2007; Honda, Tsuruta et al. 2010; 
Vos, Jacobs et al. 2010; Bohmer, Oses et 
al. 2011; Metting, Wilczak et al. 2012)  
CSF 
Osteoinductive effect of CSF 
from TBI patient does not 
correlate with protein S100-B 
levels (Gautschi, Toffoli et al. 
2007).  
Neuron specific enolase (NSE) (Kuroiwa, 
Tanabe et al. 1993; Yamazaki, Yada et al. 
1995; Ross, Cunningham et al. 1996; 
Vos, Lamers et al. 2004; Honda, Tsuruta 
et al. 2010; Bohmer, Oses et al. 2011) 
CSF (Ross, 
Cunningham et 
al. 1996) 
Serum (Yamazaki, 
Yada et al. 1995; 
Ross, 
Cunningham et 
al. 1996) 
Correlation between serum and 
CSF levels in patients with 
major head injury. No 
correlation between serum 
levels and APACHE II, ISS, GCS 
(Ross, Cunningham et al. 1996). 
Serum levels in non-survivors 
(of TBI) significantly higher than 
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survivors, as it may indicate 
quantity of brain damage 
(Yamazaki, Yada et al. 1995) 
Myelin basic protein (Yamazaki, Yada et 
al. 1995) 
Serum (Yamazaki, 
Yada et al. 1995) 
Admission serum levels in non-
survivors (of TBI) significantly 
higher than survivors as it may 
indicate quantity of brain 
damage (Yamazaki, Yada et al. 
1995) 
Cleaved tau protein (Shaw, Jauch et al. 
2002) 
Serum (Shaw, 
Jauch et al. 2002) 
Detectable serum levels 
associated with significant 
brain injury, more likely to have 
poor outcome (Shaw, Jauch et 
al. 2002). 
Glial fibrillary acidic protein (Pelinka, 
Kroepfl et al. 2004; Vos, Lamers et al. 
2004; Honda, Tsuruta et al. 2010; Vos, 
Jacobs et al. 2010; Bohmer, Oses et al. 
2011; Metting, Wilczak et al. 2012) 
Serum (Honda, 
Tsuruta et al. 
2010) 
Serum levels in first 3 days post 
injury significantly higher in TBI 
than in non-TBI (Honda, 
Tsuruta et al. 2010)  
 
To summarise, bone turnover markers are by-products of bone metabolism (and the fracture healing 
process) (Mukhopadhyay, Sinha et al. 2011). Changes in levels of these molecules over time are a 
reflection of changes in the rate of bone metabolism. Hence, these molecules are not considered to 
directly affect the rate of fracture healing, but instead are a result of changes in rate of fracture 
healing. Therefore, the association between these molecules and increased osteogenicity observed 
(Table 1.5-1) does not indicate causation. Similarly, molecules of nervous tissue breakdown would be 
expected to be elevated following traumatic brain injury. These molecules are more a reflection of 
severity of brain injury, and levels of these molecules have not been found to directly correlate with 
rate of bone metabolism and fracture healing. Finally, with molecules from the growth factor 
categories, there was some evidence of elevated levels associated with traumatic brain injury. 
However, the levels of these molecules generally were not correlated with rate of fracture healing, 
compared to healthy controls only or may be secondary to the presence of concomitant injuries 
(polytrauma). 
Therefore, ideally, to delineate the influence of traumatic brain injury on growth factors, patient 
cohorts required would be Traumatic Brain Injury with fractures, Polytrauma without TBI (to 
differentiate with additional presence of TBI), Single or Isolated fracture alone (to differentiate effect 
of multiple injuries to single) and Healthy Control (as baseline). These findings would then need to 
be correlated with patient outcome in the short term (complications, inflammatory response) and 
long term (fracture healing). 
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1.6. Introduction Summary 
Thus the basis for this study has been delineated. Currently, despite the knowledge of the roles of 
various growth factors and cells (particularly MSCs) in the fracture healing process, the effect of 
different trauma severity and additional presence of traumatic brain injury on the dynamics of 
growth factors remain unknown. Moreover, the effect on trauma on the systemic mobilisation of 
MSCs both within the systemic bone marrow and also into the peripheral circulation remains to be 
explored.     
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2. Hypothesis 
 
The study proposed in this work aimed to test the following hypotheses: 
 
Hypothesis 1: Traumatic injury upregulates anabolic growth factors (PDGF-AA, TGF-β2, 
angiogenin) and suppresses inhibitory factor (follistatin) 
 
Hypothesis 2: The selected growth factor dynamics is correlated with the inflammatory state of 
the patients 
 
Hypothesis 3: Trauma results in systemic mobilisation of MSCs  
 
Hypothesis 4: Stimulation of MSCs correlates with rise in anabolic growth factors and trauma 
severity 
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3. Aims 
These hypotheses were tested using the following experimental approach. 
 
Aim 1: To measure the serum levels of anabolic (PDGF-AA, TGF-β2, angiogenin) and inhibitory 
(follistatin) cytokines following fracture at 6 time points over a 14 day period. Enzyme 
linked immunoassays (ELISA) will be used to measure the concentrations of these 
molecules 
 
Aim 2: To compare the dynamics of molecules measured in (Aim 1) with different trauma 
severity and the additional factor of traumatic head injury. 
Both Aims 1 & 2 will be addressed in Chapter 4 
Aim 3: To correlate the dynamics of molecules measured in (Aim 1) with the inflammatory state 
of the patient. Inflammatory state of the patient will be assessed by clinical score 
(Systemic Inflammatory Response Syndrome) and biochemical parameters. 
This will be addressed in Chapter 5  
Aim 4: To enumerate MSCs in bone marrow and peripheral circulation over time following 
trauma. CFU-F assays will be used to enumerate MSCs. 
Aim 5: To correlate MSC mobilization with inflammatory response, and fracture healing outcome 
Both Aims 4 & 5 will be addressed in Chapter 6 
Aim 6: To correlate MSC mobilization with growth factor dynamics on time matched samples 
This will be addressed in Chapter 7 
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4. RESULTS: Growth factor dynamics following trauma 
4.1. Introduction 
As discussed in the earlier section (General Introduction), fracture healing is a complex physiological 
process involving osteogenic cells, governed in time by molecular mediators known as growth 
factors (Dimitriou, Tsiridis et al. 2005).  
It is currently understood that the severity of trauma influences the degree of inflammatory 
response as seen by the pattern of release (into peripheral circulation) of pro-inflammatory 
cytokines such as tumour necrosis factor (Hensler, Sauerland et al. 2002), interleukin-10(Hensler, 
Sauerland et al. 2002) and interleukin-6 (Gebhard, Pfetsch et al. 2000). As these pro-inflammatory 
cytokines have also been associated with the fracture healing process, it is reasonable to speculate 
on the influence of trauma severity on the kinetics of other growth factor release following 
fracture/trauma. Currently, the kinetics of release of molecular mediators exerting an effect on the 
fracture healing process is not well elucidated. Although it has been reported that certain growth 
factors showed an initial decline followed by gradual rise up to one week, this was limited to single 
long bone fractures only (Pountos, Georgouli et al. 2013). The effect of worsening trauma severity is 
still unclear. Moreover, the impact of traumatic head injury on the release of these autocoids 
remains obscure despite a reported enhanced osteogenic response (Newman, Stone et al. 1987; 
Perkins and Skirving 1987; Spencer 1987; Giannoudis, Mushtaq et al. 2006).  
The 3 growth factors (PDGF-AA, angiogenin and TGF-β2) and 1 inhibitory molecule (follistatin) 
studied were chosen, as they are known to play an important role in the fracture healing process 
(Dimitriou, Tsiridis et al. 2005). 
 
4.1.1. PDGF-AA 
Platelet-derived growth factor (PDGF) was first identified as a cytokine derived from platelets, which 
allowed the growth of fibroblasts in vitro (Hannink and Donoghue 1989). It contains two different 
polypeptide chains, A and B, allowing the production of at least three different PDGF-related 
molecules (A-A, B-B and A-B dimers). PDGF exerts its action by stimulating the PDGF receptor 
tyrosine kinase, in which two types (alpha and beta) of receptors have been identified (Claesson-
Welsh 1994). Specifically, these receptors undergo auto-phosphorylation which ultimately leads to 
activation of signal transduction, potentially affecting regulation of gene expression and the cell 
cycle (Claesson-Welsh 1994). PDGF is a major mitogen for MSCs and strongly induces the mitogenic 
and migratory response of MSCs (Mehrotra, Krane et al. 2004). Of the isoforms, PDGF-BB has been 
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shown to enhance fracture healing in animal models (Hollinger, Onikepe et al. 2008; Al-Zube, 
Breitbart et al. 2009). PDGF-AA isoform plays a role in osteoblast replication (Yang, Chen et al. 2000), 
but the dynamics of its expression in vivo following trauma is not well understood. 
 
4.1.2. Angiogenin 
Angiogenin is a protein that is found in human plasma (Shapiro, Strydom et al. 1987) and has been 
previously implicated in angiogenesis of tumour growth (Folkman, Merler et al. 1971). This molecule 
induces neovascularisation by augmenting the capacity of endothelial cells to digest extracellular 
matrix components and degrade basement membrane, thereby facilitating the process of 
endothelial cell invasion and angiogenesis (Hu, Riordan et al. 1994). Specifically, this formation of 
proteolytic complexes occurs via the binding of angiogenin to actin of endothelium and smooth 
muscle (Tello-Montoliu, Patel et al. 2006). Although the exact role of angiogenin in fracture healing 
remains unclear, the obligatory pre-condition of healthy tissue perfusion facilitated by new vessel 
formation would imply that angiogenin is an important component of the fracture healing process.  
 
4.1.3. TGF-β2 
Transforming growth factor-beta (TGF-β) is a cytokine that is part of the Transforming growth factor 
beta superfamily. It exists in three main isoforms (TGF-β1, TGF-β2 and TGF-β3), and have a variety of 
regulatory functions in the cell cycle. All three isoforms are secreted by osteoblasts and osteoclasts 
(Robey, Young et al. 1987) and have been shown to significantly enhance new bone formation in 
animal models(Mackie and Trechsel 1990). Immunohistochemistry analysis showed that TGF-β1 is 
found in the region of matrix synthesis and mineralization, whereas TGF-β2 is found in bone 
formation zones but within pre-osteoblastic cells only and not more differentiated osteoblasts 
(Toom, Arend et al. 2007). The TGF-β1 isoform has received most interest in its role in fracture 
healing. Following single long bone fracture, serum levels of TGF-β1 showed an initial decline, 
followed by a nearly 2-fold rise a week later (Pountos, Georgouli et al. 2013). The serum level of TGF-
β1 has been shown to be significantly lower in cases of fracture non-union (Sarahrudi, Thomas et al. 
2011) as well as delayed union (Zimmermann, Moghaddam et al. 2007). To date, no studies have 
looked at the dynamics of the TGF-β2 following fractures and trauma in humans. 
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4.1.4. Follistatin 
Follistatin is an inhibitory protein known primarily for its role in the inhibition of activin activity (part 
of the TGF-beta superfamily) (Nagamine, Imamura et al. 1998). It acts to block cell signalling by 
antagonising both type 1 and type 2 receptor binding (Thompson, Lerch et al. 2005). The osteogenic 
role of activin has been previously shown in both in vitro (Gaddy-Kurten, Coker et al. 2002) and in 
vivo studies (Sakai, Miwa et al. 1999). Additionally, follistatin has been shown to have inhibitory 
effects on various other molecules of the BMP family (Fainsod, Deissler et al. 1997; Otsuka, Moore et 
al. 2001; Amthor, Christ et al. 2002). Similar to TGF-β2, its dynamics in peripheral circulation 
following fracture is unknown. 
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4.2. Methods 
4.2.1. Patient Recruitment 
Patients were recruited for serum growth factor measurements. Approval from local ethics 
committee (Leeds West REC 06/Q1206/127) was obtained prior to commencement, with all patients 
providing written informed consent.  
To address the role of trauma severity and the additional presence of traumatic head injury on the 
pattern of growth factor release into the peripheral circulation, patients participating in this study 
were further divided into 3 groups, Group 1 polytrauma without head injury (ISS≥16, GCS>12), 
Group 2 polytrauma with head injury (ISS≥16, GCS<12) and Group 3 isolated upper/lower extremity 
fracture with no head injury (ISS<16, GCS≥12). To simplify description, Group 1 will be referred to as 
Polytrauma, Group 2 as Head Injury and Group 3 as Isolated Trauma. In addition, healthy volunteers 
were recruited to form the Control Group, to inform the baseline (non-trauma) levels of the growth 
factors. The Control Group was selected following recruitment of the trauma group, to allow for 
appropriate selection to match the age and sex distribution of the trauma group. 
 
Table 4.2-1 Growth Factor Study: Polytrauma Group (n=15) 
PATIENT ID SEX AGE ISS GCS 
NT1 M 58 16 14 
DL M 19 32 14 
BP2 M 27 25 15 
BP4 M 52 40 14 
BP6 F 25 27 15 
JM2 M 54 29 15 
BP15 M 49 24 15 
BP16 M 21 24 14 
BP12 F 24 29 15 
BP18 F 45 38 12 
BP19 M 53 24 15 
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BP20 F 41 34 15 
BP27 M 28 27 15 
BP28 M 51 24 15 
BP31 M 38 27 15 
 11M:4F 
Median age: 41 
Mean age: 39 
Median ISS: 27 
Mean ISS: 28 
Median GCS:15 
Mean GCS:14.5 
ISS=Injury Severity Score, GCS=Glasgow Coma Scale. Patients in the Polytrauma Group has ISS≥16, GCS>12 
 
 
Table 4.2-2 Growth Factor Study: Head Injury Group (n=14) 
PATIENT ID SEX AGE ISS GCS 
BH1 F 51 18 3 
BH3 F 60 27 7 
BH4 F 24 27 3 
BH6 M 28 29 4 
BH8 M 20 27 4 
BH9 M 50 27 4 
BH10 M 66 16 3 
BH11 F 44 43 3 
BH13 M 29 25 11 
BH16 M 22 27 3 
BH17 M 21 50 3 
BH18 M 41 29 3 
BH20 M 19 20 4 
BH21 M 49 34 6 
 10M:4F Median age: 35 Median ISS: 27 Median GCS: 3.5 
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Mean age: 37.4 Mean ISS: 28.5 Mean GCS: 4.4 
ISS=Injury Severity Score, GCS=Glasgow Coma Scale. Patients in the Head Injury Group has ISS≥16, GCS<12 
 
Table 4.2-3 Growth Factor Study: Isolated Trauma Group (n=15) 
PATIENT ID SEX AGE ISS GCS 
BP3 M 25 9 15 
BP7 M 53 9 15 
BP9 M 21 9 15 
BP8 M 63 4 15 
BP10 M 22 4 15 
JM8 M 21 9 15 
JM12 F 18 9 15 
JM16 M 35 9 15 
BP11 M 45 4 15 
BP13 M 51 4 15 
BP14 F 32 9 15 
BP17 M 38 8 15 
BP23 M 31 10 15 
BP22 M 20 10 15 
BP24 F 19 10 15 
 12M:3F 
Median age: 31 
Mean age: 32.9 
Median ISS: 9 
Mean ISS: 7.8 
Median GCS: 15 
Mean GCS: 15 
ISS=Injury Severity Score, GCS=Glasgow Coma Scale. Patients in the Isolated Trauma Group has ISS<16, GCS>12 
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Table 4.2-4 Growth Factor Study: Healthy volunteers (control) (n=9) 
PATIENT ID SEX AGE ISS GCS 
BP29 F 19 N/A N/A 
BP30 F 52 N/A N/A 
BP32 M 40 N/A N/A 
CM1 M 63 N/A N/A 
CM2 M 22 N/A N/A 
CM3 M 29 N/A N/A 
CF1 F 63 N/A N/A 
CF2 F 35 N/A N/A 
CF3 F 21 N/A N/A 
 4M:5F Median age: 35 
Mean age: 38.2 
N/A N/A 
 
Overall, all the 3 trauma groups are similarly sized in terms of number of patients recruited. All 4 
groups (Polytrauma, Head Injury, Isolated Trauma and Healthy Control) were essentially age (p=0.65, 
Kruskal-Wallis) and sex (p=0.31, Chi-square) matched. 
 
4.2.2. Sampling time points 
Patient samples were obtained on admission and days 1, 3, 5, 7 and 14 following injury. These 
sampling time points were chosen to best elucidate the dynamics of the growth factor in circulation 
as the fracture healing process progresses from the initial inflammatory phase (days 0-3) to a 
reparative or regenerative phase (days 12-14) (McKibbin 1978).   
4.2.3. Specimen acquisition, preparation and storage 
Peripheral blood samples (up to 20 ml) were collected in Serum Separator Tubes (BD Vacutainer®, 
Oxford, England) and allowed to stand for at least 30 minutes, to ensure that they are fully clotted 
prior to centrifugation at 2000g for 15 minutes. Serum obtained was aliquoted into 1ml cryotubes 
(1ml each, Sarstedt AG, Leicester, England), labelled appropriately and stored in a -80°C freezer prior 
to growth factor measurements. 
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4.2.4. Enzyme-linked immuno sorbent assay (ELISA) analysis 
ELISA analysis was carried out with commercially available kits (Quantikine® ELISA kit, R&D Systems, 
Minneapolis, USA), employing the quantitative sandwich enzyme immunoassay technique. Briefly, a 
monoclonal antibody specific for the molecule (PDGF-AA, TGF-β2, follistatin or angiogenin) has been 
pre-coated onto a micro plate. Standards or samples were then pipetted into the wells where 
molecules of interest were bound by relevant immobilized antibodies. After washing away any 
unbound substances, a further enzyme-linked polyclonal antibody specific for the study molecule 
(Conjugate) was then added to the well. Following further wash to remove any unbound antibody-
Conjugate, a Colour reagent (Substrate solution) was then added to the wells and colour would then 
develop in proportion to the amount of study molecule bound. The colour development was then 
stopped by adding 2N sulphuric acid before the colour intensity is read by Plate Reader (Multiskan 
Ascent, Thermo Electron Corporation, Langenselbold, Germany). Figure 4.2-1 illustrates the steps 
described. However, as each molecule has slight variations in protocol in terms of 
time/temperature/dilution/sample activations, ELISA protocols for each of the four molecules are 
described separately. Table 4.2-5 summarises the differences in protocol for 4 molecules studied. 
 
Table 4.2-5 Summary of ELISA protocol variations 
 PDGF-AA TGF-β2 ANGIOGENIN FOLLISTATIN 
Sample 
preparation 
10-fold dilution 
Activation with 
HCl followed by 
neutralisation 
with NaOH/HEPES 
200-fold dilution 
No prior 
preparation 
1st incubation 
period 
2 hours RT 2 hours RT 1 hour RT 2 hours (2-8°C) 
Wash after 1st 
incubation 
4 times 3 times 3 times 4 times 
2nd incubation 
period (after 
addition of 
Conjugate) 
2 hours RT 2 hours RT 1 hour RT 2 hours (2-8°C) 
Wash after 2nd 
incubation 
4 times 3 times 3 times 4 times 
3rd incubation 
period (after 
addition of 
Substrate) 
30 minutes RT 20 minutes RT 20 minutes RT 30 minutes RT 
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Figure 4.2-1  Double-Sandwich ELISA.  Plate is pre-coated with a capture antibody; (1) sample is added, and any antigen 
present binds to capture antibody; (2) enzyme-linked secondary antibody is added, and binds to captured antigen; (3) 
substrate is added, and is converted by enzyme to detectable form. Adapted from BioSystem® Development Website 
(biosystemdevelopment.com) 
 
4.2.4.1. ELISA protocol for measuring PDGF-AA 
Samples were thawed at room temperature (RT) and ensured to be thoroughly mixed in a roller. 
Reagent preparation was carried out per manufacturer’s instructions. In brief, samples were diluted 
10-fold as recommended by the manufacturer to allow samples to fall within sensitivity of 
calibration curve. 50μL of Standard or sample was added to 100μL of Assay Diluent (containing 
buffered protein base) per well, covered and incubated for 2 hours at RT. Standard was prepared 
earlier from recombinant human PDGF-AA as per manufacturer’s manual, and serial dilutions carried 
out to allow for standard range from 1000pg/ml to 0 pg/ml. Each well was next aspirated and 
washed with Wash Buffer for a total of 4 times. The Wash buffer is a solution of buffered surfactant, 
and this step was done to wash away any unbound substances. 150μL  of Human PDGF-AA 
Conjugate (containing monoclonal antibody against PDGF-AA) was added to each well, covered and 
incubated for further 2 hours at RT. PDGF-AA Conjugate was next aspirated and washing steps were 
repeated 4 times, to ensure removal of any unbound antibody-Conjugate. At the final stage, 200μL 
3 2 1 
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of Substrate Solution was added to each well, covered (kept from light) and incubated for 30 
minutes at room temperature. Substrate Solution contains stabilized hydrogen peroxide and 
stabilized chromogen (tetramethylbenzidine) which reacts with bound antibody-Conjugate giving an 
initial blue colour. Finally, 50μL of Stop solution (containing sulphuric acid) was added to arrest 
further activation of Substrate solution, changing the colour in the wells from blue to yellow. This 
yellow colour allows reading to be performed using 450 and 570 nm optical filters. 
 
4.2.4.2. ELISA Steps for TGF-β2 
Samples were thawed at RT and ensured to be thoroughly mixed in a roller. In serum, TGF-β2 exists 
in its latent form, and therefore requires the acid activation and neutralization to convert into its 
immuno-reactive form. Samples are activated by adding 125μL of sample to 25μL 1N HCl, mixed and 
incubated at RT for 10 minutes. Then, 25μL of 1.2N NaOH/0.5M HEPES was then added and mixed. 
Finally 800μL Calibrator Diluent (containing buffered protein base) was added to each sample, giving 
a dilution factor of 7.8. 100μL of Standard (range 0-2000 pg/ml recombinant human TGF-β2) or 
sample was added to 100μL of Assay Diluent per well, covered and incubated for 2 hours at RT. Each 
well was aspirated and washed with Wash Buffer for a total of 3 times. As for all the other cytokines, 
the Wash Buffer is a solution of buffered surfactant, and this step was done to wash away any 
unbound substances. 200μL of TGF-β2 Conjugate (containing polyclonal antibody against TGF-β2) 
was then added to each well and incubated for further 2 hours at RT. TGF-β2 Conjugate was next 
aspirated and washing steps were repeated 3 times, to ensure removal of any unbound antibody-
Conjugate. 200μL of Substrate Solution (the same as for all the other cytokines) was added to each 
well, covered (kept from light) and incubated for 20 minutes at RT. Finally, 50μL of Stop solution was 
added and reading was performed using 450 and 570nm optical filters. 
 
4.2.4.3. ELISA Steps for Angiogenin 
Samples were thawed at RT and mixed. Samples were diluted 200-fold as per manufacturer’s manual 
to allow measurements to fall within sensitivity of the calibration curve. 200μL of Standard (range 0-
5000pg/ml) or sample was added to 50μL of Assay Diluent per well, covered and incubated for 1 
hour at RT. Each well was aspirated and washed with Wash Buffer for a total of 3 times to wash 
away any unbound substances. 200μL of ANG Conjugate (containing polyclonal antibody against 
angiogenin) was added to each well, covered and incubated for further 1 hour at RT. Angiogenin 
Conjugate was next aspirated and washing steps were repeated 3 times, to ensure removal of any 
unbound antibody-Conjugate. 200μL of Substrate Solution was added to each well, covered and 
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incubated for 20 minutes at RT. Finally, 50μL of Stop solution was added and reading was performed 
using 450 and 570 nm filters. 
 
4.2.4.4. ELISA Steps for Follistatin 
Samples were thawed at RT and mixed. 100μL of Standard (range 0-16,000 pg/ml) or sample was 
added to 100μL of Assay Diluent per well, covered and incubated for 2 hours at 2-8°C. Each well was 
aspirated and washed with Wash Buffer for a total of 4 times to wash away any unbound 
substances. 200μL of cold Follistatin Conjugate (containing monoclonal antibody against Follistatin) 
was added to each well, covered and incubated for further 2 hours at 2-8°C. Follistatin Conjugate 
was next aspirated and washing steps were repeated 4 times. Then, 200μL of Substrate Solution was 
added to each well, covered and incubated for 30 minutes at RT. Finally, 50μL of Stop solution was 
added and plated were read using 450 and 570 nm filters. 
 
4.2.4.5. Plate reading and data Analysis for ELISA 
For all plates, Optical density (OD) was read within 30 minutes after the addition of Stop Solution, 
with a microplate reader (running Ascent Software for Multiskan Version 2.6) set to 450nm with 
wavelength correction at 570nm (latter to correct for contribution by the plastic well, the lamp and 
optical fluctuations). Read-out was transferred to Microsoft Excel file format for analysis. The 
duplicate readings at 450nm were averaged and subtracted to the averaged correction wavelength 
reading OD at 570nm, obtaining delta absorbance. Linearized standard curve was created by plotting 
the log mean delta absorbance (OD) for each standard on the y-axis against the log concentration 
(pg/mL) on the x-axis, and drawing a best-fit line. R-value and conversion formula was then 
obtained. Conversion formula was then applied to the data, taking into account the dilution factors 
for each individual ELISA molecule. Graphs are generated using GraphPad Prism v4.00 for Windows 
(San Diego California, USA). 
 
4.2.5. Intravenous fluid  
To investigate the influence of initial intravenous fluid resuscitation volume on the concentration of 
growth factors in peripheral circulation, the total fluid volume transfused over the first 24 hours of 
admission was recorded from the patients’ medical records.  
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4.2.6. Statistics 
Statistical analysis was carried out using PASW Statistics (SPSS) version 17.0.2 and graphing 
performed using Graph Pad Prism version 4.00 for Windows (San Diego, California, USA). As 
Gaussian distribution could not be assumed given the small sample size, non-parametric tests were 
carried out. Mann-Whitney test was used to compare differences between two independent 
samples. Wilcoxon signed-rank test was used to compare two dependent samples (same patient, 
two different time points). Chi-square test was used for comparison of nominal data (for example 
comparing sex distribution between groups). Variability of results was tested by testing the 
coefficient of variation (ratio of standard deviation to the mean). Pearson’s correlation coefficient 
was used to assess the strength of linear dependence between two variables. Statistical significance 
is assumed at p<0.05. 
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4.3. Results 
4.3.1. Validation of ELISA assay 
Standard curves for each cytokine were first assessed for linearity and compared to sensitivity 
ranges provided by the manufacturer. Commonly, the relationships between optical density (OD) 
and concentration are not linear. Therefore, standard curves were linearized by taking log10OD 
versus log10concentration and regression analysis done to obtain the formula for the conversion of 
OD to growth factor levels. Representative experiments are shown on Figure 4.3-1, Figure 4.3-2, 
Figure 4.3-3 and Figure 4.3-4. 
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Figure 4.3-1 Sample calibration curve for ELISA study (Angiogenin). The standard curve in between optical density and 
angiogenin concentration (A) was linearized by applying logarithmic transformation (B) (R=+0.99 and p<0.0001)  
 
Figure 4.3-1 shows the calibration curve (A) and linearized relationship (B) for angiogenin. The OD 
reading range for the known calibration angiogenin concentrations is 0.017 to 1.9, which is within 
the sample range, where minimum OD reading is 0.58 and maximum 1.77. According to 
manufacturer’s manual, the minimum detectable dose is 6pg/ml, which would correspond to OD of 
0.017. 
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Figure 4.3-2 Sample calibration curve for ELISA study (PDGF-AA). The standard curve in between optical density and 
PDGF-AA concentration (A) was linearized by applying logarithmic transformation (B) (R=+0.99 and p<0.001)  
 
Similarly, Figure 4.3-2  shows the calibration curve (A) and linearized relationship (B) between OD 
and PDGF-AA. The OD reading range for the known calibration PDGF-AA concentrations is 0.033 to 
2.977, which is within the sample range, where minimum OD reading is 0.033 and maximum 1.115. 
According to manufacturer’s manual, the minimum detectable dose is 2.29pg/ml, which would 
correspond to OD of 0.013. 
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Figure 4.3-3 Sample calibration curve for ELISA study (TGF-β2). The standard curve in between optical density and TGF-
β2 concentration (A) was linearized by applying logarithmic transformation (B) (R=+0.99 and p<0.0001) 
 
As per the two earlier figures, Figure 4.3-3 illustrates sample calibration curve for TGF-β2, with (A) 
showing OD versus known concentration of TGF-β2, and (B) showing the linearized relationship by 
taking log10 on both x and y-axis. The OD reading range for the known calibration TGF-β2 
concentrations is 0.062 to 2.427, which is within the sample range, where minimum OD reading is 
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0.066 and maximum 0.149. According to manufacturer’s manual, the minimum detectable dose is 
7.0pg/ml, which would correspond to OD of 0.023. 
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Figure 4.3-4 Sample calibration curve for ELISA study (Follistatin). The standard curve in between optical density and 
follistatin concentration (A) was linearized by applying logarithmic transformation (B) (R=+0.99 and p<0.001) 
 
Finally, Figure 4.3-4 shows (A) OD against follistatin concentration, which linearity is improved by 
taking log10 (OD) against log10 (follistatin concentration) (B). The OD reading range for the known 
calibration follistatin concentration is 0.0095 to 2.2345, which is within the sample range where 
minimum OD reading is 0.0695 and maximum reading of 0.7035. According to manufacturer’s 
manual, the minimum detectable dose is 29pg/ml, which would correspond to OD of 0.0025. 
 
4.3.2. Inter-individual variability (coefficient of variation) 
 
The coefficient of variation (CV) was first used to investigate patient-to-patient differences. CV is 
defined as the ratio of the standard deviation (SD) to the mean, which is then multiplied by 100 to 
allow expression as a percentage. The analysis is done separated into the 4 individual cytokines 
measured, and the three separate patient groups, to allow different injury types for the possible 
variations in CV.  
Table 4.3-1 summarises the CV for all the growth factor trauma groups and Table 4.3-2 for the 
Control groups. The following tables (in Appendix) illustrates the individual results for admission and 
days 1, 3, 5, 7 and 14 following injury/admission for growth factors PDGF-AA (Table 10.1-1), 
Angiogenin (Table 10.1-2), Follistatin (Table 10.1-3) and TGF-β2 (Table 10.1-4). 
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Table 4.3-1 Collated Coefficient of variation (%) 
 TRAUMA 
GROUPS 
Day 0 Day 1 Day 3 Day 5 Day 7 Day 14 
P
D
G
F-
A
A
 Head Injury 57.2 47.4 60.2 39.4 43.7 60.2 
Isolated 
Trauma 
25.3 32.4 30.5 24.3 21.6 51.3 
Polytrauma 59.1 33.0 45.8 44.6 27.1 62.2 
A
N
G
IO
G
EN
IN
 
Head Injury 40.3 35.7 39.3 36.2 34.4 57.8 
Isolated 
Trauma 
23.9 26.3 18.6 29.0 22.9 18.5 
Polytrauma 23.3 27.2 24.0 28.6 31.6 31.4 
FO
LL
IS
TA
TI
N
 Head Injury 49.7 41.3 91.2 78.9 59.8 36.9 
Isolated 
Trauma 
33.6 54.6 71.4 64.6 57.6 36.8 
Polytrauma 57.6 39.7 45.3 79.4 37.2 56.3 
TG
F-
β
2
 
Head Injury 43.0 38.5 45.8 43.3 45.2 34.3 
Isolated 
Trauma 
104.0 106.7 90.8 81.3 121.4 62.7 
Polytrauma 136.4 142.3 215.5 158.2 149.8 139.3 
 
 
Table 4.3-2 Inter-individual variations in control groups 
 Mean (pg/ml) Standard Deviation Coefficient of variation (%) 
PDGF-AA 4108.04 943.8 23.0 
Angiogenin 419035.2 83421.3 19.9 
Follistatin 1832.8 1211.3 66.1 
TGF-β2 1383.0 1433.4 103.6 
Manufacturer’s range (R&D Systems):   
[PDGF-AA (2156 – 5818 pg/ml), Angiogenin (196,000 - 437,000 pg/ml), Follistatin (889 – 11123 pg/ml),  
TGF-β2 (not detectable – 873 pg/ml)] 
 
Analysis of growth factor results on admission, angiogenin appeared to have the lowest CV (23.3-
40.3%) for the three groups of patients, whereas TGF-β2 had the highest (43-136.4%). Over time 
(Day 7), the CV for all molecules stayed fairly consistent; with molecules/patient groups with low CVs 
remaining low and high CVs remaining high. 
This variability showed similar trends with samples from patients in the control groups. The mean 
values for all 4 cytokines in the control groups were within the manufacturer’s range. 
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4.3.3. Growth factor dynamics over time 
To allow for comparison of the trends in growth factor dynamics over time from injury, all 4 growth 
factors, were normalized to Day 1=100, to allow for comparisons of trends in growth factor levels 
over time from injury, regardless of the variability of individual baseline levels, as shown in Table 
4.3-1. These comparisons of trends over time within individual trauma groups for all 4 growth 
factors are as illustrated in Figure 4.3-5. 
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Figure 4.3-5 Individual ELISA results normalized to Day 1. Y-axis represents normalized value to Day 1=100%. Data 
normalized to Day 1, as not all patients have Day0 samples obtained.  
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PDGF-AA 
Over the period of study, the serum levels of PDGF-AA show an increasing trend over time. 
Compared to Day 1, these changes were statistically significant (p<0.05) across most groups and 
most time points as shown in Table 4.3-3 below (individual data shown in Appendix Section, Table 
10.1-1). The changes were most pronounced in the Head Injury group, with an average 2.4-fold by 
Day 7 and 3.7-fold by Day 14 compared to Day 1 levels. Similarly, the Isolated Trauma group showed 
an almost 2-fold increase by Day 7. And finally, the Polytrauma group exhibited a rise of 2.5 and 2.7 
fold over Day 1 levels on Days 7 and 14 respectively.  
 
Table 4.3-3 PDGF-AA changes compared to Day 1  
 Day0 vs Day1 Day1 vs Day3 Day1 vs Day5 Day1 vs Day7 Day1 vs Day14 
Head Injury p=0.26 p=0.06 p<0.05* p<0.05* p<0.05* 
Isolated Trauma p<0.05* p<0.05* p<0.05* p<0.05* p=0.29 
Polytrauma p=0.43 p<0.05* p<0.05* p<0.05* p=0.08 
Wilcoxon, p<0.05 denotes statistical significance. Analysis was carried out against Day 1, as not all patients have Day0 
samples obtained. 
 
Angiogenin 
The chronological trend for angiogenin serum level was rather muted. As shown in Table 4.3-4 below 
(individual data shown in Appendix Section Table 10.1-2), over the observed time period, the Head 
Injury showed only a 1.1 fold increase on Day 7 compared to Day 1, but failed to reach statistical 
significance. Interestingly, within the Isolated Trauma group, although the average increase was only 
1.1 fold by Day 7, this trend was consistent enough to reach statistical significance. The Polytrauma 
group on average was relatively unchanged over time. 
 
Table 4.3-4 Angiogenin changes compared to Day 1 
 Day0 vs Day1 Day1 vs Day3 Day1 vs Day5 Day1 vs Day7 Day1 vs Day14 
Head Injury p=0.16 p=0.09 p=0.09 p=0.12 p=0.93 
Isolated Trauma p<0.05* p<0.05* p=0.11 p<0.05* p=1.00 
Polytrauma p=0.78 p=0.36 p=0.64 p=0.94 p=0.46 
Wilcoxon, p<0.05 denotes statistical significance 
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Follistatin 
Follistatin showed a decreasing trend over time across all trauma groups. This reached statistical 
significance by Day 7 for the Polytrauma (average 70% of Day 1 value)) and Head Injury group by Day 
14 (average 79% of Day 1 value), as shown in Table 4.3-5 (individual data shown in Appendix Section 
Table 10.1-3). The presence of an extreme outlier on Day 7 for the Isolated Trauma group probably 
caused the changes for this group to remain not significant (p=0.25), unlike the other 2 groups.   
 
Table 4.3-5 Follistatin changes compared to Day 1 
 Day0 vs Day1 Day1 vs Day3 Day1 vs Day5 Day1 vs Day7 Day1 vs Day14 
Head Injury p=0.89 p=0.15 p=0.97 p=0.10 p<0.05* 
Isolated Trauma p=0.46 p=0.51 p=0.86 p=0.25 p=0.59 
Polytrauma p=0.87 p=0.36 p=0.39 p<0.05* p<0.05* 
Wilcoxon, p<0.05 denotes statistical significance 
 
 
TGF-β2 
Finally, the serum levels of TGF-β2 did not show any significant (p>0.05) changes, apart for 
Polytrauma Day 0 to Day 1 comparison. The dynamics within the group displayed considerable 
variability, especially marked in the Isolated Trauma group. As previously shown in Table 4.3-1 
(individual data shown in Appendix Section Table 10.1-4), this molecule exhibited high variability (CV 
range 38.5-149.8%). Altogether these data showed highly variable TGF-β2 levels in all patient groups 
and at all the time points studied. 
 
Table 4.3-6 TGF-β2 changes compared to Day 1 
 Day0 vs Day1 Day1 vs Day3 Day1 vs Day5 Day1 vs Day7 Day1 vs Day14 
Head Injury p=0.67 p=0.86 p=0.86 p=0.24 p=0.48 
Isolated Trauma p=0.61 p=0.64 p=0.21 p=0.55 p=0.47 
Polytrauma p<0.05* p=0.91 p=0.36 p=0.12 p=0.60 
Wilcoxon, p<0.05 denotes statistical significance 
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4.3.4. Influence of trauma severity and head injury 
In order to analyse the influence of trauma severity and the additional presence of traumatic head 
injury on the dynamics and pattern of growth factor release, the growth factors are analysed 
individually, and comparisons are made at identical time points (admission, days 1, 3, 5, 7 and 14 
post injury) across the different trauma groups (Head Injury, Isolated trauma, Polytrauma) and 
Healthy Control group. 
 
PDGF-AA 
The analysis of PDGF-AA levels across the trauma groups are shown in Figure 4.3-6 and further 
detailed in Table 10.1-5. This showed an initial statistically significant (p<0.05) suppression across all 
3 trauma groups compared to the control levels. Across the trauma groups, both Head Injury (1740 
pg/ml) and Polytrauma (2593 pg/ml) groups had statistically (p<0.05) more pronounced suppression 
compared to Isolated Trauma Group (3491 pg/ml). The levels in all trauma groups then started to 
rise over time, but remains statistically suppressed compared to controls up to Day 3. By Day 7, the 
levels across all groups have risen, and in the Polytrauma and Isolated Trauma groups, levels were 
higher than control. By Day 14, levels of PDGF-AA across all trauma groups were higher than control, 
although this rise did not reach statistical significance compared to control. I would conclude from 
the figure that the levels were suppressed post trauma, in correlation with trauma severity, and by 
the end of 2 weeks reached the control levels.   
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Figure 4.3-6 Comparison of PDGF-AA levels across trauma groups (*denotes statistically significant, p<0.05, Mann-
Whitney) over 6 intervals between Day 0 and 14. There was an initial suppression of PDGF-AA levels rising to levels of 
control by Day 7. 
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Angiogenin 
On admission, the serum levels of angiogenin were suppressed in both the Head Injury (359751 
pg/ml) and Polytrauma (343304 pg/ml) group (Figure 4.3-7) compared to Control (419035 pg/ml) 
and Isolated Trauma (435025 pg/ml) groups, although they were only statistically significant (p<0.05) 
in the Polytrauma Group. While the levels in the Polytrauma group appeared to increase over time, 
by Day 7 post injury, the levels has reduced significantly (p<0.05) compared to all the other trauma 
groups (Head Injury and Isolated Trauma) as well as Control. By the end of the second post injury 
week, this group remained depressed, with the levels from the Head Injury group similarly 
depressed. Interestingly, the Isolated Trauma group appeared to have increased above the Control 
levels, but failed to reach statistical significance (p=0.76). Overall the levels are less variable over 
time across groups and compared to controls compared to PDGF-AA. 
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Figure 4.3-7 Comparison of Angiogenin levels across trauma groups (*denotes statistically significant, p<0.05, Mann-
Whitney) over 6 intervals between Day 0 and 14. There was an initial suppression of angiogenin levels in Polytrauma 
and Head Injury group rising to levels of control by Day 5. 
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Follistatin 
Serum follistatin levels was initially elevated post injury, with the more severely injured groups 
[Head Injury (2888 pg/ml) and Polytrauma (2723 pg/ml)] exhibiting statistically significant (p<0.05) 
higher levels compared to Control (1833 pg/ml) by Day 1 post injury (See Figure 4.3-8). Across 
groups, these levels started to drop down to the levels of Control by Day 7. The levels of serum 
follistatin in the Isolated Trauma group started to rise again over the course of the second week, and 
were significantly (p<0.05) elevated compared to the other 2 trauma groups as well as control. In 
conclusion, the levels were upregulated post trauma across groups in correlation with trauma 
severity, and returned back to baseline level by day 7 post trauma. Levels start to rise again inversely 
related to trauma severity in the second week post trauma.   
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Figure 4.3-8 Comparison of Follistatin levels across trauma groups (*denotes statistically significant, p<0.05, Mann-
Whitney) over 6 intervals between Day 0 and 14. There was an initial upregulation of follistatin levels which return to 
levels of control by Day 7. 
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TGF-β2 
Finally, the serum concentration of TGF-β2 within each trauma group has displayed a wide 
coefficient of variation, as shown previously (Table 10.1-4). The Head Injury group has displayed 
consistently suppressed levels compared to Control across all observed time points (Figure 4.3-9). 
Similarly, although statistically significant differences (p<0.05) were found between Polytrauma and 
Control groups for Days 1, 3, and 5, the levels for the Polytrauma group exhibited high variability for 
each of these time points. The Isolated Trauma group displayed a progressive increase in levels over 
the first post-injury week, but was then depressed by the end of second week, although the changes 
in concentrations over time failed to reach statistical significance compared to Control.  
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Figure 4.3-9 Comparison of TGF-β2 levels across trauma groups (*denotes statistically significant, p<0.05, Mann-
Whitney) over 6 intervals between Day 0 and 14. There was a consistent suppression of TGF-β2 levels compared to 
controls in the Head Injury group.  
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4.3.5. Influence of fluid dilution 
Patients admitted following trauma often receive intravenous fluid as part of their resuscitation. In 
fact, the Advanced Trauma Life Support principle advocates rapid infusion of up to two litres of 
intravenous crystalloid solutions (2012). Fluid resuscitation requirement often reflects the severity of 
trauma. A comparison of intravenous fluid infusion in the first 24 hours following presentation to 
hospital (See Figure 4.3-10) revealed that the Head Injury group of patients received the highest 
volume, with median of 3.4 litres (range 0.3-8.1),  Polytrauma group 3.0 litres (range 1.4-9.5), and 
Isolated trauma 2.0 litres (range 1.0-3.0). The difference in fluid resuscitation was not statistically 
significant between Head Injury and Polytrauma groups (p=0.79, Mann-Whitney), but reach 
statistical significance between both Head Injury (p=0.05, Mann-Whitney) and Polytrauma (p<0.01, 
Mann-Whitney) compared with Isolated trauma. Therefore, the observed depression in the initial 
admission concentrations of growth factors (PDGF-AA, TGF-β2, angiogenin) could be due to the 
differences in fluid volume transfused. 
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Figure 4.3-10 Box and Whisker plot of total volume of intravenous fluid infused in the first 24 hours of admission.  Top 
line represents maximum value, bottom line represents minimum value. Middle line inside box represents median 
value. *Denotes statistical significance between median values, p<0.05, Mann-Whitney 
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The blood sample for Day 0 was obtained as soon as possible after admission. Therefore, an analysis 
of association between concentrations of growth factors (PDGF-AA, angiogenin, TGF-β2, follistatin) 
would be erroneous, as most of the intravenous fluid transfusion would have occurred after the Day 
0 blood sample was taken. On the contrary, the blood sample taken for Day1 would have occurred 
soon after the first 24 hours of admission (and hence fluid infusion). Therefore, analyses were 
carried out to compare the concentrations of growth factors on Day 1 versus total fluid infusion in 
first 24 hours (just prior to Day 1 blood sample). 
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Figure 4.3-11 Association between PDGF-AA concentration in peripheral circulation on Day 1 against total fluid 
transfused in the first 24 hours following admission. No significant correlation was found across all trauma groups   
 
As can be seen in Figure 4.3-11, there are no significant (p>0.39) associations between levels of 
PDGF-AA on Day 1 and the volume of intravenous fluid transfused in the previous 24 hours, across 
all trauma groups.  
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Figure 4.3-12 Association between Angiogenin concentration in peripheral circulation on Day 1 against total fluid 
transfused in the first 24 hours following admission. No significant correlation was found across all trauma groups. 
 
 
Similarly, there appears to be no correlation between initial fluid transfusion volume (first 24 hours) 
and levels of angiogenin in the peripheral circulation at 24 hours (Day 1) following admission (Figure 
4.3-12). This trend was comparable across all trauma groups. 
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Figure 4.3-13 Association between Follistatin concentration in peripheral circulation on Day 1 against total fluid 
transfused in the first 24 hours following admission. No significant correlation was found across all trauma groups. 
 
The results of the analysis for follistatin (Figure 4.3-8) were similar to those shown previously for 
PDGF-AA and angiogenin, with no significant (p>0.28) correlations between follistatin concentrations 
and total intravenous fluid transfusion, across all trauma groups. 
 
Page 49 
 
H e a d  In ju ry  G r o u p
IV  F lu id  V o lu m e  (m l)
T
G
F
- 
2
 (
p
g
/m
l)
0 2 0 0 0 4 0 0 0 6 0 0 0 8 0 0 0 1 0 0 0 0
0
2 0 0
4 0 0
6 0 0
R = + 0 .0 4 , p = 0 .9 1
P o ly tr a u m a  G r o u p
IV  F lu id  V o lu m e  (m l)
T
G
F
- 
2
 (
p
g
/m
l)
0 5 0 0 0 1 0 0 0 0 1 5 0 0 0
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
5 0 0 0
R = + 0 .1 9 , p = 0 .5 2
Is o la te d  T r a u m a  G r o u p
IV  F lu id  V o lu m e  (m l)
T
G
F
- 
2
 (
p
g
/m
l)
0 1 0 0 0 2 0 0 0 3 0 0 0 4 0 0 0
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
R = -0 .1 1 , p = 0 .7 4
T G F  C o m b in e d  D a y 1  v s   F lu id  0
IV  F lu id  V o lu m e  (m l)
T
G
F
- 
2
 (
p
g
/m
l)
0 5 0 0 0 1 0 0 0 0 1 5 0 0 0
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
5 0 0 0
R = + 0 .1 7 , p = 0 .4 3
 
Figure 4.3-14 Association between TGF-β2 concentration in peripheral circulation on Day 1 against total fluid transfused 
in the first 24 hours following admission. No significant correlation was found across all trauma groups 
 
Finally, analysis of the concentration of TGF-β2 (Figure 4.3-9) also showed no association with 
amount of fluid transfused, in keeping with findings of the other molecules (PDGF-AA, angiogenin, 
follistatin) detailed above. 
 
In summary, there was statistically significant (p<0.05) higher volume of initial intravenous fluid 
transfused in both the Head Injury and Polytrauma Groups compared to the Isolated Trauma Group 
(as shown in Figure 4.3-10). However, within the individual trauma groups, the variability in volume 
of fluid transfused did not correlate with the variability in concentrations for all 4 measured growth 
factors (PDGF-AA, angiogenin, follistatin, TGF-β2).  
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4.4. Discussion 
4.4.1. Study population 
Across all trauma groups, there is a positive skew towards male patients, with an average of 3-fold 
more males compared to females. This male predominance has been previously reported in other 
polytrauma (Edwards, Di Bartolomeo et al. 2007; Christensen, Ridley et al. 2008) as well as traumatic 
head injury (Fuller, Bouamra et al. 2011) studies. However, all four patient groups were age and sex 
matched, allowing valid comparisons across groups. Additionally, the Injury Severity Score between 
the Polytrauma and Head Injury group was similar, thus allowing us to speculate that any differences 
observed within the growth factor kinetics measured to be attributed to the additional presence of 
traumatic brain injury alone. 
 
4.4.2. Serum levels of growth factors in Healthy Controls 
In this study, all 4 growth factors studied were detected at measurable levels in healthy non trauma 
controls. The mean serum concentrations of our control group were the following; PDGF-AA 4108 
pg/ml (range 2482-5261, standard deviation 944), angiogenin 419,035 pg/ml (range 232,385-
528,411, standard deviation 83421), follistatin 1833 pg/ml (range 865-2180, standard deviation 
1211) and TGF-β2 1383 pg/ml (range 452-4727, standard deviation 1433). This is in agreement with 
the data from the commercial kit used to analyse these samples, which reported a mean serum 
concentration in healthy controls of PDGF-AA 4208 pg/ml (range 2156-5818), angiogenin 360,000 
(range 196,000-437,000), follistatin 2483 pg/ml (range 889-11,123) and TGF-β2 386 pg/ml (range not 
detectable to 873) in healthy controls. The levels of these growth factors in our control group are by 
and large also in keeping with the literature. Serum follistatin levels in healthy control have been 
previously reported to range between 3500pg/ml (Sakamoto, Shintani et al. 1996) to 13,300pg/ml 
(Wakatsuki, Shintani et al. 1996). Previous publications reported the average serum angiogenin in 
healthy control to range between 177,000 and 336,000pg/ml (Molica, Vitelli et al. 2004; 
Dziankowska-Bartkowiak, Gerlicz-Kowalczuk et al. 2011).  Although Doupis et al (Doupis, Lyons et al. 
2009) reported a mean control population serum PDGF-AA levels of 23200pg/ml, his population 
cohort differs slightly from ours (older age, on medication for hypertension, hypercholesterolemia), 
and measured with different assay techniques (Luminex), which may contribute to this observed 
difference. The detection and presence of these growth factors in the serum of healthy controls 
naturally reflect their roles in maintaining the balance and homeostasis in daily human physiological 
functions. And finally, TGF-β2 in healthy control have been reported to range from 83.3 
(Kapetanakis, Drygiannakis et al. 2010), 10,500(Wu, Wu et al. 2010) to 59,410 (Ma, Miao et al. 2013) 
Page 51 
 
pg/ml. Although the published levels differ, this may be due to dilution or calculation error on their 
part, as the levels found within this study agrees with those provided by the manufacturer. 
 
4.4.3. Influence of Fluid Dilution 
I have shown that there was a statistically significant (p<0.05) larger volume of fluid resuscitation in 
the Head Injury and Polytrauma groups compared to Isolated Trauma group. Therefore, it was 
possible that the observed initial depression (compared to control) in serum concentration of PDGF-
AA and angiogenin was due to fluid dilution. However, further analysis did not show any statistically 
significant (p>0.05) correlations between volume of fluid and growth factors concentrations, across 
all trauma groups, for all growth factors (Figure 4.3-11, Figure 4.3-12, Figure 4.3-13, Figure 4.3-14). 
Furthermore, should the dilutional factor be fully accountable for my observations, then I should 
similarly expect a depression of follistatin (compared to control); which was contrary to measured 
follistatin values in my cohort of patients (Figure 4.3-8). 
Additionally, the in vivo half-lives of the molecules measured are relatively short [PDGF-AA (2 
minutes) (Cianciolo, Stefoni et al. 1999), follistatin (4 minutes) (Kogure, Zhang et al. 1996), TGF-β2 (2 
minutes) (Kaminska, Wesolowska et al. 2005), angiogenin (12 hours) (Hatzi, Bassaglia et al. 2000)]. 
This implies that the concentrations of these growth factors detected represented what was being 
actively synthesised and released into the peripheral circulation at that moment in time. The volume 
of fluid transfused would then have less of influence on the concentrations. 
Therefore, the observed initial depression of growth factors noted in the more severely injured 
group was unlikely to be due to the influence of fluid dilution, but rather a depression in the rate of 
synthesis and release into the peripheral circulation.  
 
4.4.4. Inter-individual variability 
As presented earlier, within the same trauma group and time points, all 4 growth factors exhibited 
variations in baseline levels, as well as changes over time. Within each time point/trauma group, this 
coefficient of variation (CV) varied between 21.6-215.5% (Table 4.3-1). Comparisons of CVs between 
trauma groups showed that the Isolated Trauma group was least variable followed by the Head 
Injury group with the Polytrauma group to be most variable. Most patients recruited from the 
Isolated Trauma group presented with a single long bone fracture (most likely of the tibia) and 
underwent relatively similar post-injury course and treatment. In contrast, the Polytrauma Group is 
far more heterogeneous in terms of the assortment of injuries that each patient suffered. These 
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differences in type, locations, severity and post-injury management may account for the high CVs 
observed in the major trauma groups especially Polytrauma. This is borne out by the differences in 
the Injury Severity Score range of 4-9 in the Isolated Trauma group, versus 16-40 in Polytrauma and 
16-50 in the Head Injury Group. 
The other possible reason for the observed inter-individual variability could be due to the known 
circadian variations in levels of various cytokines in humans (Chan, Spieth et al. 2012). This effect has 
been minimized by ensuring that, apart from admission samples, the remaining samples were taken 
fasted in the morning. 
Finally, the role of patients’ own inherent (genetic) response following injury may play a role. The 
influence of genetic polymorphisms on the systemic inflammatory response following trauma has 
been well documented (Waterer and Wunderink 2003; Imahara and O'Keefe 2004). In fact, patients 
with certain polymorphism (to the NOG and SMAD6 genes) are significantly associated with a 
greater risk of fracture non-union (Dimitriou, Carr et al. 2011). Therefore, taking into account the 
influence of genetic polymorphism on the initial post-injury response through to fracture union rate, 
it would be reasonable to infer that similarly, some of the inter-individual responses observed in this 
study, is due to the individual patient’s inherent response following trauma. This could also explain 
the variation in growth factors levels in the healthy control population found in this study as well. 
  
4.4.5. Comparison against hypothesis – Anabolic growth factors 
As previously mentioned in this chapter, the molecules PDGF-AA, angiogenin and TGF-β2 are known 
to be anabolic growth factors for the bone fracture healing process.  
My study has shown that following trauma, serum levels of PDGF-AA rise over time, with an 
incremental rise observed in association with the patients in the severe trauma groups (Head Injury 
and Polytrauma). However, this conclusion would have been erroneous as, compared to our age and 
sex matched Healthy Control group, initially, the actual serum concentration of PDGF-AA across all 
groups was significantly (p<0.05) lower; with more pronounced suppression in Head Injury group, 
followed by Polytrauma and Isolated Trauma Groups respectively. In fact, over the period of one 
week, levels of serum PDGF-AA would rise to recover back to baseline (Healthy Control) levels. As 
previously discussed, PDGF-AA exerts its effect on MSCs and plays an important role in osteoblast 
replication. Based on McKibbin’s (McKibbin 1978) classic model of the phases of fracture healing, the 
first week following fracture coincides with the inflammatory phase, to be followed by the 
osteogenic repair phase from day 12 onwards. Therefore, PDGF-AA would be expected to exert its 
maximal effect during this repair phase, hence a rise in level from initial trauma. What remains 
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unclear is the mechanism responsible for causing the initial suppression of serum PDGF-AA levels. 
This will be addressed in Section 5.3.1, in which PDGF-AA and platelet levels are measured in 
parallel, in the same cohort of patients. 
In addition, activation of the PDGF-A receptor has been found to contribute towards impairment of 
the blood brain barrier (Ma, Huang et al. 2011). Therefore, following traumatic brain injury, it would 
be reasonable to speculate on the possible downregulation of PDGF-AA ligand production in order to 
induce a neuroprotective effect. 
A previous study has reported post-fracture serum angiogenin to exhibit an early peak (1 week), with 
a steady decline over a 24-week period (Weiss, Zimmermann et al. 2009).  Moreover, a DNA micro-
array analysis in a murine model showed that the gene cluster responsible for angiopoiesis is 
upregulated from days 10 to 21 post fracture (Khan, Solaris et al. 2008). This may explain the 
relatively muted response observed in our cohort of patients, as we only measured levels up to one 
week post fracture. Additionally, angiogenin is predominantly synthesized in the liver, colon and 
small intestine (Strydom 1998), and as previously stated, the average healthy control concentration 
of angiogenin in this study was on average 420,00pg/ml . Therefore, even if there was an increase in 
angiogenin level in response to trauma (fracture), this increase may be too small to be detectable 
statistically. 
TGF-β2 has been shown to be expressed locally on sites of fracture callus formation (Robey, Young 
et al. 1987) and plays a significant role in new bone formation (Mackie and Trechsel 1990). Its role as 
a topical bone graft augmentation agent has been previously demonstrated(Dailiana, Kantzanou et 
al. 2004). Interestingly, in the presence of SIRS, TGF-β2 level in peripheral circulation was reported to 
be significantly lower than healthy controls (Stoiser, Knapp et al. 1998). A similar observation was 
made in this study within the Polytrauma group with a significant (p<0.05) decrease in the first 24 
hours following admission. Compared to bone marrow, TGF-β2 has shown high levels of expression 
in cardiac (5-fold) and skeletal (4-fold) muscle cells (GeneAtlas U133A, BioGPS). Therefore, the high 
variability (up to 10-fold difference) seen within the control group, could be due to the differences in 
expression/secretion in cells of cardiac/skeletal muscle origin. The invariable muscular cellular, and 
sometimes cardiac cellular injuries associated with trauma may thus be responsible for the 
observations seen in this study. Little else is known about the dynamics of circulating TGF-β2 
following fractures and trauma in the literature. 
Overall, the findings do not support the hypothesis that bone anabolic growth factors are further up-
regulated by worsening severity of trauma and the additional presence of traumatic head injury.  
 
Page 54 
 
4.4.6. Comparison against hypothesis – Inhibitory cytokine 
In this study, follistatin was found to be upregulated (compared to healthy control) initially across all 
trauma groups, and gradually drop to control level at one week post trauma.  
The molecule follistatin is known to be an inhibitory molecule in the process of fracture healing 
(Dimitriou, Tsiridis et al. 2005). Additionally, follistatin has been shown to have inhibitory effects on 
various other molecules of the BMP family (Fainsod, Deissler et al. 1997; Otsuka, Moore et al. 2001; 
Amthor, Christ et al. 2002). Similar to angiogenin, the dynamics of its expression following fracture is 
unknown. However, activin has been found to have neuroprotective effects in vitro (Krieglstein, 
Suter-Crazzolara et al. 1995; Iwahori, Saito et al. 1997) and in animal model experiments (Wu, Lai et 
al. 1999). The presence of brain injury has been found to up-regulate the expression of activin 
(Munz, Hubner et al. 1999) and down-regulate expression of follistatin (Wu, Lai et al. 1999) 
compared to controls in murine models.  
Follistatin inhibits the activities of activin by binding the high affinity folistatin-activin complex. The 
osteogenic role of activin has been previously shown in both in vitro (Gaddy-Kurten, Coker et al. 
2002) and in vivo studies (Sakai, Miwa et al. 1999). The initial rise in levels of follistatin in my trauma 
groups (compared to control) would imply high levels of free follistatin (not binding to activin) and 
hence a lower level of activin. The fact that activin is a known acute phase reactant protein (de 
Kretser, Hedger et al. 1999) that is upregulated by inflammatory response (Phillips, Jones et al. 2001) 
(such a trauma) appeared contradictory to this conclusion. Could the initial upregulation of follistatin 
be due to its interaction with the BMPs instead of activin? The concentration of activin would need 
to be measured in parallel with follistatin to address this issue. 
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4.4.7. Limitations 
Ideally, for the growth factor release study, serial blood samples should be taken for up to two 
weeks following trauma. However, the duration that the patient is admitted in hospital varies and 
from experience sometimes gets discharged 5 days post-injury. However, despite this, about half the 
patients blood samples were obtained to Day 14. The trend over time from initial trauma (either 
progressive rise or decrease) was also consistent towards Day 14; hence despite the incomplete 
patient samples obtained, the results obtained for Day 14 would be expected to be similar had the 
samples been fully collected from all patients.  
This study could potentially be limited with regards to the number of patients recruited. However, 
for the growth factors PDGF-AA, angiogenin and follistatin, the low inter-individual variability seen 
within the control population, together with the clear trends exhibited by these molecules probably 
implied that the sample size in this study was sufficient for analysis. However, the growth factor 
TGF-β2 had up to 10-fold difference in variability within the control population, and hence I was 
unable to exhibit any clear trends in the trauma groups. Unless the variability within the control 
group could be addressed or explained, it would be very difficult to address its dynamics following 
fracture/trauma. 
  
Page 56 
 
5. Results – Growth factor dynamics and inflammatory response 
5.1. Introduction 
Following trauma, there is an initiation of a cascade of physiological responses, which has been 
recognized and defined as both an inflammatory and counter-inflammatory response(Lenz, Franklin 
et al. 2007). Signalling molecules such as IL-1β, IL-6, IL-8, IL-12, TNF and IFN-gamma (therein referred 
to as inflammatory cytokines) have been well described and shown to have potential roles in the 
inflammatory process following trauma (Hoover, Bochicchio et al. 2006). These cytokines, however, 
have also been shown to be expressed and involved in the early stages of bone healing. However, it 
is as yet unclear the degree of influence trauma severity plays on the production of these molecules 
and hence the evolution of bone healing. Given the overlap and cross-over of molecules involved in 
the trauma inflammatory response and bone healing, it is reasonable to speculate that severity of 
trauma has local and systemic effects on bone healing via a production of these signalling molecules. 
 
5.1.1. Inflammatory response following trauma 
It is currently understood and accepted that there is a positive correlation between the severity of 
inflammatory response observed clinically and upregulation of inflammatory cytokines in these 
patients’ peripheral circulation (Gebhard, Pfetsch et al. 2000; Hensler, Sauerland et al. 2002). 
One of the recognized phenomena of a severe degree of inflammatory response is known as the 
systemic inflammatory response syndrome (SIRS). It is a serious condition, which is associated with 
complications such as organ dysfunction, organ failure and death.  
The criteria for SIRS were set in 1991 by the American College of Chest Physicians/Society of Critical 
Care Medicine Consensus Conference (1992). It contained 3 clinical parameters (core temperature, 
heart rate and respiratory rate) and one laboratory parameter (white cell count). Table 5.1-1 below 
details the values within each parameter with any combination of 2 or more would define the 
presence of SIRS. These parameters were simplified from an earlier study, which reported an 
association between an increasing APACHE (acute physiology, age, chronic health evaluation) III 
Score and subsequent risk of hospital mortality(Knaus, Sun et al. 1992). APACHE III is a complex 
scoring system consisting of 17 physiologic measurements of changes and presence of co-
morbidities (Knaus, Wagner et al. 1991). An increasing APACHE III score was found to be correlated 
with an increasing risk of hospital mortality (Knaus, Wagner et al. 1991). Further analysis of these 
parameters found that patients who met the criteria for SIRS on the first day of admission to the 
Page 57 
 
intensive care unit accurately predicted (96.9%) patients who were deemed clinically to have 
developed sepsis (severe systemic response to infection) (Knaus, Wagner et al. 1991). 
However, SIRS may have multiple aetiologies of origin apart from infection. It may also be caused by 
trauma, pancreatitis, and burns. Figure 5.1-1 illustrates the interrelationship between SIRS, sepsis 
and infection. 
 
Table 5.1-1 Criteria for Systemic Inflammatory Response Syndrome (1992). SIRS is diagnosed when 2 or more of the 
parameters are present 
Parameters Value 
Temperature <36 °C  or >38 °C 
Heart rate >90/min 
Respiratory rate >20/min or PaCO2<32 mmHg (4.3 kPa) 
WCC 
<4x109/L (<4000/mm³), >12x109/L (>12,000/mm³),  
or 10% bands (immature neutrophils) 
 
 
Figure 5.1-1 illustrates the interrelationship between SIRS, sepsis and infection. From Bone et al. (1992) 
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5.1.2. Hospital blood test for clinical monitoring 
Following an admission to the hospital after trauma, patients may undergo various investigations to 
help with clinical diagnosis, management and monitoring. This may include analysis of patient’s 
blood samples, which provides a window to the patient’s physiological state at that moment. Some 
of the routine blood tests requested in post-traumatic patients are summarized in Table 5.1-2 and 
Table 5.1-3. 
  
 
Table 5.1-2  Routine Haematology laboratory parameters. From Wallach’s (Williamson, Snyder et al. 2011). 
Test Unit 
Normal 
range 
Role/function/implication 
Haemoglobin (Hb) g/dL 
13.5-
18.0 
Respiratory protein for red blood cells. Levels reduced in 
all anaemias 
Total white cell 
count (WCC) 
109/L 
4.00-
11.00 
Numerical total of the white cell components: neutrophils 
(including bands), lymphocytes, monocytes, eosinophils 
and basophils. 
Platelet (Plt) 109/L 150-400 
Involved in the blood clotting process. May have a reactive 
rise to inflammatory response such as severe trauma and 
infection 
Prothrombin time 
(PT) 
s 9-14 
Assess the coagulation activity of the extrinsic and 
common coagulation pathways. 
Activated partial 
thromboplastin time 
(APTT) 
s 25-39 
Assesses the coagulation activity of the intrinsic and 
common pathways of coagulation. Best screening test for 
disorders of coagulation that do not involve factor VII 
(extrinsic pathway) and platelet function 
International 
Normalized Ratio 
(INR) 
n/a n/a 
Derived as a ratio of patient’s prothrombin time to normal 
control raised to the power of the International Sensitivity 
Index of the analytical system used(1985).  
Derived Fibrinogen 
(Fib) 
g/L 1.6-5.9 
A glycoprotein synthesized in the liver, which is modified 
by thrombin to become fibrin. Derived fibrinogen is 
calculated based on prothrombin time. 
 
Table 5.1-3  Routine Chemical pathology laboratory parameters. From Wallach’s (Williamson, Snyder et al. 2011). 
Test Unit 
Normal 
range 
Role/function/implication 
Sodium (Na) mmol/L 135-145 
Major extracellular constituent, and plays central role in 
maintaining water distribution and osmotic pressure 
Potassium (K) mmol/L 3.5-5.0 
Primary intracellular ion, the ionic gradient (compared to 
extracellular) is required for nerve impulse transmission and 
cardiac/skeletal muscle contractility 
Urea mmol/L 2.1-8.0 
Low molecular weight substance, which is a measure of 
protein breakdown in the body. As urea is excreted by 
kidneys, excretion of urea may reflect kidney function 
Creatinine µmol/L 80-115 Synthesized at a steady rate from amino acids in the kidney, 
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(Creat) liver and pancreas. Urinary and serum creatinine used in 
conjunction calculates creatinine clearance, a measure of 
renal function 
Alanine 
transaminase 
(ALT) 
iu/L <40 
Found primarily in liver. Most sensitive tests for acute 
hepatocellular injury 
Total Bilirubin µmol/L 5-21 
By-product of erythrocytes breakdown. 
Metabolized/excreted by liver. Therefore commonly used to 
assess liver function 
Alkaline 
phosphatase 
(ALP) 
iu/L 70-300 Family of enzymes that catalyze hydrolysis of phosphate 
esters at an alkaline pH. Majority of ALP activity from bone 
and liver (1:1 ratio). Increased in bone and liver disease 
Albumin (Alb) g/L 34-48 Constitutes 55-65% of total plasma protein. Decreased levels 
may be due to decreased synthesis in liver, acute 
inflammatory process, and increased loss secondary to 
pathologies such as burns and trauma. 
Adjusted 
Calcium (Ca2+) 
mmol/L 2.20-
2.60 
Also known as ionized calcium. Plays crucial roles in many 
physiological processes. The majority of calcium in human is 
unavailable, in bone(Guyton and Hall 2006). 
C-reactive 
protein (CRP) 
mg/L <10.0 Acute phase reactant protein produced by hepatocytes and 
induced by the release of inteleukin-1 and 6. It reflects 
activation of systemic inflammation. 
 
Although all the blood investigation parameters may be affected by trauma, as a result of disruption 
to the normal physiological function of the haematological, renal and liver systems, a few 
parameters are known to be directly influenced by an inflammatory process. The following 
parameters have been previously reported to be associated with an acute inflammatory process, 
such as following trauma. 
 
C-reactive protein 
Ever since the discovery of C-reactive protein (CRP) in the 1930s (Tillett and Francis 1930), it has 
been studied extensively due to its association with the inflammatory process.  CRP is produced in 
the liver (Hurlimann, Thorbecke et al. 1966) and formation is principally induced by the 
inflammatory cytokine interleukin-6 (IL-6),  and enhanced by the additional presence of interleukin-
1(IL-1) (Kushner, Jiang et al. 1995).  Functionally, CRP is believed to function as a mediator of the 
inflammatory process, inducing the release of pro-inflammatory cytokines (IL-1, IL-6, IL-18, TNF-α) 
(Ballou and Lozanski 1992), to activate the complement system (Mold, Gewurz et al. 1999) and to 
enhance phagocytosis by macrophages (Hokama, Coleman et al. 1962). 
Clinically, CRP is a useful tool to the attending clinicians, as a sensitive but non-specific marker of 
inflammation. Serum CRP concentration rises in response to tissue injury, infection and 
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inflammation, and are therefore useful as a tool to monitor the patient’s disease activity and 
response to treatment (Thompson, Pepys et al. 1999).  
Overall, the influence of CRP on the dynamics of growth factors remains unknown. The inflammatory 
cytokines (such as IL-6 and IL-1) have been implicated in the early phase of the fracture repair 
processes (Einhorn, Majeska et al. 1995), and thus may influence subsequent release of other 
growth factors. CRP, with its close association with the inflammatory cytokines, may by inference 
also influence the dynamics of growth factors in general. 
 
Total White Cell Count 
The total white cell (leucocyte) count is used by the managing physician to assess the patient’s 
immunological status. A rise in total white cell count, or leucocytosis would commonly alert the 
physician to the possible presence of an infectious pathology (Kumar and Clark 2009). However, the 
phenomenon of leucocytosis can also occur following other inflammatory processes such as trauma 
(Keel and Trentz 2005). A brief description of the cellular constituents that make up the total white 
cell count is shown in Table 5.1-4. Further discussion would be limited to the leucocyte response 
following trauma. 
 
Table 5.1-4  Constituents of the Total White Cell Count. Adapted from  (Alberts 2002)
  
and  (Kumar and Clark 2009) 
Cell type 
Typical concentration in 
human blood (cells/litre) 
% of total 
white cell 
count 
Brief description of function 
Neutrophil 5 × 109 57.9 
Phagocytosis and destruction of 
invading bacteria 
Monocyte 4 × 108 4.6 
Phagocytosis of microorganisms, 
foreign body and damaged cells 
Lymphocyte B-
cells 
2 × 109 23.1 Production of antibodies 
Lymphocyte T-
cells 
1 × 109 11.6 
Plays central role in cell-mediated 
immunity 
Basophil 4 × 107 0.5 Release histamine 
Eosinophil 2 × 108 2.3 
Anti-parasitic activities and 
modulation of allergic response 
 
The leucocyte response following trauma is secondary to a complex cascade of inter-dependent 
signalling molecules. In brief, trauma and fracture cause local cellular death. This causes the dead 
cells to release their intracellular contents, including molecules known as damage-associated 
molecular patterns (DAMPs). Example of DAMPS include the high mobility group box 1 protein 
(HMGB1) (Scaffidi, Misteli et al. 2002), heat shock proteins (HSPs) (Prohaszka, Singh et al. 2002), 
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monosodium urate (Shi, Evans et al. 2003), mitochondrial damage associated protein (Zhang, Raoof 
et al. 2010),  and even (previously intracellular) double stranded deoxyribonucleic acid (DNAs) (Ishii, 
Suzuki et al. 2001). These molecules then exert their effects in two different ways. Firstly, DAMPs are 
recognized by receptors (such as Toll-like receptors (Piccinini and Midwood 2010))  on leucocytes 
and other cells, which are then stimulated to release pro-inflammatory cytokines such as IL-1. These 
cytokines initiate an increase in the permeability of the local vasculature, dilatation of arterioles and 
venules thus giving rise to an overall increase in blood volume and delivery of plasma and leucocytes 
to the injured region (Kono and Rock 2008). Secondly, upregulation of pro-inflammatory cytokines, 
stimulated by DAMPs, stimulates the activation, migration and accumulation of leucocytes (Keel and 
Trentz 2005) and hence leucocytosis. However, sometimes during severe inflammatory response 
(such as SIRS mentioned above), leukopenia (drop in total white cell count) may occur instead. This 
has been postulated to be related to increased apoptosis, triggered by stress and cell death proteins 
(Keel and Trentz 2005). 
 
Platelets 
Platelets are non-nucleated disc shaped cells found within the peripheral circulation. They are 
produced by bone marrow megakaryocytes, regulated physiologically by thrombopoietin(Burstein 
1997). Functionally, platelets play a central role in haemostasis, via the formation of the haemostatic 
plug(Kumar and Clark 2009). Additionally, platelets contain storage compartments known as alpha 
granules, which contain a plethora of cytokines (See Table 5.1-5). These stored cytokines are 
released following platelet activation in the process of haemostatic plug formation. 
Following trauma, platelet numbers in peripheral circulation are known to be raised, a process 
known as reactive thrombocytosis (Kumar and Clark 2009).  This process is determined by elevated 
levels of thrombopoietin, interleukin-6 and other cytokines produced by the accompanying 
inflammatory process. Table 5.1-6 summarises the main cytokines that are known stimulators of 
platelet production. 
Although platelet production is known to be stimulated by trauma, the effect of different trauma 
severity is less clear. Platelet number in peripheral circulation is not only affected by rate of 
production, but also rate of platelet destruction, pooling, consumption and blood loss. As such, the 
effect of circulating platelets and its cytokine function and influence following trauma of different 
severity remains to be studied.    
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Table 5.1-5 Platelet Alpha Granule Constituents (From  (McNicol and Israels 2008)) 
Adhesive Proteins Chemokines Other 
Fibrinogen α chain 
Fibrinogen β chain 
Fibrinogen γ chain 
Fibronectin 
Thrombospondin 1 
Vitronectin 
Von Willebrand Factor 
(vWF) 
Connective Tissue-Activating Peptide (CTAPIII; 
CXCL7) 
Epithelial Neutrophil Activating Peptide (ENA-
78; CXCL5) 
GRO-α (CXCL1) 
I-309 (CCL1) 
Interleukin-8 (IL-8; CXCL8) 
Macrophage Inflammatory Protein 1α (MIP-
1α; CCL3) 
Monocyte Chemoattractant Protein-1 (MCP-1; 
CCL2) 
Monocyte Chemoattractant Protein-3 (MCP-3; 
CCL7) 
Neutrophil-Activating Peptide-2 (NAP-2; 
CXCL7) 
Platelet Basic Protein (CXCL7) 
Platelet Factor (PF4; CXCL4) 
Platelet Factor 4 variant 1 (PF4alt; CXCL4L1) 
Regulated upon Activation, Normal T-cell 
Expressed, and Secreted 
(RANTES; CCL5) 
Stromal Cell-Derived Factor (SDF-1; CXCL12) 
Thymus and Activation-Regulated Chemokine 
(TARC; CCL17) 
β-Thromboglobulin (β-TG; CXCL7) 
 
Albumin 
Amyloid β-A4 protein 
Angiopoietin-1 
Angiostatin 
Clusterin 
Endostatin 
Factor V 
Factor XI 
Factor XIII 
High-molecular weight 
kininogen (HMWK) 
Matrix 
metalloproteinase-2 
(MMP-2) 
Metalloproteinase 
inhibitor-1 
Multimerin 
Osteonectin 
Plasminogen 
Plasminogen activator 
inhibitor (PAI-1) 
Protein C inhibitor 
Protein S 
Secretory granule 
proteoglycan core 
protein 
(SGPCP) 
Thrombocidin-1 (TC-1) 
Thrombocidin-2 (TC-2) 
Thymosin β-4 
Tissue inhibitor of 
metalloproteinase 
(TIMP-4) 
von Willebrand antigen-
II 
α2 macroglobulin 
α2-antiplasmin 
α-actinin 1 
α-actinin 2 
α-actinin 4 
Cytokines Growth Factors 
Interleukin-1β (IL-1β) 
High Mobility Group 
Box 
Chromosomal Protein-1 
(HMGB1) 
 
Basic fibroblast growth factor (bFGF) 
Epidermal growth factor (EGF) 
Hepatocyte growth factor (HGF) 
Insulin-like growth factor-1 (IGF-1) 
Insulin-like growth factor-2 (IGF-2) 
Platelet-derived endothelial cell growth factor 
(PD-ECGF) 
Platelet-derived growth factor (PDGF) 
Transforming growth factor (TGF-β) 
Vascular endothelial growth factor A (VEGF-A) 
Vascular endothelial growth factor C (VEGF-C) 
 
 
  
Page 63 
 
Table 5.1-6 Cytokines known to stimulate thrombocytosis (From (Klinger and Jelkmann 2002)) 
Cytokines 
Stem cell factor 
Thrombopoietin 
Granulocyte-monocyte colony stimulating factor 
Granulocyte- colony stimulating factor 
Interleukin-1 
Interleukin-3 
Interleukin-6 
Interleukin-11 
Leukaemia inhibitory factor 
Interferon gamma 
Erythropoietin 
Oncostatin 
 
In summary, the previous results chapter has shown that the growth factor dynamics for the 
molecules PDGF-AA, angiogenin, follistatin and TGF-β2 changes over time following trauma. 
Differences were also observed between the different trauma groups, with the more severely 
injured (Head Injury and Polytrauma) showing marked initial suppression (PDGF-AA) or elevation 
(follistatin) compared to the less severely injured group (Isolated Trauma). As discussed above, 
worsening severity of trauma is associated with increased inflammatory response.  
This chapter therefore aims to elucidate if these differences in growth factor dynamics observed was 
influenced by the degree of inflammatory response both biochemically (CRP, WCC, platelets) and 
clinically (SIRS score). In addition, this chapter also aims to clarify if the early dynamics of growth 
factors measured (PDGF-AA, angiogenin, follistatin, TGF-β2) had an influence on eventual fracture 
healing outcome.   
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5.2. Methods 
5.2.1. Patient recruitment, serum sampling and growth factor 
analysis 
Details of the method are as described in Chapter 4. Briefly, the patient population recruited is 
divided into Traumatic Head Injury, Polytrauma and Isolated Trauma groups. Blood sampling time 
points are at admission, and Days 1, 3, 5, 7 and 14 post-injury. Growth factors analysed are PDGF-
AA, angiogenin, TGF-β2 and follistatin. Hospital laboratory parameters analysed were C-reactive 
protein, total white cell count, platelet. 
 
5.2.2. Hospital blood laboratory results 
Patients admitted to our unit following injury frequently have blood samples taken and sent for 
analysis in the hospital laboratory as part of their clinical care, as required. Therefore, not all time 
points captured in the Growth Factor analysis have time-matched samples from the hospital 
laboratory analysis. Available data was obtained from the Leeds Teaching Hospital Results Service 
System. Routine laboratory analyses undertaken are briefly divided into the Haematology and 
Chemical Pathology Department. Details of parameters captured as well as brief explanation of the 
role of these tests are shown in Table 5.1-2 for Haematology and Table 5.1-3 for Chemical Pathology. 
However, for the purpose of analysis, only the parameters identified to be associated with an acute 
inflammatory process will be reported. 
 
5.2.3. Clinical data 
Clinical data was collected to match with the blood sample (growth factor) time points. In addition 
to total white cell count (obtained from the Leeds Teaching Hospitals Haematology laboratory), the 
parameters of core temperature, heart rate and respiratory rate were obtained daily. The results 
were then tabulated and SIRS was diagnosed when two or more criteria were met (Table 5.1-1). 
Requirement of intensive or higher dependency care was also noted together with the total duration 
of hospitalization. 
Additionally, following discharge from hospital, patients who were followed up in the Leeds Teaching 
Hospitals outpatient fracture clinic department also had their longer term outcome recorded; 
specifically, rate of fracture healing and requirement for re-operation due to non-healing of 
fractures. 
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Fracture healing can be ascertained radiologically or clinically. However clinical diagnosis of fracture 
healing can be subjective. Therefore, the radiological method is used to ascertain fracture healing in 
this study. A fracture is considered healed when bridging callus across the fracture site is seen on 
two orthogonal views on plain film X-rays.  For the purpose of analysis, patients requiring 24 weeks 
or more to achieve radiological healing would be considered delayed union (Calori, Phillips et al. 
2008).  
 
5.2.4. Statistical analysis 
Statistical analysis was carried out using PASW Statistics (SPSS) version 17.0.2 and graphing 
performed using Graph Pad Prism version 4.00 for Windows (San Diego, California, USA). As 
Gaussian distribution could not be assumed given the small sample size, non-parametric tests were 
carried out. Mann-Whitney test was used to compare differences between two independent 
samples, in cases of three or more groups. Kruskal-Wallis one-way analysis of variance was used (3 
different trauma groups). Wilcoxon signed-rank test was used to compare two dependent samples 
(same patient, two different time points). Chi-square test was used for comparison of nominal data 
(for example comparing sex distribution between groups).  
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5.3. Results 
In order to further understand the relationship between serum concentrations of the measured 
growth factors (PDGF-AA, follistatin, angiogenin and TGF-β2) and the clinical course and outcome of 
the patients, the growth factors were analysed against time matched hospital laboratory parameters 
as well as patients’ early (SIRS) and late (non-union) complications.  
 
5.3.1. Comparison against Hospital laboratory parameters 
Patients admitted to the hospital following acute trauma and injury undergo regular sampling of 
their peripheral blood for analysis of their physiological state. Details have been explained in Section 
5.1.2 above. It has been hypothesised that the growth factor dynamics in peripheral circulation is 
positively influenced by the degree of inflammatory response. Within the routine blood tests carried 
out in the hospital for these patients, the following parameters have been associated with changes 
in the inflammatory state of the body (as discussed in Section 5.2.2): C-reactive protein, total white 
cell count, and platelet.  It must be noted, however that these data derived from the hospital 
laboratory measurements do not cover all time points as measured in the growth factor study, as 
these tests were carried out based on the individual patients’ needs. Therefore, analyses were 
carried out on a sub-group of patients recruited. 
 
C-reactive protein (CRP) 
C-reactive protein levels matching growth factor measurements were available on 13 patients from 
Head Injury, 11 from Polytrauma and 6 from Isolated Trauma Group, as detailed in Table 5.3-1. As 
can be seen in Figure 5.3-1, CRP in these patients showed an overall increasing trend from 
admission, peaking between days 3 and 5 before subsiding. Overall, the Polytrauma Group appeared 
to have the highest mean CRP values across all time points studied, with peak value of up to 4-fold 
admission values. 
To enable analysis of any correlations between growth factors and CRP values, only matched growth 
factor values were used. Figure 5.3-2 summarizes the growth factor values for the CRP sub-group of 
patients.  
Each individual growth factor was then further analyzed to ascertain the relationship (if any) 
between matched CRP and growth factor levels. Data were analyzed separated into individual 
trauma groups, as well as overall. As the aim of this analysis was to determine relationship between 
two matched values, therefore, values for all time points within each group were analysed 
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collectively. Additionally, data was analysed for the influence of the different trauma groups, and 
also collectively. 
 
 
Table 5.3-1 Patients with matched Growth Factor and CRP data 
Trauma Groups Patient ID 
Head Injury (n=13) 
BH1, BH3, BH4, BH6, BH8, BH9, BH10, BH11, 
BH13, BH16, BH17, BH18, BH21 
Polytrauma (n=11) 
NT1, DL, BP2, BP4, BP6, BP12, BP15, BP16, BP18, 
BP20, BP27 
Isolated Trauma (n=6) BP8, BP9, BP10, BP11, BP13, BP14 
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Figure 5.3-1 Mean CRP values over time across trauma groups. All values were above 10mg/L. Error bars represent one 
standard deviation. Overall trends showing CRP rising over time reaching peaks at day 3-5 before gradually subsiding 
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Figure 5.3-2 CRP sub-group: Trends of growth factors over time across trauma groups. Error bars represent one standard 
deviation. No obvious trends were seen across all 4 growth factors over the 6 time intervals measured. 
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Figure 5.3-3 Relationship between matched CRP and PDGF-AA levels. No statistically significant correlations were found 
between CRP and PDGF-AA levels across all trauma groups. 
 
As can be seen in Figure 5.3-3, across all trauma groups there are only very weak correlations 
between the values for CRP and PDGF-AA. Application of simple linear regression shows a negative 
correlation throughout, with R values ranging from -0.45 (Isolated trauma group) to -0.04 (Head 
Injury group). 
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Figure 5.3-4 Relationship between matched CRP and Angiogenin levels. CRP was weakly correlated with angiogenin in 
the isolated trauma group, but overall, no correlations were found. 
 
 
Analysis of the values for angiogenin (Figure 5.3-4), however, revealed a significant negative 
correlation within the isolated trauma group (R=-0.58, p=0.05). This finding may have to be 
interpreted with caution, however, as relatively low numbers of matched time points in this trauma 
group may give rise to statistical sampling errors.  This observed correlation was not repeated with 
the other 2 trauma groups, or with the combined analysis. 
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Figure 5.3-5 Relationship between matched CRP and Follistatin levels. CRP was weakly correlated with follistatin in the 
more severely injured group (Head Injury, Polytrauma) 
 
 
Patients in both the Head Injury and Polytrauma Group appeared to show a positive statistically 
strong correlation between follistatin and CRP levels (Figure 5.3-5). Both groups exhibit similar 
positive R values (0.54 for Head Injury, 0.58 for Polytrauma) on regression analysis, which in 
combination with data from Isolated trauma group, gave a weak positive correlation in the 
combined analysis (R=+0.36, p<0.01). Although the association was relatively weak, these analysis 
suggest that the levels of follistatin were more influenced by the degree of inflammatory response 
reflected by CRP levels, in patients from the more severely injured trauma groups compared to 
Isolated Trauma alone. 
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Figure 5.3-6 Relationship between matched CRP and TGF-β2 levels. No correlations were observed between CRP and 
TGF-β2 across all trauma groups. 
 
 
And finally, association analysis between TGF-β2 and CRP levels (Figure 5.3-6) revealed that the 2 
parameters are unlikely to be correlated with R values ranging from 0.07 to 0.14. This is especially 
evident in the combined analysis, with CRP values appearing to be independent of TGF-β2. 
The relationship between the growth factors, trauma groups and CRP levels are summarised in Table 
10.2-1. In summary, no correlations were found between CRP and measured growth factors across 
all trauma groups, except a weakly positive correlation with follistatin in the more severely injured 
group. 
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Total White Cell Count (WCC) 
Similarly, data for total white cell count which are time-matched to growth factor measurements are 
available for 14 patients in Head Injury, 14 in Poly trauma and 12 in Isolated Trauma patients 
respectively. (Table 5.3-2) 
Table 5.3-2 Patients with matched Growth Factor and WCC data 
Trauma Groups Patient ID 
Head Injury (n=14) 
BH1, BH3, BH4, BH6, BH8, BH9, BH10, BH11, 
BH13, BH16, BH17, BH18, BH20, BH21 
Polytrauma (n=14) 
NT1, DL, BP2, BP4, BP6, BP12, BP15, BP16, BP18, 
BP19, BP20, BP27, BP28, BP31 
Isolated Trauma (n=12) 
BP3, BP7, BP8, BP9, BP10, BP11, BP13, BP14, 
BP17, BP22, BP23, BP24 
 
Figure 5.3-7 summarises the overall trends of WCC values over time across the 3 trauma groups. 
There is an initial acute rise on admission across all trauma groups which then subsided by day 3 
before rising again towards day 14 post trauma. The Isolated Trauma appeared to have highest 
initial values for WCC in contrast to the Polytrauma group, which rose to the highest value across 
groups towards day 14 post trauma. 
As not all time points for the growth factor measurements has matched WCC data, only matched 
growth factor measurements are used for analysis. Figure 5.3-8 shows the summary trends over 
time across all trauma groups for the growth factors measured. 
 
D a y s  p o s t t ra u m a
T
o
ta
l 
W
h
it
e
 C
e
ll
 C
o
u
n
t 
(1
0
9
/L
)
0 1 3 5 7 1 4
0
5
1 0
1 5
2 0
2 5
H e a d  In ju ry
P o ly tra u m a
Iso la te d  T ra u m a
 
Figure 5.3-7 Mean WCC values over time across trauma groups. Normal WCC values 4-11X10
9
/L. Error bars represent one 
standard deviation 
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Figure 5.3-8 WCC sub-group: Trends of growth factors over time across trauma groups. Error bars represent one 
standard deviation 
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Figure 5.3-9 Relationship between matched WCC and PDGF-AA levels. Weak positive correlations were observed across 
all trauma groups  
 
Analysis of the molecule PDGF-AA with WCC values (Figure 5.3-9) showed a positive correlation 
between these 2 parameters, albeit a weak one. Regression analysis revealed R-values ranging 
between +0.10 to +0.27. This weak association was fairly consistent across all trauma groups, with 
visual examination of the graphs revealing PDGF-AA values from Isolated Trauma to be least 
associated with WCC among all 3 groups. 
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Figure 5.3-10 Relationship between matched WCC and Angiogenin levels. No association was observed between 
matched  WCC and angiogenin values 
 
 
Regression analysis of angiogenin with WCC (Figure 5.3-10) showed even weaker associations 
compared to PDGF-AA, with R-values consistently nearing zero (range +0.02 to 0.18). This is not 
surprising, given the relatively muted dynamics of angiogenin levels over time (Figure 5.3-8). 
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Figure 5.3-11 Relationship between matched WCC and Follistatin levels. No correlations were observed between 
matched WCC and follistatin levels.. 
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Figure 5.3-12 Inverse relationship between matched WCC and Follistatin levels. Weak inverse relationship observed with 
Head Injury and Isolated Trauma groups only.   
 
 
Simple linear regression analysis between follistatin and WCC (Figure 5.3-11) showed little 
associations (R values between -0.28 and +0.04). However, visual inspections of the scattergrams 
(Figure 5.3-11) hinted at a possible inverse relationship. Therefore, the values were further analysed 
for an inverse relationship (Figure 5.3-12).  Interestingly, only the Head Injury and Isolated Trauma 
group revealed a possible inverse relationship between WCC and Follistatin levels, with R values of 
over 0.30 for both groups (and p<0.05 for both groups). Overall, the inverse associations remain 
relatively weak although better than direct linear relationships. 
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Figure 5.3-13 Relationship between matched WCC and TGF-β2 levels. No associations were found between WCC and 
TGF-β2. 
 
 
Finally, similar to analysis of association with CRP above, TGF-β2 (Figure 5.3-6) was overall weakly 
associated with WCC levels. This is weakest in the Head Injury group (R=-0.06, p=0.61). 
In summary, the 4 growth factors measured showed little associations with patient’s matched total 
WCC levels. Table 10.2-2 illustrates the statistical results of regression analysis for all growth factors, 
across trauma groups against matched WCC values. 
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Platelets 
Finally, time-matched data for platelet as measured in the patient’s routine hospital laboratory were 
analysed against the growth factors. The sub-group of patients who had time matched samples were 
identical to the ones in the WCC sub-group (Table 5.3-2). Therefore, the summary trends over time 
across all trauma groups for the growth factors measured for this sub-group would also be identical 
to the WCC sub-group (Figure 5.3-8). 
As can be seen in Figure 5.3-14, levels of platelet progressively rose over time following trauma, with 
levels up to 4-fold higher (Polytrauma group) by day 14 post trauma. This rise was consistent across 
all trauma groups. 
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Figure 5.3-14 Mean Platelet values over time across trauma groups. Normal platelet values range 150-400X10
9
/L.  Error 
bars represent one standard deviation 
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Figure 5.3-15 Relationship between matched Platelets and PDGF-AA levels. Statistically significant association (p<0.01) 
found between matched samples of platelets and PDGF-AA across all trauma groups.  
 
 
As can be seen in Figure 5.3-15, PDGF-AA was significantly (p<0.01) correlated with time matched 
platelets values. This was independent of trauma type/severity, as can been seen by the statistically 
significant association seen when data from all groups were combined.  
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Figure 5.3-16 Relationship between matched Platelets and Angiogenin levels. Weak correlation found between matched 
platelet and angiogenin levels for the Isolated Trauma Group only. 
 
 
However, similar to previous analyses with CRP and WCC, angiogenin was only weakly associated 
with platelet levels Figure 5.3-16). The strongest association was exhibited by the Isolated Trauma 
group (R=+0.38, p=0.03). In contrast, although both severe trauma groups (Head Injury and 
Polytrauma) showed a negative association, this was weak (R values -0.06 and -0.11 respectively) 
and likely to represent an absence of correlations. 
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Figure 5.3-17 Relationship between matched Platelets and Follistatin levels. Weak negative correlation found between 
matched samples of platelet and follistatin in the Head Injury Group only.  
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Figure 5.3-18 Inverse relationship between matched Platelets and Follistatin levels. Value for follistatin underwent 
inverse transformation. Statistically significant relationship found between platelet and inverse follistatin levels in the 
Head Injury group only. 
 
 
Analysis of a linear relationship between follistatin and platelet (Figure 5.3-17) revealed relatively 
weak negative correlations across all trauma groups. However, similar to analyses with WCC, visual 
inspection of again hinted at a possible inverse relationship, especially in the Head Injury group. An 
inverse relationship analysis (Figure 5.3-18) showed an improved but still weak relationship within 
patients from the Head Injury group (R=+0.52, p<0.01), with the Polytrauma group exhibiting slightly 
weaker association (+0.14, p=0.27) and the Isolated Trauma group the weakest (R=+0.04, p=0.81). 
However, it appeared overall that follistatin is more likely to be inversely related to platelet levels as 
seen by the overall improvement in R and p-values on regression analysis. 
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Figure 5.3-19 Relationship between matched Platelets and TGF-β2 levels. No correlation found between matched levels 
of platelets and TGF-β2. 
 
Finally, regression analysis between TGF-β2 and platelet did not reveal any association, with R values 
weakly positive (range +0.03 to +0.15). This association appeared consistent with previous 
association analysis with CRP and WCC. In summary, PDGF-AA was strongly correlated with platelet 
levels independent of trauma types or severity, and follistatin was inversely correlated with platelet, 
especially in the Head Injury group of patients. Table 10.2-3 summarises statistical findings following 
regression analysis across all trauma groups against platelets.  
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5.3.2. Comparison against early complications (SIRS score) 
So far, the relationship between the dynamics of growth factor release and inflammatory response 
has been explored with regards to levels of different parameters associated with inflammatory 
response (Section 5.3.1 and 5.3.2) as measured from the peripheral blood. Overall, this did not 
support the hypothesis that growth factor release was further upregulated by increasing 
inflammatory response following trauma. 
 To further analyse this hypothesis, an investigation was carried out on the patients’ clinical response 
(degree of inflammatory response) following trauma. The Systemic Inflammatory Response 
Syndrome (SIRS) score was used as it represents a measure for a hyper-inflammatory clinical state, 
and have been predictive of poor outcome such as mortality(1992). 
Data representing SIRS score for every matched time point to growth factor measurement were 
available for 12 Head Injury patients (Table 10.2-4), 14 Polytrauma patients (Table 10.2-5) and 11 
Isolated Trauma patients (Table 10.2-6). 
For the purpose of analysis, patients were divided into those that had a SIRS score 2 or more at any 
point during the observed period (herein called the SIRS group), and those that did not (herein called 
the No SIRS group).  
Based on these criteria therefore, 8 out of 12 Head Injury patients, 10 out of 14 Polytrauma patients 
and 3 out of 11 Isolated Trauma patients would be considered to have developed a clinically 
significant inflammatory response to their injury.   The differences in proportion of patients who 
developed early SIRS between all groups failed to reach statistical significance (chi-square test, Table 
5.3-3).  
 
Table 5.3-3 Comparison of proportion of patients with SIRS within first 24 hours of admission  
Trauma Groups p-value 
Head Injury versus Polytrauma 0.79 
Head Injury versus Isolated Trauma 0.14 
Polytrauma versus Isolated Trauma 0.07 
chi-square test, p<0.05 is statistically significant 
 
In addition, analyses were separated according to trauma groups for each growth factor, to allow for 
any observed effect to be due to development of clinical SIRS only, and not the types or number of 
injuries that the patients sustained. 
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PDGF-AA 
Within the Head Injury group, patients who developed SIRS appeared to have a more suppressed 
level of PDGF-AA over time, reaching a statistically significant (p=0.03) difference compared non-SIRS 
patients by Day 14 post injury (Figure 5.3-20). A similar pattern of suppression is observed in 
patients from the Isolated Trauma group. However, the presence of SIRS appears to exert the 
opposite effect on patients from the Polytrauma group. The differences observed in both the 
Polytrauma and Isolated trauma group failed to reach statistical significance across all time points 
(Mann-Whitney, Table 10.2-7). 
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Figure 5.3-20 Comparison of PDGF-AA values between patients who developed SIRs to those who did not. Statistically 
significant differences were found on day 14 in the Head Injury group between SIRS and no SIRS group of patients. 
*denotes statistical significance at p<0.05 
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Angiogenin 
Overall, there were no statistically significant differences (p>0.05) in angiogenin levels across all time 
points and all 3 trauma groups (Mann-Whitney, Table 10.2-8). There were no clear patterns of 
influence by the additional presence of SIRS on the dynamics of angiogenin over time (Figure 
5.3-21). 
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Figure 5.3-21 Comparison of Angiogenin values between patient who developed SIRs to those who did not. No 
significant differences were found.  *denotes statistical significance at p<0.05 
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Follistatin 
The presence of SIRS appears to have a stimulatory effect on levels of follistatin over time within 
patients from the Polytrauma group, with the higher levels reaching statistical significance (p<0.01) 
on Day 1 post trauma (Figure 5.3-22). The influence on patients from Head Injury and Isolated 
Trauma is less pronounced. Within the Head Injury group, presence of SIRS appear to have an initial 
stimulatory effect on the first 48 hours following trauma and a later stimulatory effect on patients 
from the Isolated Trauma group from Day 5 onwards. However, these observed differences failed to 
reach statistical significance (Mann-Whitney, Table 10.2-9). 
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Figure 5.3-22 Comparison of Follistatin values between patient who developed SIRs to those who did not. Statistically 
significant difference was found on day 1 values within Polytrauma Group between those with SIRs compared to No 
SIRs. *denotes statistical significance at p<0.05 
TGF-β2 
Analysis of the effect of SIRS on levels of TGF-β2 was complicated by the high inter-individual 
variability, which has been previously discussed. Patients with SIRS from the Isolated Trauma group 
appeared to have an overall higher level compared to those who did not develop SIRS. However, 
both the Head Injury and Polytrauma group of patients do not exhibit any clear influence from the 
presence of SIRS on their TGF-β2 levels. None of the observed differences reached statistical 
significance (Mann-Whitney, Table 10.2-10). 
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Figure 5.3-23 Comparison of TGF-β2 values between patient who developed SIRs to those who did not. No statistically 
significant difference found across all trauma group and time invervals. *denotes statistical significance at p<0.05 
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5.3.3. Comparison against late complications (delayed union, re-
operation) 
 
Following discharge from in-patient care, patients who were followed up in Leeds General Infirmary 
fracture clinic had their fracture healing outcomes recorded. This included the rate of fracture 
healing as well as requirement for revision surgery relating to the fracture.  
In total, fracture healing data were available on 4 patients from the Head Injury Group, 11 patients 
from the Polytrauma Group, and 10 patients from the Isolated Trauma Group. One patient (BP8) 
from the Isolated Trauma group was excluded from this analysis as he was recruited to a clinical drug 
trial (potentially affecting bone metabolism) following discharge from the unit.  
The purpose of this analysis was to ascertain whether the early growth factor dynamics (first 14 days 
post trauma) affected the fracture healing process (problem healers). As can be seen in Table 
10.2-11, patients who experienced complications with their fracture healing process sustained either 
tibia or ulna fractures. To allow a comparative normal healing population, therefore, only patients 
who sustained long bone diaphyseal fractures (femur, tibia) formed the “control” or normal healing 
population. 
6 patients were considered problem healers (BP4, BP15, BP18, BP3, BP7, BP13) whilst 14 patients 
made up the normal healing population (BH9, BH17, BP6, BP12, BP20, BP27, BP9, BP8, BP10, BP11, 
BP14, BP23, BP22, BP24). The median time to heal in the problem healer group was 42 weeks (range 
28-84), whereas the median time to heal in the normal healer group was 12 weeks (range 7-20). This 
difference was statistically significant (p<0.01, Mann-Whitney). 
The dynamics of both PDGF-AA and angiogenin did not show any difference between the problem 
and normal healing groups. Both groups and molecules exhibited similar trends of rise and fall in 
values over time (Figure 5.3-24). This commonality was confirmed with all the comparative analysis 
between the two healing groups failing to reach statistical significance for both PDGF-AA and 
angiogenin (Table 10.2-12). 
Earlier analysis of general trends of follistatin showed an initial upregulation, with levels dropping 
over time from trauma. Interestingly, when values were analysed to differentiate the dynamics 
between problem and normal healers, a clear pattern of upregulation from trauma admission levels, 
sustained over the observed 2 week period, in the problem healing group. In fact, the median levels 
of follistatin in the normal healing group dropped nearly 25% from the first 24 hours to day 3 post 
trauma, whereas the problem healing group’s follistatin level rose nearly 2-fold in the same time 
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period. This difference of median levels at Day 3 post trauma between both groups were statistically 
significant (p=0.03, Mann-Whitney). 
And finally, the molecule TGF-β2 in analysis thus far has always presented difficulty due to its high 
inter-individual variability. However, despite this issue, when patients were sub-analysed based on 
their healing outcome, a clear pattern of difference emerged. Patients from the problem healing 
group showed a clear suppression of levels of TGF-β2 compared to the normal healing group. This 
difference was significantly different on Days 1 and 3 post trauma (p<0.05, Mann-Whitney). 
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Figure 5.3-24 Comparative analysis of growth factor dynamics between patients with normal healing (n=14) versus 
delayed healing (n=6). Statistically significant depression of TGF-β2 levels were observed in patients who developed 
delayed healing compared to normal healing group.  *denotes statistically significant difference at p<0.05 
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5.4. Discussion 
 
5.4.1. Overview 
In this chapter, I have attempted to further study the correlations between trauma severity and 
dynamics of growth factor release.  The relationship between trauma severities as determined by 
the Injury Severity Score has already been discussed in the previous chapter. As trauma is known to 
elicit an inflammatory response, the correlations between growth factors and parameters from 
routine hospital blood tests known to be reflective of inflammation (C-reactive protein, total white 
cell count, platelets) were studied. Then, the patients’ acute or early response to trauma, as 
measured by the Systemic Inflammatory Response Syndrome (SIRS) criteria was studied in 
correlation with growth factors. Finally, the relationship between the early dynamics of growth 
factors and fracture healing outcome was analysed. 
To allow discussion and synopsis of the analyses, the growth factors are discussed in turn, bringing 
together all the laboratory and clinical elements  
      
5.4.2. Comparison against hospital blood parameters 
 
C-reactive protein (CRP) 
Overall, levels of C-reactive protein were statistically significant both between trauma groups and 
over time (p<0.0001, 2-way ANOVA). It is unsurprising that Polytrauma and Head Injury groups 
exhibited the highest levels, given the known relationship between CRP and degree of inflammatory 
response (Black, Kushner et al. 2004).  
 
Total white cell count 
In contrast, the levels of total white cell count over time exhibited fewer degrees of changes. 
Although there was still significant difference over time (p<0.0001), the differences between groups 
failed to reach statistical significance (p=0.19, 2-way ANOVA). All groups showed highest levels on 
admission, reflecting the early role that leucocytes play following an acute injury or trauma. 
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Platelets 
Generally, platelet levels were higher in Isolated Trauma groups (p<0.0001) compared to Polytrauma 
and Head Injury groups. This probably reflects a higher degree of consumption, blood loss or 
intravenous fluid dilution inherent in patients with more severe trauma. All groups showed an initial 
drop, before rising over time. This trend is in agreement with current literature(Akca, Haji-Michael et 
al. 2002).  However, by the second week, the significant rise (p=0.02, 2-way ANOVA) was observed in 
levels of platelet in Polytrauma and Head Injury groups reflecting a higher degree of reactive 
thrombocytosis in these more severely injured groups (Figure 5.3-14). 
 
5.4.3. Validity of SIRS parameter 
The criteria for SIRS were used to reflect the systemic inflammatory response of a patient. These 
were set out based on the seminal work by Bone et al, which shows that patient who fits the criteria 
for SIRS on the first day of admission to intensive care unit has significantly higher risk of 
mortality(1992). Elevation of total white cell (leukocytosis) reflects the degree of release of pro-
inflammatory cytokines (Keel and Trentz 2005). Conversely, cellular apoptosis could lead to a drop in 
total white cell (leukopenia) (Keel and Trentz 2005).  
An increase in core temperature or fever is due to the presence of mediators called endogenous 
pyrogens. These include pro-inflammatory cytokines such as interleukin-1 (IL-1), tumour necrosis 
factor alpha (TNF-α), interleukin-6 (IL-6) and interferon gamma (IFN-γ). These cytokines induce the 
production of prostaglandins in the central nervous system, leading to fever. Although the 
mechanism for hypothermia (<36°C) in SIRS remains unclear, the presence of hypothermia in unwell 
patients (intensive care unit) is associated with a significantly higher risk of mortality (Clemmer, 
Fisher et al. 1992). Murine models of SIRS showed that hypothermia was associated with 
significantly higher levels of IL-6, reflecting a more severe inflammatory response(Remick and Xioa 
2006).  
As previously discussed local inflammatory response lead to vasodilatation and increased tissue 
permeability. This causes a drop in blood pressure and a compensatory rise in heart rate to maintain 
cardiac output(Foex 1999).  
And finally, the release of inflammatory mediators may cause endothelial lung injury, resulting in 
pulmonary oedema. This is then accompanied by a worsening ventilation perfusion mis-match and 
resultant hypoxaemia. The body compensates by increasing its respiratory rate, which is also 
reflected by a drop in arterial levels of carbon dioxide (metabolic alkalosis) (Bernard, Artigas et al. 
1994).  
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Individually, these parameters may not necessarily represent the onset of SIRS. For example, a 
patient admitted acutely following trauma may present with a raised heart and respiratory rate, 
secondary to pain. Even Professor Bone in his consensus paper cautioned that these guidelines need 
to be assessed in relation to the overall clinical presentations (1992). However, in the context of 
trauma and this study, these criteria taken collectively are a simple and quick way to detect unwell 
patients, and to represent patients with a heightened inflammatory response. 
 
5.4.4. Platelet derived growth factor (PDGF)-AA 
PDGF-AA showed a statistically significant (p<0.01) direct correlation with platelet count. This was 
independent of trauma severity and type. In fact, 5 of the patients within this analysed cohort 
received platelet transfusions during the period of analysis. This implies that the correlation 
between PDGF-AA with platelet is independent of whether the source of platelet is endogenous or 
transfused.  
PDGF-AA was only weakly correlated with CRP levels and total WCC. The relationship between PDGF-
AA and CRP is probably mediated through the cytokine interleukin-6. A positive correlation was 
found between IL-6 and PDGF-AB (and not –AA) levels in synovial fluid of rheumatoid arthritis 
patients, but neither affected the growth rate of murine fibroblastic cell lines (Monier, Reme et al. 
1994). Although a negative correlation between PDGF-AA and IL-6 levels (both plasma and serum) 
was found in this study, this was not statistically significant. Additionally, when patients were divided 
based on their clinical presence of SIRS, no differences were found in the levels of PDGF-AA in the 
first week following trauma. 
Overall, this implies circulating platelet as a source of PDGF-AA in peripheral circulation, a level 
which is not influenced by trauma severity. 
 
5.4.5. Angiogenin 
Overall, the dynamics of angiogenin in the first two weeks following trauma have been rather muted 
across all trauma groups. The positive correlations found when compared against matched serum 
levels of IL-6, agrees with a previous study which found that IL-6 directly increases angiogenin 
protein and mRNA expressions in a murine model (Verselis, Olson et al. 1999).  Therefore, the 
general lack of associations in Head Injury and Polytrauma group, and the negative association in 
Isolated Trauma between angiogenin and CRP was a surprising finding. This was further confirmed 
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when angiogenin levels were also not influenced by the additional presence of SIRS in these cohort 
of patients. 
 
5.4.6. Follistatin 
Follistatin is involved following trauma, through its complex relationship with Activin A and the 
inflammatory cytokines (See Figure 5.4-1).  Therefore, the positive correlations between CRP and 
follistatin levels observed in this study would agree with this relationship. This is in agreement with 
reported literature on septic patients, where follistatin, activin and CRP levels paralleled each other 
(Michel, Ebert et al. 2003). Additionally, the strong positive correlations between serum IL-6 and 
follistatin observed in my study further confirms this relationship, given that CRP production is 
directly stimulated by IL-6 (Kushner, Jiang et al. 1995). 
The lack of relationship with white cell count is in agreement with published literature (Michel, Ebert 
et al. 2003). Interestingly, despite its association with CRP levels, overall the additional presence of 
SIRS failed to show any statistically significant difference in follistatin levels. The lack of relationship 
with WCC (which is a parameter for SIRS diagnosis) may have contributed to this lack of difference.  
 
 
Figure 5.4-1 The interrelationships between activin A, follistatin and the proinflammatory cytokines, IL-1 and IL-6 (From 
Kretser 1999) (de Kretser, Hedger et al. 1999). 
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5.4.7. Transforming growth factor (TGF)-β2 
Generally, levels of TGF-β2 failed to show any associations with all the measured parameters (CRP, 
WCC, platelets). When the patient cohorts were divided based on the presence of SIRS, this did not 
show any statistically significant differences, probably due to the high inter-individual variability 
previously discussed.  
 
5.4.8. Late complications following trauma (non-union, revision 
surgery) 
Two of the molecules (follistatin, TGF-β2) showed very interesting dynamics when patients were 
divided based on whether they had normal or problem with their fracture healing. 
Patients with normal healing profile showed decreasing trends in follistatin levels, from admission 
level above healthy control, dropping significantly (p<0.05) by the third day post trauma. However, 
patients in the “problem” healing cohort were observed to exhibit the reverse trend. Not only were 
the admission levels lower than the healing cohort, this group then showed a rising trend, reaching 
statistical significance by Day 3 post trauma. A previous work by Dimitriou et al (Dimitriou, Carr et al. 
2011), showed that genetic polymorphism for the noggin gene (an inhibitory molecule) was 
significantly associated with risk of fracture non-union. The authors postulated whether these 
patients with noggin polymorphism may exhibit higher levels of noggin following fracture, and hence 
affecting the fracture healing process. Similarly, in this study, the abnormal rise in follistatin level 
following trauma may either imply an abnormality in the fracture healing process, or these patients 
may be similarly genetically predisposed to possess a different follistatin expression following 
trauma. 
Patients with “problem” healing showed a clear suppression in levels of TGF-β2 across all time 
points. This was despite the high inter-individual variability exhibited in the levels of this particular 
growth factor. A previous study showed a statistically significant decline in TGF-β1 at Week 4 
occurring in patients with delayed healing (Zimmermann, Henle et al. 2005), implying the major role 
played by the TGF-β isoforms in the fracture healing process. This was further supported by another 
genetic polymorphism study confirming the association of TGF-β codon 10 mutant T and T/C allele to 
predispose to impairment of fracture healing (Szczesny, Olszewski et al. 2011).  
In conclusion, the levels of PDGF-AA were reflected and influenced by levels of platelets only. 
Angiogenin did not show any association with both measured biochemical parameters (WCC, CRP, 
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platelets) and clinical parameters (SIRS) of inflammatory response. Finally, early dynamics of 
follistatin and TGF-β2 may potentially be indicative of fracture healing outcome. 
 
 
5.4.9. Limitations 
This study was limited by the availability of matched hospital laboratory results to the measured 
time points for growth factor analysis. The hospital laboratory tests were carried out based on 
clinical needs. 
Following discharge from hospital, some patients were lost to follow up, mostly due to them being 
followed up in other hospitals. A few patients unfortunately also died prior to their healing status 
being confirmed. 
The exact time to fracture healing is almost impossible to determine, unless patients are followed up 
every day up to the point of fracture healing. However, most fractures would be expected to heal by 
six months, and together with the additional criteria of revision surgery requirement, the decisions 
to decide on the cohort of “problem” healing patients would be considered reasonably robust. 
However, the need to allow a more uniform patient cohort in terms of fracture type, led to analysis 
of patients in both groups presenting with long bone fractures only. This resulted in a lower number 
of patients to be analysed. 
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6. RESULTS:  Mesenchymal Stem Cell (MSC) and Trauma 
6.1. Introduction 
 
MSCs are multipotent cells capable of differentiating and giving rise to diverse cells such as 
osteoblasts, chrondrocytes, and adipocytes (Bianco, Cao et al. 2013). They were first identified from 
BM as colony-forming unit-fibroblasts (CFU-Fs) by Friedenstein (Friedenstein, Gorskaja et al. 1976). 
Since then, MSCs have been found in the stroma of spleen, thymus (Friedenstein, Gorskaja et al. 
1976), trabecular bone (Tuli, Seghatoleslami et al. 2003), cartilage, synovium, periosteum (De Bari, 
Dell'Accio et al. 2008), adipose tissues (Zhu, Liu et al. 2009), arterial walls (Abedin, Tintut et al. 2004), 
as well as umbilical cord (Erices, Conget et al. 2000) and fetal circulation (Campagnoli, Roberts et al. 
2001). However, it is generally accepted that osteogenic potential and by inference bone repair is 
best from MSCs obtained from tissue of osseous origin (De Bari, Dell'Accio et al. 2008).  
 
6.1.1. Definition and enumeration of MSCs 
The International Society of Cellular Therapy (Dominici, Le Blanc et al. 2006) defines MSCs by three 
main characteristics:  
• adherence to plastic in standard culture conditions 
• expression of a set of molecules (CD105, CD73, CD90) with absence of other markers (CD45, 
CD34, CD14/CD11b, CD79α/CD19, HLA-DR) 
• in vitro differentiation into osteoblasts, adipocytes, chondroblasts (demonstrated by staining 
of differentiation cultures) (Pittenger, Mackay et al. 1999; Bianchi, Muraglia et al. 2001). 
The ability of MSCs to adhere to plastic and proliferate has been exploited in the colony forming unit 
fibroblast (CFU-F) assay. Briefly, the culture of BM cells either as direct from aspirate (Galotto, 
Berisso et al. 1999) or separated by differential gradient centrifugation first (Castro-Malaspina, Gay 
et al. 1980) has been shown to produce proliferating colonies of fibroblasts. Each colony has been 
shown to originate from a single colony-forming cell or CFU-F (Castro-Malaspina, Gay et al. 1980) 
and to have an osteogenic potential (D'Ippolito, Schiller et al. 1999). Normally, MSCs are 
enumerated based on this assay and counted as CFU-Fs. 
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6.1.2. MSCs in peripheral circulation 
Various sources of MSCs have been previously discussed. However, of considerable interest is the 
issue of the presence of MSCs in peripheral circulation. Fibroblast-like cells with osteogenic and 
adipogenic potential, resembling MSCs has been isolated in animal and human peripheral blood 
(Kuznetsov, Mankani et al. 2001) but in very low numbers. Similar experiments have found a small 
population of CD34-negative mononuclear cells with MSC-like features (Zvaifler, Marinova-
Mutafchieva et al. 2000) with significantly higher amounts seen in peripheral circulation of burn 
victims(Mansilla, Marin et al. 2006) or following muscular tissue damage (Ramirez, Lucia et al. 2006). 
However, it must be pointed out that a physiologically relevant pool of circulating MSCs as possible 
vehicles aimed at fracture repair is extremely contentious. Application of rigorous phenotypic and 
functional criteria has failed to show evidence for such a population in healthy donors(Jones and 
McGonagle 2008). 
 
6.1.3. MSCs and trauma 
Traditionally, the frequency of these MSCs in the iliac crest bone marrow (ICBM) aspirates is 
believed to be as low as 30 in a million mononuclear cells (Cuthbert, Boxall et al. 2012). However, 
recently the Leeds MSC Group (Jones, English et al. 2010) have shown that cells with MSC colony-
forming capacity and the surface phenotype are abundant in the trabecular bone niche and 
incorporated into a three-dimensional network composed of stromal reticular cells and intracellular 
matrix. Matrix-bound MSCs are however, not released during normal marrow aspiration but can be 
readily procured using enzymatic release techniques. 
Given the known inflammatory response and growth factor release following trauma, it could be 
speculated that these post-traumatic molecular responses may lead to mobilisation of MSCs from 
their in vivo niches into peripheral circulation.  
Although Seebach (Seebach, Henrich et al. 2007) reported a significant difference in ICBM MSC CFU-
F numbers between “multiple trauma” and “monofracture” patients, the timing of sample 
acquisition was unclear and therefore could have influenced their findings. As growth factor in 
circulation has been shown to be dynamic, it is possible that MSC numbers at different timings 
following trauma are also dynamic. My study sampled both the bone marrow and peripheral blood 
at the same time points, and also correlated with levels of growth factors measured at these same 
time points. 
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6.2. Methods 
6.2.1. Patient Recruitment 
Patients were recruited for bone marrow MSC response investigation. Approval from local ethics 
committee (Leeds West REC 06/Q1206/127) was obtained prior to commencement, with all patients 
providing informed written consent. 
To address the role of trauma severity on the MSC dynamics in iliac crest bone marrow and in 
peripheral circulation, patients recruited into the MSC study were divided into 2 groups, Polytrauma 
(ISS≥16) and Isolated Trauma (ISS<16).  
 
6.2.2. Sampling time points 
Patient ICBM samples can only be obtained when the patient undergoes surgery, as clinically clean 
and sterile conditions are required during bone marrow aspiration. In addition, due to the expected 
high inter-individual variations in MSC CFU-F count (Castro-Malaspina, Gay et al. 1980), in order to 
study the effect of trauma over time on ICBM MSC numbers, at least 2 sampling time points were 
required, with the first sampling time point (on admission, within 24 hours of injury) acting as 
baseline value for the individual patients. Hence, for the purpose of recruitment, all patients within 
the MSC study had to have injuries requiring surgery on admission, followed by another surgery a 
few days later. 
  
6.2.3. Sample acquisition 
Iliac crest bone marrow (ICBM) aspirates were collected on every episode that the patient was in 
theatre for their operative treatments. Under sterile conditions, ICBM was aspirated from the 
anterior iliac crest using a trocar (11 Gauge 5” Bevel Tip Match-Ground Introduction Needle, Stryker 
306-111) and a 20ml syringe. The trocar/syringe setup was pre-flushed with heparinised saline. 
Samples obtained were immediately transferred to 5ml EDTA-containing tubes (Vacutainer® BD) to 
prevent clotting and gently agitated prior to transfer to tissue-culture facility. For each episode of 
ICBM collection, prior to start of the patient’s operative procedure 20ml of peripheral blood (PB) 
was obtained and collected in 5ml EDTA-containing tubes. 
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6.2.4. CFU-F assay using ICBM – Direct plating 
The assay was performed as described previously by Galotto (Galotto, Berisso et al. 1999). Both 
ICBM and PB samples were used for direct plating. Nucleated cell count (NCC) enumeration was 
performed using 3% acetic acid. The counting procedure is described in section 6.2.7. ICBM samples 
were then seeded volumetrically (300μL per 10-cm diameter Petri dish, in triplicate) in 10ml of 
attachment media (DMEM/10% FCS/Pen-Strep) and incubated at 37°C, 5% CO2 for 48 hours. Non-
adherent cells were then washed off with two 10-ml PBS washes and adherent cells were allowed to 
grow in non-haemopoietic (NH) Media (Miltenyi Biotec) with twice-weekly half-media changes, for 
14 days. On day 14, all media was gently removed from dish, and adherent cells were gently washed 
with 2 ml PBS. Adherent cells were fixed with 2ml of 3.7% formaldehyde (Fischer Scientific) at RT for 
15 minutes. Following removal of formaldehyde, colonies were stained with 2mL 1% Crystal violet 
(BD Lab) for 2 minutes, washed and air dried. Scoring was performed macroscopically and colony 
counts over triplicates were calculated to give an average CFU-F score per sample.  
 
6.2.5. CFU-F assay using ICBM – MNC plating 
Direct plating is a simple method for the evaluation of CFU-F/ml in a given BM sample but it has 
potential disadvantages including an occasional formation of clots in which CFU-Fs can be trapped 
(noticed previously in our laboratory) as well as potential interference from red cells that could 
inhibit MSC attachment. Hence in this study a parallel evaluation of CFU-F content of ICBM samples 
was performed based on the isolation and plating of 3X106 mononuclear cells (MNCs) (Castro-
Malaspina, Gay et al. 1980) with subsequent calculations of CFU-Fs/ml performed using to the 
following formula:  
CFU-F/ml = CFU-F/106 MNCs x MNCs/ml  
To perform this assay, sample volumes were first measured prior to 1:1 dilution with PBS. Up to 
20mL of diluted samples were then carefully layered onto 20mL of Lymphoprep (Axis-Shield) and 
underwent centrifugation at 650g at brake rate 0, room temperature (RT) for 25 minutes, to isolate 
the MNC fraction. The MNC fraction (the interphase) was then collected using a Pasteur pipette, 
placed into a fresh 50ml Falcon tube and 10ml of PBS was next added to perform washes aimed to 
remove the residual Lymphoprep. Cells were washed by centrifugation at 400g at brake rate 9, RT 
for 5 minutes, after which the Lymphoprep/PBS mixture was removed by decanting, leaving the 
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MNC pellet intact. The pellet was broken by gentle tapping and re-suspended in appropriate volume 
of PBS (2-10ml), depending on the size of the pellet. 
MNC count was next performed using trypan blue exclusion. Counting was performed as described 
in Section 6.2.7. The MNCs were then seeded in triplicate 10-cm diameter Petri dishes in 10ml of 
attachment media (3x106 MNC/dish) and incubated at 37°C, 5% CO2 for 48 hours. Non-adherent cells 
were removed with two 10-ml PBS washes and adherent cells were allowed to grow in NH Media 
with twice-weekly half-media changes, for 14 days, after which CFU-F staining and enumeration was 
performed as described above (Section 6.2.7). 
 
6.2.6. CFU-F assay using PB – Direct and MNC plating 
Methods described above for Direct and MNC plating of ICBM were similarly applied to PB obtained 
at the same time as ICBM sampling. 20ml of PB was obtained from antecubital vein of the patient 
and collected in 5ml EDTA-containing vacutainer tubes. The seeding density for Direct plating is 
similar, volumetrically at 300µL per dish in duplicate. The seeding density for MNC plating is 
however, higher at 1x107 MNC/dish in duplicate, as circulating MSCs are exceptionally rare in man 
(Kuznetsov, Mankani et al. 2001) and therefore a higher seeding density would allow the detection 
(as CFU-F colonies) of such a rare population.  
 
6.2.7. Cell counting 
NCC was performed to identify the density of nucleated cells in PB and ICBM sample. As the cell 
suspension contains red blood cells, 3% acetic acid was initially used to lyse red blood cells. MNC 
counts were performed using trypan blue. The purpose of trypan blue is to distinguish non-viable 
cells (which would absorb the dye) and live cells. For counting 10μL of diluted cell suspension is 
pipetted onto the haemocytometer chamber. The haemocytometer was first prepared by 
positioning the moist cover slip onto the haemocytometer and ensured to be properly fitted by the 
presence of Newton’s rings. The number of viable cells would then be counted over 1mm2 grid 
(Figure 6.2-1) under a light microscope. The number of cells per ml of sample would then be 
calculated with the formula: MNC or NCC/ml= number of viable cells in 1mm2 grid X dilution X 104. 
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Figure 6.2-1 Schematic of a hemocytometer counting grid. The grid measures 3 mm on each side and is divided into nine 
large squares (From Fey 2007) (Fey, Kowal et al. 2007) 
 
6.2.8. CFU-F assay – Surface area 
The resultant CFU-F colony sizes vary within the same plates, and therefore, larger colony sizes, 
although still considered a single colony, may represent a higher proliferative (growth) potential of 
the MSC in culture. For this, dishes were scanned using an Epson 3590 digital scanner and digital 
images were analyzed using NIS elements BR 2.20 imaging software (Nikon, Tokyo, Japan), giving a 
readout of total colony area per dish. This would then allow the calculation of average surface area 
per colony to be made. 
 
6.2.9. Statistics 
Statistical analysis was carried out using PASW Statistics (SPSS) version 17.0.2 and graphing 
performed using Graph Pad Prism version 4.00 for Windows (San Diego, California, USA). As 
Gaussian distribution could not be assumed given the small sample size, non-parametric tests were 
carried out. Mann-Whitney test was used to compare differences between two independent 
samples, in cases of three or more groups. Wilcoxon signed-rank test was used to compare two 
dependent samples (same patient, two different time points). Chi-square test was used for 
comparison of nominal data (for example comparing sex distribution between groups). Coefficient of 
variation was used to assess the variability of results. Statistical significance is assumed at p<0.05. 
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6.3. Results 
6.3.1. Patient Recruitment 
In total, 17 patients were recruited into the Polytrauma group (Table 6.3-1) and 8 patients were 
recruited into the Isolated Trauma group (Table 6.3-2). In addition, 3 healthy control patients (Table 
6.3-3), undergoing elective pelvic surgery were recruited. 
 
Table 6.3-1 MSC Study: Polytrauma patients (n=17) 
PATIENT 
ID 
SEX 
AGE 
(years) 
ISS 
NCC/ML (10
6
) OF 
ICBM SAMPLE ON 
ADMISSION** 
MNC/ML (10
6
) OF 
ICBM SAMPLE ON 
ADMISSION** 
SAMPLING 
TIME POINTS 
(days)*** 
BT001 M 27 25 n/a 16.7 0, 5 
BT005 F 25 27 20.7 18.7 0, 1, 21 
BT010* M 21 50 18.0 11.4 0, 2, 22 
BT015 M 50 24 18.0 9.0 0, 2 
BT016 M 21 24 23.7 2.2 0, 4, 25 
BT017 F 45 38 19.6 7.4 0, 32 
BT018 M 54 24 19.4 5.9 0, 5 
BT019 F 40 34 20 16 0, 15 
BT020* M 41 29 19.9 20.4 0, 2 
BT021 M 27 27 18.9 7.8 0, 4, 12 
BT025 M 37 22 20 14.35 0, 2, 4 
BT027* M 49 34 18.2 6.6 0, 5 
BT028 M 44 22 19.2 10.1 0, 2, 5 
BT029* M 22 34 13 7.2 0, 3 
BT031 F 23 27 26.5 16.7 0, 3, 11 
BT033 M 49 25 20.0 7.5 0, 2, 8 
BT034 M 44 24 48.4 20.3 0, 8, 12 
 13M/4F 
Median 
40 
Range 
21-54 
Median 
27 
Range 
22-50 
Median 19.8 
Range 13-48.4 
Median 10.1 
Range 2.2-20.4 
 
*denotes presence of head injury 
**Method for the assessment of NCC/ml and MNC/ml is described in Section 6.2.7 
***As addressed further in Section 6.2.2 
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Table 6.3-2 MSC Study: Isolated Trauma patients (n=8) 
PATIENT 
ID 
SEX 
AGE 
(years) 
ISS 
NCC/ML (10
6
) OF 
ICBM SAMPLE ON 
ADMISSION* 
MNC/ML (10
6
) OF 
ICBM SAMPLE ON 
ADMISSION* 
SAMPLING TIME 
POINTS (days)** 
BT004 M 33 9 n/a 22.2 0, 2, 16 
BT006 M 54 9 8.7 15.6 0, 3 
BT007 M 21 4 20.0 14.2 0, 3 
BT008 M 64 4 14.7 9.5 0, 8 
BT009 M 22 8 18.5 10.6 0, 12, 16 
BT011 M 45 4 22.2 14.0 0, 9 
BT013 M 51 4 14.1 17.1 0, 3 
BT014 F 33 9 21.1 14.2 0, 7 
 7M/1F 
Median 
39 
Range 
21-64 
Median 
6 
Range 
4-9 
Median 18.5 
Range 8.7-22.2 
Median 14.2 
Range 9.5-22.2 
 
*Method for the assessment of NCC/ml and MNC/ml is described in Section 6.2.7 
**As addressed further in Section 6.2.2 
 
Table 6.3-3 MSC Study: Healthy Control (Non-trauma) patients (n=3) 
PATIENT 
ID 
SEX AGE 
NCC/ML (10
6
) OF ICBM SAMPLE 
ON ADMISSION* 
MNC/ML (10
6
) OF ICBM SAMPLE 
ON ADMISSION* 
BT023 F 52 17.8 8.4 
BT024 F 19 16 12.3 
BT026 M 40 20 3.5 
 1M/2F 
Median 40 
Range 19-52 
Median 17.8 
Range 16-20 
Median 8.4 
Range 3.5-12.3 
*Method for the assessment of NCC/ml and MNC/ml is described in Section 6.2.7 
 
Within both the Polytrauma and Isolated Trauma group, as seen in Table 6.3-1 and Table 6.3-2, there 
was a male dominance, similar to the findings in the Growth Factor Study. Both trauma groups were 
matched in terms of age (p=0.50, Mann-Whitney) and sex ratio (p=1.00, chi-square).  
Although there were more females in the Healthy Control group, this difference did not reach 
statistical significance when compared with both the Polytrauma Group (p=0.20, chi-square) and 
Isolated Trauma Group (p=0.15, chi-square). Similarly, there were no statistically significant 
differences in age between the Healthy Control and Polytrauma (p=0.92, Mann-Whitney) and 
Isolated Trauma (p=0.68, Mann-Whitney) patients.  
The median NCC/ml in both the Polytrauma and Isolated Trauma groups were similar (p=0.37, 
Mann-Whitney. Similarly, the MNC/ml counts between Polytrauma and Simple trauma group did not 
show a significant difference (p=0.22, Mann-Whitney). 
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6.3.2. Validation of CFU-F assay 
The CFU-F assay is a long (2 weeks in duration) functional assay, which was performed in triplicates. 
Intra-donor variation was first assessed to evaluate the coefficient of variations (CV) between the 
triplicates (Table 6.3-4 and Table 6.3-5). CV is defined as the ratio of the standard deviation (SD) to 
the mean, which is then multiplied by 100 to allow expression as a percentage.  
 
Table 6.3-4 CFU-F assay validation using MNC Plating (n= 28 patients) 
GROUP PT ID CFU-F (1)* CFU-F (2)* CFU-F (3)* MEAN SD CV (%) 
P
O
LY
TR
A
U
M
A
 
BT001 14 10 12 12.0 2.0 16.7 
BT005 1 2 2 1.7 0.6 34.6 
BT010 19 17 16 17.3 1.5 8.8 
BT015 17 22 18 19.0 2.6 13.9 
BT016 22 16 20 19.3 3.1 15.8 
BT017 13 12 10 11.7 1.5 13.1 
BT018 64 45 52 53.7 9.6 17.9 
BT019 198 190 150 179.3 25.7 14.3 
BT020 80 66 56 67.3 12.1 17.9 
BT021 102 96 102 100.0 3.5 3.5 
BT025 73 50 69 64.0 12.3 19.2 
BT027 27 33 37 32.3 5.0 15.6 
BT028 18 18 25 20.3 4.0 19.9 
BT029 16 10 8 11.3 4.2 36.7 
BT031 26 28 27 27.0 1.0 3.7 
BT033 14 21 20 18.3 3.8 20.7 
BT034 41 42 12 31.7 17.0 53.8 
IS
O
LA
TE
D
 T
R
A
U
M
A
 BT004 26 26 26 26.0 0.0 0.0 
BT006 0 0 1 0.3 0.6 173.2 
BT007 51 50 55 52.0 2.6 5.1 
BT008 56 35 33 41.3 12.7 30.8 
BT009 50 53 43 48.7 5.1 10.5 
BT011 16 20 15 17.0 2.6 15.6 
BT013 2 5 3 3.3 1.5 45.8 
BT014 49 54 60 54.3 5.5 10.1 
CONTROL 
BT023 56 47 47 50.0 5.2 10.4 
BT024 39 41 51 43.7 6.4 14.7 
BT026 25 29 30 28.0 2.6 9.4 
     MEAN CV (%) 23.3 
*Results are shown as colonies/dish 
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Table 6.3-5 CFU-F assay validation using Direct Plating (n= 25 patients) 
GROUP PT ID CFU-F (1)* CFU-F (2)* CFU-F (3)* MEAN SD CV (%) 
P
O
LY
TR
A
U
M
A
 
BT010 44 34 43 40.3 5.5 13.7 
BT015 14 17 19 16.7 2.5 15.1 
BT016 63 52 58 57.7 5.5 9.6 
BT017 10 12 15 12.3 2.5 20.4 
BT018 37 54 62 51.0 12.8 25.0 
BT019 145 175 234 184.7 45.3 24.5 
BT020 138 149 134 140.3 7.8 5.5 
BT021 78 75 104 85.7 15.9 18.6 
BT025 135 126 134 131.7 4.9 3.7 
BT027 43 36 47 42.0 5.6 13.3 
BT028 42 49 53 48.0 5.6 11.6 
BT029 14 13 16 14.3 1.5 10.7 
BT031 65 67 61 64.3 3.1 4.7 
BT033 34 28 39 33.7 5.5 16.4 
BT034 41 42 43 42.0 1.0 2.4 
IS
O
LA
TE
D
 
TR
A
U
M
A
 
BT006 0 2 2 1.3 1.2 86.6 
BT007 140 142 139 140.3 1.5 1.1 
BT008 60 67 60 62.3 4.0 6.5 
BT009 69 53 71 64.3 9.9 15.3 
BT011 54 56 52 54.0 2.0 3.7 
BT013 1 3 2 2.0 1.0 50.0 
BT014 57 38 47 47.3 9.5 20.1 
CONTROL 
BT023 134 117 52 101.0 43.3 42.8 
BT024 18 11 9 12.7 4.7 37.3 
BT026 36 48 38 40.7 6.4 15.8 
      MEAN CV (%) 19.0 
*Results are shown as colonies/dish 
The average mean CVs of 23.3% (MNC plating) and 19% (Direct plating) were comparable with the 
data obtained by others in the laboratory and deemed acceptable for the evaluation of differences 
in CFU-Fs between different time-points following injury in the same patient. Highest CVs were 
observed for the patients with lowest numbers of colonies/dish, as expected (BT006, BT013, BT005). 
Direct plating appeared to be slightly less variable, with lower CVs (19%) compared to MNC plating 
(23.3%). But these differences were small and not statistically significant (p=0.52, Mann-Whitney), 
indicating that both direct plating and MNC plating techniques were equally acceptable for the 
purpose of this study. 
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6.3.3. Validation of CFU-F colony area 
To account for the observations that the sizes of CFU-F colonies differ in size and thus may reflect 
different cellular proliferative potential in culture, the CFU-F colonies were calculated for total 
stained area per dish. Coefficient of variations was calculated to investigate intra-donor differences 
in terms of stained colony area per dish for both MNC (Table 6.3-6) and Direct (Table 6.3-7) plating 
methods. 
 
Table 6.3-6 CFU-F total area validation using MNC Plating (n=27 patients) 
GROUP PT ID Area (1)* Area (2)* Area (3)* MEAN SD CV (%) 
P
O
LY
TR
A
U
M
A
 
BT001 0.23 0.22 0.22 0.22 0.01 2.59 
BT005 2.13 1.86 1.57 1.85 0.28 15.11 
BT010 5.87 3.93 4.46 4.75 1.00 21.09 
BT015 13.33 11.31 12.41 12.35 1.01 8.19 
BT016 8.54 14.43 8.61 10.53 3.38 32.11 
BT017 14.56 14.56 12.35 13.82 1.28 9.23 
BT018 19.48 13.79 11.13 14.80 4.27 28.82 
BT019 63.32 60.57 63.73 62.54 1.72 2.75 
BT020 8.90 10.81 7.79 9.17 1.53 16.66 
BT021 36.00 32.73 36.38 35.04 2.01 5.73 
BT025 3.73 4.83 6.14 4.90 1.21 24.62 
BT027 3.78 4.23 1.45 3.15 1.49 47.32 
BT028 33.61 32.97 24.64 30.41 5.00 16.46 
BT029 37.78 14.41 22.63 24.94 11.86 47.53 
BT031 28.12 33.09 21.28 27.50 5.93 21.56 
BT033 42.33 47.91 43.54 44.59 2.94 6.58 
BT034 24.17 18.19 20.11 20.82 3.05 14.66 
IS
O
LA
TE
D
 
TR
A
U
M
A
 
BT004 8.72 12.90 9.18 10.27 2.29 22.33 
BT007 3.64 3.27 3.21 3.37 0.23 6.90 
BT008 14.65 19.98 23.29 19.31 4.36 22.58 
BT009 7.85 12.09 14.21 11.38 3.24 28.45 
BT011 7.19 6.09 6.30 6.53 0.58 8.95 
BT013 5.78 6.31 6.05 6.05 0.27 4.38 
BT014 22.58 30.38 20.93 24.63 5.05 20.49 
CONTROL 
BT023 5.05 4.76 6.39 5.40 0.87 16.10 
BT024 1.31 1.02 0.97 1.10 0.18 16.69 
BT026 2.87 3.67 3.57 3.37 0.44 12.93 
     MEAN CV (%) 17.81 
*Results are shown as total colony area per dish (cm2) 
 
  
Page 111 
 
Table 6.3-7 CFU-F total area validation using Direct Plating (n=25 patients) 
GROUP PT ID CFU-F (1)* CFU-F (2)* CFU-F (3)* MEAN SD CV (%) 
P
O
LY
TR
A
U
M
A
 
BT010 21.95 16.34 25.61 21.30 4.67 21.92 
BT015 9.17 11.03 9.28 9.83 1.04 10.62 
BT016 8.54 14.43 8.61 10.53 3.38 32.11 
BT017 8.40 7.43 6.99 7.61 0.72 9.48 
BT018 24.00 21.82 30.73 25.52 4.64 18.20 
BT019 59.83 65.09 70.22 65.05 5.20 7.99 
BT020 45.69 48.47 43.72 45.96 2.39 5.19 
BT021 27.06 40.14 28.61 31.94 7.15 22.38 
BT025 44.98 52.06 44.77 47.27 4.15 8.78 
BT027 5.02 2.54 4.32 3.96 1.28 32.29 
BT028 62.98 57.45 65.33 61.92 4.05 6.53 
BT029 7.88 6.44 6.75 7.02 0.76 10.79 
BT031 17.86 18.72 14.72 17.10 2.11 12.31 
BT033 24.18 46.91 28.85 33.31 12.00 36.03 
BT034 17.55 11.78 13.28 14.20 2.99 21.08 
IS
O
LA
TE
D
 
TR
A
U
M
A
 
BT006 3.99 3.34 4.22 3.85 0.46 11.85 
BT007 64.53 70.26 64.31 66.37 3.37 5.08 
BT008 39.28 33.54 29.93 34.25 4.72 13.77 
BT009 12.50 43.73 46.10 34.11 18.75 54.98 
BT011 18.46 16.00 15.89 16.78 1.45 8.66 
BT013 0.19 0.19 0.26 0.21 0.04 18.94 
BT014 12.53 16.79 13.27 14.20 2.28 16.03 
CONTROL 
BT023 2.36 3.88 6.92 4.39 2.32 52.93 
BT024 26.84 4.46 - 15.65 15.83 101.12 
BT026 6.83 6.77 5.77 6.46 0.60 9.22 
      MEAN CV (%) 21.93 
*Results are shown as total colony area per dish (cm2) 
In the assay of total colony area per dish, the mean CV of 17% (MNC Plating) and 22% (Direct Plating) 
were comparable with the analysis for CV of CFU-F assays. This method may provide additional 
insight into not just colony (MSC) numbers, but its proliferative potential. 
 
6.3.4. Relationship between CFU-F MNC and Direct plating Methods 
As stated above ICBM aspirates obtained were plated to both the MNC and Direct method. Matched 
samples were analysed for relationship between both MNC and Direct methods. 
Analysis of the relationship between matched samples showed statistically significant (p<0.05) 
correlations between CFU-F values of MNC and Direct Plating methods when data were normalized 
to CFU-F per ml of ICBM. As can be seen in Figure 6.3-1, this was independent of trauma severity 
(both Polytrauma and Isolated Trauma groups were significantly associated). The weak relationship 
observed in the Control group may be due to sampling error, as only 3 time points (patients) were 
available. 
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Figure 6.3-1 Relationship between CFU-F MNC and Direct Plating Methods. Matched samples were statistically 
correlated between MNC and Direct methods across both trauma groups. Data was expressed in logarithmic scales, and 
statistically significant correlations was found across both Polytrauma and Isolated Trauma 
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However, this relationship was not similarly seen when the samples were analysed in terms of CFU-F 
Area. Samples were normalized to average surface area per colony for this analysis (Table 10.3-1).  
 As can be seen in Figure 6.3-2, there were no correlations between the average CFU-F colony size 
between MNC and Direct plating methods. 
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Figure 6.3-2  Relationship of average CFU-F colony size between MNC and Direct Plating Methods. There were no 
correlations between matched samples across all trauma groups.  
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However, within the same method, when the relationships between the number of CFU-F colonies 
and CFU-F surface area were analysed, they showed overall significant (p<0.05) associations 
independent of trauma severity (Polytrauma and Isolated Trauma). This was true for both the MNC 
(Figure 6.3-3) and Direct (Figure 6.3-4) Plating methods. 
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Figure 6.3-3 Relationship between CFU-F Count and Area per Dish using MNC Method. Matched samples were 
statistically correlated between CFU-F and area per dish. Data was expressed in logarithmic scales, and statistically 
significant correlations was found across both Polytrauma and Isolated Trauma. 
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Figure 6.3-4 Relationship between CFU-F Count and Area per dish by Direct Plating Method. Matched samples were 
statistically correlated between CFU-F and area per dish. Data was expressed in logarithmic scales, and statistically 
significant correlations was found across both Polytrauma and Isolated Trauma. 
 
Finally, the relationship over time between CFU-F count, CFU-F area and average colony size within 
the same patient were explored. Representative examples were chosen from patients recruited from 
the Polytrauma Group (Figure 6.3-5) and Isolated Trauma Group (Figure 6.3-6). In both examples 
(BT019 and BT009), across both MNC and Direct plating methods, it was observed that the CFU-F 
count per dish and total CFU-F area changes proportionate to each other. This was not surprising, as 
more colonies would result in more total surface area. However, when compared with average 
colony size, the changes are less variable and did not change proportionately to colony count 
changes. This implied that the rate of proliferation (average colony size) was independent of MSC 
concentration (in ICBM) and most likely was intrinsically determined from the patient himself. 
Taken together, these findings implied that both total surface areas per dish could be used as a 
surrogate of CFU-F colony numbers. However, given the findings of unequal average colony sizes 
between both MNC and Direct plating methods (as shown in Figure 6.3-2) this method (total surface 
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areas per dish) is unlikely to be accurate enough to reflect changes in the number of MSCs in ICBM 
over time. Therefore, to address the hypothesis of systemic upregulation of MSCs over time 
following trauma, analyses will be carried out with the CFU-F count method only. 
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Figure 6.3-5 Representative figure from Polytrauma Group (BT019) showing relationship between CFU-F count, CFU-F 
area and average colony size over time (Day 0 and Day 16). Top row represents data from MNC Plating and bottom row 
represents data from Direct plating methods respectively 
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Figure 6.3-6 Representative figure from Polytrauma Group (BT009) showing relationship between CFU-F count, CFU-F 
area and average colony size over time (Days 0, 12, and 16). Top row represents data from MNC Plating and bottom row 
represents data from Direct plating methods respectively 
 
6.3.5. Dynamics of CFU-F over time 
As previously shown in Section 6.3.2, there is high inter-individual variability in baseline ICBM CFU-F 
count. This was further confirmed by the 3 Healthy Control donors CFU-F counts for both the MNC 
(range 33-180) and Direct (range 42-333) Plating Methods. Therefore, to further investigate the 
effect of trauma on MSC ICBM dynamics, all patients were analysed based on their CFU-F changes 
from baseline (Day 0) to the next time points of BM aspiration. 
As can be seen in Figure 6.3-7, within the Isolated Trauma group of patients, half the patients 
(BT006, BT008, BT009, BT013) showed a rising trend in CFU-F count from admission levels. The other 
half within the group (BT004, BT007, BT011, BT014) showed either a falling trend or minimal 
changes from baseline. For the 4 patients with rising CFU-F levels, the change in CFUF/ml from first 
time point to second ranged between 1.2 to 10-fold (median 4.6) with the MNC plating technique, 
and between 1.4 to 18-fold increase (median 2.8) for the Direct plating technique. Within the sub-
group that showed decreasing CFU-F/ml levels, the changes ranged between 15% to 89% (median 
45%) with the MNC plating technique and between 59 to 80% (median 70%) with the Direct plating 
technique. Trends (either increasing or decreasing) were similar with both plating techniques. Taking 
into account intra-patient CVs of between 21 and 28%, any changes around 1.3 fold could be purely 
due to technical limitations. 
Page 118 
 
Similarly, Figure 6.3-8 and Figure 6.3-9 showed the changes in CFU-F/ml in Polytrauma sub-group of 
patients displaying an increasing trend over time, whereas Figure 6.3-10 shows the changes in CFU-
F/ml in the Polytrauma sub-group of patients displaying either a decreasing or minimal changes from 
baseline over time.  
Within the rising sub-group, the maximum increase observed was 40-fold (BT016) with the MNC 
plating technique and 15-fold (BT017) with the Direct plating technique. The maximum decrease 
seen in MNC plating was 31% of Day0 value (BT015) and 90% for Direct plating (BT019). There was 
less agreement between the two different techniques in this group, as patient BT015 showed a 
decreasing trend (0.3-fold) in MNC plating, and increasing trend in direct plating (1.4-fold). However, 
taking into consideration the intra-patient variability shown in Sections 0 and 6.2.5, decreasing 
trends observed within this sub-group could be caused simply by technical limitations.  
Overall, these data indicated that Polytrauma groups of patients appeared to show more 
pronounced changes in CFU-F dynamics compared to the Isolated Trauma groups. It is noteworthy, 
that patients showing more pronounced increasing trends had lower baseline (Day 0) CFU-F counts 
compared to patients with a decreasing trend, which was observed for both Simple Trauma and 
Polytrauma groups. 
 
CFU-F in Peripheral Blood 
All the PB samples plated for CFU-F with both MNC and Direct plating failed to reveal any colonies. A 
total of 100 [n=25 patients, plated with two techniques (MNC and Direct), in duplicates] dishes were 
set-up in total. Representative dishes are shown in the next section. 
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Figure 6.3-7 CFU-F/ml changes over time in Isolated Trauma Group of patients. MNC refers to MNC plating technique, 
Direct refers to Direct plating technique. Samples are mean of dishes plated in triplicates. Section with gap (y=0) implies 
no colonies were found. 
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Figure 6.3-8 CFU-F/ml changes over time in Polytrauma Trauma Group of patients (Rising Trend Sub-group 1). MNC 
refers to MNC plating technique, Direct refers to Direct plating technique. Samples are mean of dishes plated in 
triplicates. Section with gap (y=0) implies no colonies were found. 
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Figure 6.3-9 CFU-F/ml changes over time in Polytrauma Trauma Group of patients (Rising Trend Sub-group 2). MNC 
refers to MNC plating technique, Direct refers to Direct plating technique. Samples are mean of dishes plated in 
triplicates. Section with gap (y=0) implies no colonies were found.  
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Figure 6.3-10 CFU-F/ml changes over time in Polytrauma Trauma Group of patients (Falling Trends). MNC refers to MNC 
plating technique, Direct refers to Direct plating technique. Samples are mean of dishes plated in triplicates. Section 
with gap (y=0) implies no colonies were found. 
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Representative dishes in the Isolated Trauma (Figure 6.3-11) and Polytrauma (Figure 6.3-12) groups 
are shown. 
 
Figure 6.3-11 Patient 1 (BT009) (top) samples taken on Day0 (admission) and days 12 and 16 post-injury. Patient 2 
(BT008) (bottom) sample taken on Day0 (admission) and day 8 post-injury. For BM sample, there is progressive increase 
in CFU-F count over time. No CFU-F colonies were found in PB samples 
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Figure 6.3-12 Patient 3 (BT010) (top) samples taken on Day0 (admission) and days 2 and 25 post-injury. Patient 4 (BT018) 
(bottom) sample taken on Day0 (admission) and day 5 post-injury. For BM sample, there is progressive increase in CFU-F 
count over time. No CFU-F colonies were found in PB samples 
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BM4 
PB4 
Day 5 
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6.3.6. CFU-F dynamics and clinical course 
It is evident from the previous analyses that the MSC numbers in BM aspirate, as measured by the 
CFU-F assays, do not show any differences in trends between trauma groups, and within trauma 
groups no single trend was observed. It is likely that the dynamic changes in CFU-F over time 
observed in this study are secondary to other stimulus apart from trauma severity. 
Within the trauma group, the immediate post-traumatic (first 2 weeks) sequelae may differ between 
patients. As discussed in the previous chapter, following trauma some patients develop 
complications, such as the Systemic Inflammatory Response Syndrome (SIRS). Given the known 
cytokine storm that accompanies SIRS (Yiu, Graham et al. 2012), it is possible that the MSC CFU-F 
dynamics are influenced by the presence of SIRS. 
Patients recruited into the MSC study were analysed for presence of SIRS, based on established 
criteria of core temperature, respiratory rate, heart rate and total white cell counts (1992). Further 
details regarding SIRS have already been discussed in the previous chapter. Data for determination 
of SIRS were available on 16 Polytrauma patients (Table 6.3-8) and 7 Isolated Trauma Patients (Table 
6.3-9). 
Overall, within the first 2 weeks following trauma, 11 out of 16 patients within the Polytrauma 
Group developed a SIRS score of 2 or more. In contrast, only 2 out of 8 patients within the Isolated 
Trauma Group developed SIRS, a difference which nearly reached statistical significance (p=0.08, 
Chi-square test).  
When analysed against CFU-F trends, within the Polytrauma Group, 6 patients with SIRS had a falling 
trend, compared to 5 rising. Two patients without SIRS had a falling trend and 3 showed a rising. 
Against our expectation, the CFU-F dynamics in the Polytrauma group was not determined by 
presence of SIRS (p=1.00, Chi-square test). 
Within the Isolated Trauma group, half of patients with SIRS had a rising trend, and half of patients 
without SIRS had a falling trend, and therefore similar to the Polytrauma group, the CFU-F dynamics 
was not determined by presence of SIRS (p=1.00, Chi-square test). 
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Table 6.3-8 SIRS Score in first 14 days post trauma in Polytrauma Group (n=16) 
SIRS? Patient ID Admission Day 1 Day 3 Day 5 Day 7 Day 14 
Yes BT001 2 0 0 2 3 2 
Yes BT005 1 0 1 3 2 2 
No BT010 1 0 1 1 1 1 
Yes BT015 2 1 0 0 0 
 
Yes BT016 0 1 0 0 3 2 
Yes BT017 2 1 1 1 
  
No BT018 1 0 0 0 1 1 
Yes BT019 2 1 0 3 2 1 
Yes BT020 2 0 0 0 3 1 
No BT021 1 1 0 0 0 
 
Yes BT025 2 1 0 0 
  
Yes BT027 2 0 1 2 2 
 
Yes BT029 1 1 0 1 2  
Yes BT031 1 1 3 3 3 2 
No BT033 1 0 0 0 0  
No BT034 1 0 1 0 0 0 
 
 
Table 6.3-9 SIRS Score in first 14 days post trauma in Isolated Trauma Group (n=8) 
SIRS? Patient ID Admission Day 1 Day 3 Day 5 Day 7 Day 14 
Yes BT004 0 1 0 2 1 1 
No BT006 1 0 0 0 0 
 Yes BT008 2 1 0 0 0 1 
No BT009 0 0 0 0 0 0 
No BT011 0 0 0 0 0 0 
No BT013 1 0 0 0 0 
 
No BT014 1 0 0 0 0 
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Table 6.3-10 Correlation between presence of SIRS and CFU-F Trends in Polytrauma Patients 
Patient ID SIRS? CFU-F Trends* 
BT001 Yes Declining 
BT005 Yes Rising 
BT010 No Rising 
BT015 Yes Declining 
BT016 Yes Rising 
BT017 Yes Rising 
BT018 No Rising 
BT019 Yes Declining 
BT020 Yes Declining 
BT021 No Declining 
BT025 Yes Rising 
BT027 Yes Rising 
BT029 Yes Declining 
BT031 Yes Declining 
BT033 No Declining 
BT034 No Rising 
*Trends were based on both MNC and Direct Plating 
 
Table 6.3-11 Correlation between presence of SIRS and CFU-F trends in Isolated Trauma Patients 
Patient ID SIRS? CFU-F Trends* 
BT004 Yes Declining 
BT006 No Rising 
BT008 Yes Rising 
BT009 No Rising 
BT011 No Declining 
BT013 No Rising 
BT014 No Declining 
*Trends were based on both MNC and Direct Plating 
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Finally, similar to analysis carried out with Growth Factor dynamics, the relationship between CFU-F 
trends and fracture healing outcome was explored. Data regarding fracture healing was available on 
13 patients from the Polytrauma Group and 7 patients from the Isolated Trauma Group (Table 
6.3-12). There were 3 patients who had delayed or non-union of their fractures, in both the 
Polytrauma and Isolated Trauma Groups respectively. 
Within the Polytrauma Group, when the fracture healing status was analysed against CFU-F trends, 2 
of the “problem healers” had declining trends, with the remaining patient showing a rising trend. 
Normal healers from the Polytrauma Group had 6 rising and 4 declining CFU-F trends. Overall, early 
trends in CFU-F were not significantly associated with fracture healing outcome in this group 
(p=0.56, chi-square test). 
Similar analysis within the Isolated Trauma group revealed 2 rising and 1 declining in the “problem 
healers” and half rising and half declining in the normal healers. Again, the CFU-F trends were not 
correlated with fracture healing outcome in this group (p=1.00, chi-square test). 
  
Table 6.3-12 Correlation between Fracture Healing Status and CFU-F Trends 
GROUP Patient ID Fracture location Healing status CFU-F Trends* 
P
O
LY
TR
A
U
M
A
 
BT001 Pelvic Normal Declining 
BT005 Femur Normal Rising 
BT010 Femur Normal Rising 
BT015 Ulna Non-union Declining 
BT016 Pelvic Normal Rising 
BT017 Ulna Non-union Rising 
BT018 Pelvic  Normal Rising 
BT019 Femur Normal Declining 
BT021 Tibia Normal Declining 
BT028 Femur Normal Rising 
BT029 Tibia Delayed union Declining 
BT033 Elbow Normal Declining 
BT034 Ankle Normal Rising 
IS
O
LA
TE
D
 T
R
A
U
M
A
 BT004 Tibia Delayed union Declining 
BT006 Tibia Delayed union Rising 
BT008 Tibia Normal Rising 
BT009 Ankle Normal Rising 
BT011 Tibia Normal Declining 
BT013 Tibia Non-union Rising 
BT014 Tibia Normal Declining 
*Trends were based on both MNC and Direct Plating,  
** Healing status: Delayed healing (>6 months), Non-union (Requiring surgical re-interventions) 
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6.4. Discussion 
6.4.1. Review of culture technique used 
In this section, I analysed the effect of trauma severity on MSC numbers in ICBM and their changes 
over time. I used several validated techniques (Castro-Malaspina, Gay et al. 1980; Galotto, Berisso et 
al. 1999) for these investigations (CFU-F) assay and evaluated their utility for the purpose of this 
investigation. The CFU-F count in healthy adults using the Direct plating technique can vary from 50 
to 2300 CFU-F/ml (Galotto, Berisso et al. 1999; Cox, McGonagle et al. 2011) whereas using the MNC 
plating technique, colonies counts were affected by seeding density (Castro-Malaspina, Gay et al. 
1980; Van Landuyt, Jones et al. 2010). All the CFU-F data in this study were on average within the 
published reference range (Van Landuyt, Jones et al. 2010; Cox, Boxall et al. 2011). 
 
6.4.2. Review of bone marrow aspiration technique 
It has been previously reported in our laboratory that the method of BM aspiration may affect CFU-F 
MSC count (Cuthbert, Boxall et al. 2012). The volume of bone marrow aspirate affects the cellular 
content obtained (Batinic, Marusic et al. 1990; Muschler, Boehm et al. 1997). In fact, the Leeds MSC 
Group recently showed that the first 5ml of ICBM aspiration volume had far higher density of 
MSC/CFU-F compared to the next 15ml combined (Cuthbert, Boxall et al. 2012). All patients 
recruited into this CFU-F study underwent their bone marrow aspiration by me. For all patient 
sampling time points, I consistently used the same technique in terms of surgeon (myself only), 
aspirate location (anterior iliac crest), tools (Stryker 306-111, 11-gauge, bevel tipped trocar), volume 
of aspirate (20ml) and draw method (single draw to fill full 20ml syringe). With measures taken, it is 
likely that the CFU-F dynamics observed are genuine rather than due to inadvertent inconsistencies 
during bone marrow aspiration.  
 
6.4.3. Relationship between CFU-F Count and CFU-F Area 
I then attempted to analyse the issue of CFU-F colony sizes. Each CFU-F colony represents a progeny 
of single MSC, which proliferates forming a typical fibroblast concentric pattern (Castro-Malaspina, 
Gay et al. 1980). Therefore, the bigger the colony size, the higher the rate of division and 
proliferation, given the fixed time (14 days) between seeding and staining. Although both MNC and 
Direct plating methods showed associations between CFU-F count and total surface area per dish 
(See Figure 6.3-3 and Figure 6.3-4), the variability in average colony areas, and the variability in 
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colony sizes per dish implies that the CFU-F total area method cannot directly replace CFU-F count to 
assess MSC numbers arising from ICBM plating. 
   
6.4.4. Relationship between CFU-F MNC and Direct plating 
Iliac crest bone marrow aspirate obtained were plated using both the MNC and Direct methods. The 
Direct method’s potential advantage was that it better represented the original BM sample obtained 
and the volumetric based method was simpler and less likely to incur errors. However, this method 
meant that the presence of other cellular phenotypes in abundance such as red blood cells may 
cause an “overcrowding” of the dish in culture, resulting in failure of adherence of some MSC to the 
plate and hence failure to form CFU-F colonies. Furthermore, a fibrin layer occasionally forms within 
the first 24 hours of culture, which may lead “MSC losses” secondary to adherence to that layer 
instead of the plastic surface. Additionally, ICBM MSCs can also be trapped in clots (Centeno, Busse 
et al. 2008), which sometimes form on the dish following direct plating. 
On the other hand, MNC plating appealed as the culture method is based on cellular density seeding. 
Additionally, as by and large only the mononuclear cells remain during seeding, leading to a better 
availability of surface area for MSC adhesion. However, the CFU-F count has been shown to be 
inversely related to the seeding density (Veyrat-Masson, Boiret-Dupre et al. 2007), and therefore 
valid comparisons can only be made between samples with identical seeding densities. Additionally, 
the MNC method requires more processing and some MSCs are likely to be lost during the 
Lymphoprep separation process.  
To my best knowledge, this is the first study to assess the relationship between MNC (as described 
by Castro-Malaspina(Castro-Malaspina, Gay et al. 1980)) and Direct Plating Method (as described by 
Galotto (Galotto, Berisso et al. 1999)) for the assessment of MSC numbers in ICBM aspirate. 
 
6.4.5. Systemic stimulation of MSC by trauma and relationship with 
SIRS 
There were no clear trends on the effect of trauma over BM MSC over time. Interestingly, patients 
with higher baseline (Day 0) levels of MSCs appeared more likely to have a decreasing trend over 
time. Presence of Isolated Trauma appeared to upregulate MSC (CFU-F count) up to 18-fold over a 
period from 3 to 8 days post-trauma in some patients, but in others the CFU-F count dropped to a 
median of 45% Day 0 value over similar periods of time. Within the Polytrauma group, patients with 
increasing trend showed an increase up to 40-fold over a period from 4 to 32 days post injury. 
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Patients with a decreasing trend in the polytrauma group has relatively higher Day 0 CFU-F count 
(450-900 CFU-F/ml) compared to patients with an increasing trend (14-100), thus possibly reflecting 
an already upregulated MSC state in the former group.  
Although Seebach et al (Seebach, Henrich et al. 2007) reported a higher CFU-F ICBM MSC from their 
“Multiple trauma” cohort, their comparative “Monofracture” cohort all presented with pelvic 
fractures as well, despite using ISS≥16 as criteria for inclusion into their Multiple Trauma cohort. 
There are no other similar studies previously published. My study has shown that MSC in bone 
marrow is dynamic and changes over time following trauma, and therefore the timing of bone 
marrow aspirate may affect CFU-F MSC numbers. It remains unclear whether the time of sampling in 
Seebach’s work is consistent between both trauma groups. 
My study also failed to find any associations between MSC/CFU-F trends and the presence of SIRS. 
This in agreement with previously reported lack of associations between bone marrow CFU-F 
numbers and levels of the pro-inflammatory cytokine interleukin-6 as well as total white cell count in 
peripheral circulation (Seebach, Henrich et al. 2007).  
It is therefore likely, that the MSC dynamics may be influenced by cytokines, other than 
inflammatory ones, including anabolic growth factors such as platelet derived growth factor, 
epidermal growth factors and basic fibroblast growth factor(Short, Brouard et al. 2003). 
 
6.4.6. MSC in peripheral circulation 
No CFU-F colonies were isolated from all the peripheral blood samples obtained in this study. Animal 
models have previously found that MSCs are present in peripheral circulation (Kuznetsov, Mankani 
et al. 2001; Rochefort, Delorme et al. 2006), with ability to mobilise (Duan, Yang et al. 2006; Yoon, 
Park et al. 2010) and migrate to sites of injury from remote bone marrow cavity (Shirley, Marsh et al. 
2005). Similarly, human studies have suggested the presence of MSCs in peripheral circulation in 
healthy controls (Zvaifler, Marinova-Mutafchieva et al. 2000; Kuznetsov, Mankani et al. 2001; Khosla 
and Eghbali-Fatourechi 2006; Mansilla, Marin et al. 2006). However, criteria used by these authors 
do not fully conform to the criteria of MSCs as set out by the ISCT definition (Dominici, Le Blanc et al. 
2006). The use of a single cell surface marker alone (Zvaifler, Marinova-Mutafchieva et al. 2000; 
Khosla and Eghbali-Fatourechi 2006) , or properties of plastic adherence and osteogenecity without 
confirming the trilineage potentiality of these cells (Zvaifler, Marinova-Mutafchieva et al. 2000; 
Kuznetsov, Mankani et al. 2001) may be inadequately rigorous. By application of scrupulous 
functional and phenotypic standards, our group previously failed to prove the existence of MSC in 
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peripheral circulation despite having a total sample volume of over 500ml (multiple patients) (Jones 
and McGonagle 2008). 
Interestingly, a previous study found the presence of MSCs in peripheral circulation in about half 
their lower limb fracture patients (Alm, Koivu et al. 2010). However, all their positive samples were 
obtained soon after surgery. This differs from my study, where peripheral blood samples (for CFU-F) 
were obtained immediately prior to their surgery. The positive findings in Alm et al (Alm, Koivu et al. 
2010) could be due to physical release or translocation of MSCs during surgery (similar to fat 
embolus) rather than as a result of systemic mobilisation of MSCs following trauma. 
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6.4.7. Limitations 
In order to investigate the temporal dynamics of MSC following trauma, suitable patients need to 
have operative procedures at least twice during the same admission. Ideally, for the CFU-F study, all 
samples would be taken on fixed time points from injury, such as on admission and day 5 following 
trauma. However, ICBM samples can only be obtained when the patients go to theatre for their 
planned operative procedures. As most trauma cases require either one or no operative procedures, 
this very much limits the pool of suitable patients to recruit. In addition, identical time points for BM 
sample collection were very hard to obtain as timing for the patient’s operative procedures was 
dictated by clinical needs. This made comparison of data within the same group (Isolated trauma or 
Polytrauma) difficult as the BM samples were taken at different time points to each other. 
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7. RESULTS: Relationship between MSC and Growth factors 
dynamics following Trauma  
 
7.1. Introduction 
Thus far, this study has shown that within the same patient, following trauma, bone marrow MSC 
colony-forming unit fibroblast (CFU-F) numbers tend to dynamically change over time. Attempts to 
correlate these MSC changes to trauma severity and presence of acute complications (SIRS) did not 
reveal particularly strong relationships.  
As mentioned in previous chapters, following fracture, there is an inflammatory response locally, 
with aggregation of leucocytes and other inflammatory cell types (Bolander 1992). These trigger 
release of further cascades of growth factors and cytokines (Bolander 1992).   Some of these 
molecules “escape” into the peripheral circulation and get rapidly diluted explaining why some of 
these growth factors in peripheral circulation occur in areas distant from the fracture site 
(Zimmermann, Henle et al. 2005). 
This study has also shown that circulating levels of growth factors such as platelet derived growth 
factor-AA (PDGF-AA), angiogenin, follistatin and transforming growth factor beta 2 (TGF-β2) are 
affected by trauma severity/types. In turn, follistatin and TGF-β2 impact on the fracture healing 
outcome (delayed healing). As MSCs are precursors of osteoblasts (Justesen, Stenderup et al. 2002; 
Bielby, Jones et al. 2007; Chagastelles, Nardi et al. 2010), and therefore integral in the fracture 
healing process, it would be reasonable to infer that at least PDGF-AA and TGF-β2 could be 
responsible for the observed systemic bone marrow MSC changes following trauma.  
Some of the growth factor measured has already been shown to exhibit in vitro effects on MSCs. 
Although PDGF-BB has been reported to have both a proliferative and osteogenic stimulatory effect 
on MSC in in vitro culture (Pountos, Georgouli et al. 2010), other studies reported that stimulation of 
the PDGF β receptor site induces MSC proliferation (Kumar, Salimath et al. 2010) and may inhibit 
osteogenic differentiation (Tokunaga, Oya et al. 2008).  Co-culture of MSC with TGF-β in different 
concentrations upregulated the expression of several extracellular matrix proteins and promotes 
MSC proliferation (Zhao, Li et al. 2011). The effect of follistatin on MSCs has not previously been 
reported, although Activin A (which is inhibited by follistatin) was shown to play a pivotal role in 
osteogenic differentiation of MSCs (Djouad, Jackson et al. 2010) suggesting that follistatin may be 
inhibitory. It has been suggested that the initial inflammatory response on the fracture site creates 
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an avascular region (Bolander 1992), and therefore, angiogenin’s ability to improve MSC survival in 
hypoxic conditions (Liu, Bai et al. 2008) may be pivotal in the fracture healing process.  
Therefore, the aim of this chapter is study the influence that growth factors in peripheral circulation 
may exert on bone marrow MSCs. Given the previously documented influence that PDGF and TGF-β 
exerts on MSC, the relationship between PDGF-AA and TGF-β2 with MSC will be studied in more 
details. As this study did not explore the osteogenic potential of MSC (in relationship to follistatin) or 
hypoxic survivability (in relationship to angiogenin), detailed analysis for these 2 molecules will not 
be carried out. 
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7.2. Methods 
7.2.1. Patient Selection 
In order to further understand the changes in bone marrow MSC CFU-F over time, and whether 
these changes could be influenced by PDGF-AA, angiogenin, follistatin and TGF-β2 in peripheral 
circulation, a group of patients was chosen to participate in both the Growth Factor and MSC 
studies, allowing direct correlations to be made between cytokine release in peripheral blood 
(Growth Factor study) and MSC dynamics (MSC study). Patients were only included within this group 
if samples for both Growth Factor and MSC study were time-matched (in terms of time post injury). 
The characteristics of patients (n=15) participating in both Growth Factor and MSC Study are shown 
in Table 7.2-1.  
 
Table 7.2-1 Patients participating in both Growth Factor and MSC Study (n=15) 
 MSC ID Growth Factor ID Sex Age ISS 
IS
O
LA
TE
D
 T
R
A
U
M
A
 
BT006 BP7 M 53 9 
BT007 BP8 M 21 9 
BT008 BP9 M 63 9 
BT013 BP13 M 51 4 
BT014 BP14 F 32 9 
  4M/1F 
Median 51 
Range 21-63 
Median 9 
Range 4-9 
P
O
LY
TR
A
U
M
A
 
*BT005 BP6 F 25 27 
BT015 BP15 M 49 24 
*BT016 BP16 M 21 24 
BT017 BP18 F 45 38 
BT018 BP19 M 53 24 
BT019 BP20 F 41 34 
BT020 BH18 M 41 29 
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*BT021 BP27 M 28 27 
*BT025 BP31 M 38 27 
BT027 BH21 M 49 34 
  7M/3F 
Median 41 
Range 21-49 
Median 27 
Range 24-38 
*denotes patients with 3 matched time-points, all other patients have 2 matched time-points 
 
7.2.2. Growth Factor and MSC Assays 
Details of both the method for both Growth Factor and MSC assays have been previously described 
in Sections 4.2.4 and 6.2. Briefly, growth factors PDGF-AA, angiogenin, follistatin and TGF-β2 were 
analyzed using the ELISA method. MSC assays are carried out based on the CFU-F colony counts 
using both MNC and Direct Plating methods. 
Serum samples identical to those already measured for growth factors PDGF-AA, angiogenin, 
follistatin and TGF-β2, were additionally analyzed for levels of PDGF-BB. This was carried out with a 
commercially available kit from R&D Systems, employing the quantitative sandwich enzyme 
immunoassay technique, similarly to those measured for the other growth factors factors PDGF-AA, 
angiogenin, follistatin and TGF-β2.  
In brief, a monoclonal antibody specific for PDGF-BB has been pre-coated onto a micro plate. 
Standards or samples (pre-diluted 20 fold) were then pipetted into the wells where molecules of 
interest were bound by relevant immobilized antibodies, by incubating for 2 hours at room 
temperature. After washing away any unbound substances (4 washes), a further enzyme-linked 
polyclonal antibody specific for the study molecule (Conjugate) was then added to the well, and 
incubated a further 2 hours at room temperature. Following a further 4-wash cycle to remove any 
unbound antibody-Conjugate, a Colour reagent (Substrate solution) was then added to the wells and 
colour would then develop in proportion to the amount of study molecule bound. The colour 
development occurs at room temperature over 30 minutes before being stopped by adding 
sulphuric acid before the colour intensity is read by Plate Reader. The methods of using Plate 
Readers and interpretation of data have been previously described in Section 4.2.4.5. 
Given the high inter-individual variations in baseline (Day 0) values for both Growth Factors and MSC 
studies, subsequent analyses were carried out based on changes from baseline, with baseline values 
normalized to 100%, and all further time points represented as percentage change from baseline. 
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The differences in Growth Factor values between Polytrauma and Isolated Trauma patients have 
already been previously described in Section 4.3.4 and showed a more pronounced suppression of 
PDGF-AA and angiogenin and elevation of follistatin in the first 48 hours post injury within the 
Polytrauma group compared to Isolated Trauma. There was no clear difference in TGF-β2 dynamics 
between these two trauma groups. Therefore, the inter-individual differences between both trauma 
groups would have been taken into consideration, allowing for collation of data from all the patients 
within this cohort, to investigate the relationship between growth factor and MSC dynamics. In 
other words, for this section of analysis, patients in both trauma groups are analysed together. 
Finally, as previously discussed in Chapter 5, platelets are a potential source of growth factors, 
including PDGF-AA, PDGF-BB and TGF-β2. The statistically significant (p<0.01) relationship between 
circulating levels of PDGF-AA and platelet has already been previously shown (Section 5.3.1), 
whereas TGF-β2 did not exhibit a relationship with circulating platelet levels. Therefore, in addition 
to analysis of the relationship between the measured growth factors and MSC/CFU-F, further 
analysis was carried out to determine whether circulating platelets level influences MSC/CFU-F 
numbers. 
7.2.3. Statistics 
Statistical analysis was carried out using PASW Statistics (SPSS) version 17.0.2 and graphing 
performed using Graph Pad Prism version 4.00 for Windows (San Diego, California, USA). As 
Gaussian distribution could not be assumed given the small sample size, non-parametric tests were 
carried out. Spearman’s rank correlation coefficient was used to test relationship between two 
variables (for example correlations between changes in cytokine levels in circulation with changes in 
CFU-F counts). Statistical significance is assumed at p<0.05. 
 
  
Page 139 
 
7.3. Results 
In order to further understand the relationship between serum concentrations of the measured 
growth factors (PDGF-AA, follistatin, angiogenin and TGF-β2) and the bone marrow (BM) MSC/CFU-F 
dynamics, the growth factors were analysed against time matched BM MSC/CFU-F (both MNC and 
Direct Plating methods) (Figure 7.3-1).  
 
7.3.1. Relationship between Growth Factor and BM MSC 
As can be seen in Figure 7.3-1, no correlations were found between all the growth factors and CFU-F 
(Direct Method). However, when the growth factors were analysed against CFU-F (MNC Method), 
correlations were observed with 2 growth factors. Firstly, follistatin was negatively correlated (R=-
0.41, p=0.02) with CFU-F. Secondly, PDGF-AA showed a strong statistically significant positive 
correlation (R=+0.55, p<0.01). 
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Figure 7.3-1 Relationship between Growth Factor and CFU-F. Values for both CFU-F and growth factors are normalized to 
Day0=100 and then transformed by applying the logarithmic scale. There was a statistically significant relationship 
between time matched PDGF-AA levels and CFU-F count via MNC method. 
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7.3.2. Relationship between Platelets, PDGF-AA and BM MSC 
It has been observed that the amount of PDGF-AA isoform in peripheral circulation had the strongest 
systemic effect on bone marrow MSC (Figure 7.3-1). In order to further investigate the underlying 
causes of this relationship between PDGF-AA and bone marrow MSC, further investigations were 
carried out.  
Firstly, the positive relationship between circulating levels of PDGF-AA and platelets have already 
been previously shown (Section 5.3.1, implicating platelets as the source of PDGF-AA (reproduced 
here as Figure 7.3-2-A). This statistically significant relationship was maintained when analysed by 
data derived from the sub-group of patients participating in the Growth Factor/MSC-CFU-F analysis 
(Figure 7.3-2-B).  
However, platelets, as a source of cytokine storage, also release the PDGF-BB isoform and other 
growth factors such as TGF-β2 on activation (McNicol and Israels 2008). PDGF-BB isoform is one of 
the 3 common PDGF isoforms (the third one being –AB) and are able to bind to both the PDGF 
receptor-α and β types (Heidaran, Pierce et al. 1991).  The relationship between circulating levels of 
PDGF-BB and platelets (Figure 7.3-2-B) is less significant (R=+0.55) compared to the PDGF-
AA/platelets association (R=+0.68). However, an investigation of the relationship between both the –
AA and –BB isoforms (Figure 7.3-2-D) illustrated a statistically significant correlation (R=+0.61,  
p<0.05) between both isoforms. 
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Figure 7.3-2 Relationship between platelets, PDGF-AA and PDGF-BB. 
(A) Represents the relationship between matched time points for levels of platelets and PDGF-AA in peripheral 
circulation for all patients recruited in this study. (B) Represents the sub-group of 15 patients who have matched growth 
factor and CFU-F time points and hence represents the relationship between matched time points for levels of platelets 
and PDGF-AA in peripheral circulation in this sub-group. (C) Represents the relationship between matched time points 
between platelets and PDGF-BB in peripheral circulation in the same 15 patient cohort as in B. (D) represents the 
relationship between matched samples for levels of PDGF-AA and PDGF-BB in the same sub-group of patients as in B. 
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However, not only has the PDGF-BB isoform which have been shown to be most potent in in 
inducing collagen synthesis and alkaline phosphatase activity in osteoblastic cells of murine origin 
(Pfeilschifter, Krempien et al. 1992), it is also isoform which has been shown to affect MSC 
proliferation (Pountos, Georgouli et al. 2010). Therefore, given the relationship with PDGF-AA and 
platelets seen in Figure 7.3-2, the relationship between PDGF-BB and MSC/CFU-F were next 
investigated. 
As expected, given the relationships shown above, an investigation on the relationship between 
PDGF-BB and CFU-F (MNC Plating) (Figure 7.3-3) showed a similar positive correlation between these 
two parameters (R=+0.38, p=0.03). However, this relationship was weaker compared to PDGF-AA, 
implying that it may be the –AA isoform which was responsible for the observed relationships. The 
relationship between PDGF-BB and CFU-F (Direct Plating) remains similarly weak.  
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Figure 7.3-3 Relationship between PDGF-AA, PDGF-BB and CFU-F. Values for CFU-F, PDGF-AA and –BB are normalized to 
Day0=100 and then transformed by applying the logarithmic scale. There was a statistically significant correlation 
between PDGF-AA and CFU-F (MNC plating). 
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Having analysed the influence of PDGF-AA and –BB peripheral circulation on ICBM CFU-F, I next 
analysed the influence of both PDGF isoforms on cellular proliferation. Given identical in vitro culture 
conditions, any changes in the average CFU-F colony size (and hence rate of proliferation) over time 
in the same patient, would therefore be derived from in vivo changes in that patient. Interestingly, 
as seen in Figure 7.3-4, changes in average colony size over time was not influenced by changes in 
levels of PDGF-AA and –BB. This implies that circulating PDGF-AA and –BB does not exert an 
influence on in vitro cellular MSC proliferation. The duration the ICBM MSCs were exposed to in vitro 
conditions (14 days) may have diminished the in vivo influence on the proliferative rate of these 
cells.  
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Figure 7.3-4 Relationship between Average CFU-F size and PDGF-AA/BB. Values for both CFU-F and PDGF-AA/BB are 
normalized to Day0=100 and then transformed by applying the logarithmic scale.  No correlation found between CFU-F 
area and PDGF-AA/-BB levels. 
  
Page 145 
 
Finally, given the association between platelets and PDGF-AA/BB levels shown in Figure 7.3-2, the 
influence of platelets levels on CFU-F levels were next investigated. 
As can be seen in Figure 7.3-5, there is a positive relationship between changes in platelet levels and 
CFU-F (MNC Plating) from baseline levels, but is weaker compared to the relationship between 
PDGF-AA and CFU-F (MNC Plating). Similar to analysis with PDGF-AA and -BB, the relationship 
between platelets and CFU-F (Direct plating) is weak. 
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Figure 7.3-5 Relationship between Platelets and CFU-F. Values for both CFU-F and platelets are normalized to Day0=100 
and then transformed by applying the logarithmic scale. Statistically significant correlation found between matched 
platelets and CFU-F (MNC) levels. 
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7.4. Discussion 
 
7.4.1. Influence of PDGF-AA on MSC dynamics 
Histological studies of callus formation site revealed a presence of PDGF-AA expression in all stages 
of fracture healing, and predominating in the early (reactive) and late (remodelling) phase of 
fracture healing, with the –BB isoform being dominant in between(Andrew, Hoyland et al. 1995). 
Most of the current literature relates to the stimulatory effect of PDGF-BB isoform on MSC 
proliferation in vitro(Pountos, Georgouli et al. 2010), accelerated fracture healing in rat (Lee, Park et 
al. 2000; Hollinger, Onikepe et al. 2008; Moore, Ehrlich et al. 2009) and rabbit (Nash, Howlett et al. 
1994) models and improved osseous closure as part of synthetic bone scaffold in human periodontal 
defect (Nevins, Giannobile et al. 2005). In this study, there appears to be a strong correlation 
between changes in CFU-F levels in MNC plating with changes in both PDGF-AA and -BB levels in 
peripheral circulation following fracture/trauma. Although the associations with the –AA isoform is 
more statistically significant, given the wealth of literature on the effect of the –BB isoform on MSC 
stimulation and bone healing, it is highly likely that both isoforms play a role in the observed 
relationship. The relationship with Direct plating however was not significant. This could be due to 
the inclusion of whole bone marrow constituent during the plating process, including platelets 
(compared to mononuclear cells only during MNC plating). This constituent may contain additional 
cytokines which exert an influence on MSC in culture (such as increased proliferation), resulting in an 
artificially inflated CFU-F count and hence MSC enumeration. As a result, MNC plating in comparison 
provided a “cleaner” readout, and better representing MSC enumeration from the ICBM aspirate.  
Unfortunately, only a single patient (BP31/BT025) received platelet transfusion between sampling 
time points. This was insufficient to carry out an analysis of whether patients who have received 
platelet transfusion could exhibit similar effects on MSC dynamics compared to patients with 
endogenous platelets fluctuations only. 
 
7.4.2. MSC-pericytes-PDGF relationship 
It remains unclear the mechanism underpinning the changes in MSC CFU-F over time following 
trauma. MSCs within the trabecular bone have been shown to be far more abundant in numbers 
compared to those obtained on bone marrow aspiration (Sakaguchi, Sekiya et al. 2004; Jones, 
English et al. 2010). The increased/decreased numbers of MSC on bone marrow aspiration may be 
due to a change in MSC proliferation (total number) or increased availability (mobilisation).  
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Recently, there have been suggestions that cell lining the blood vessels (pericyte) may be a source of 
MSC (Crisan, Yap et al. 2008; Crisan, Chen et al. 2009; Caplan and Correa 2011). Based on this model, 
PDGF-BB has been suggested to play a key role in mobilizing MSC from its pericyte origin (Caplan and 
Correa 2011). To my knowledge, this is the first study to show the in vivo relationship between 
PDGF-AA/BB in peripheral circulation and its systemic effect on bone marrow MSCs. If the pericyte 
hypothesis is true, then the changes in BM MSC CFU-F are due to increased mobilisation rather than 
proliferation.  
 
7.4.3. Influence of Follistatin on MSC Dynamics 
The influence of serum follistatin on MSC dynamics is likely related to its close inhibitory relationship 
with activin A (de Kretser, Hedger et al. 1999). Activin A has already been shown to affect MSC 
proliferation (Stewart, Guan et al. 2010) and osteogenic differentiation (Djouad, Jackson et al. 2010). 
Therefore, being an inhibitory molecule, it would be in keeping with current literature that follistatin 
has a negative correlation with bone marrow MSC CFU-F changes. 
 
7.4.4. Future work arising 
The most interesting finding within the chapter is the association found between PDGF-
AA/BB/platelets and MSCs. This finding however does not prove causation. There would be potential 
to further this work, firstly to prove causation in an animal model. Preferably, due to the known 
short half-life of PDGF, it is likely that this model would involve the transfusion of platelets and the 
comparison of its effect on bone marrow MSCs pre- and post-transfusion. 
 
7.4.5. Limitations 
This study did not conclusively show whether the influence of PDGF on MSC BM dynamics was due 
to increased mobilization from its cellular niche (increased availability) or increased cellular 
proliferation. Further investigations would need to be carried out to unravel this question. This may 
involve concomitant trephine core biopsy with bone marrow aspiration, and immunohisto-staining 
of MSC cells to show changes in numbers in its native bony environment. 
Secondly, the observation of the negative effect follistatin has on MSC dynamics, can be 
extrapolated to a positive relationship between serum activin and MSC changes. The serum levels of 
activin have not been measured within this study. 
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8. Conclusion and Future Work 
8.1. Growth Factors and Trauma 
 
 In my first results chapter, I assessed the early dynamics of growth factors (PDGF-AA, angiogenin, 
TGF-β2, follistatin) over time following trauma, across 4 different groups of patients (Head Injury, 
Polytrauma, Isolated Trauma, Healthy Control).  
The growth factors were chosen, as they are known to play an important role in the fracture healing 
process (Dimitriou, Tsiridis et al. 2005).  PDGF is a major mitogen for MSCs and strongly induces the 
mitogenic and migratory response of MSCs (Mehrotra, Krane et al. 2004) with the PDGF-AA isoform 
playing a crucial role in osteoblast replication (Yang, Chen et al. 2000).  Angiogenin facilitates the 
process of endothelial cell invasion and angiogenesis (Hu, Riordan et al. 1994), creating the 
obligatory pre-condition of healthy tissue perfusion in the fracture healing environment. TGF-β2 is 
secreted by osteoblasts and osteoclasts (Robey, Young et al. 1987) and have been shown to 
significantly enhance new bone formation in animal models(Mackie and Trechsel 1990). Finally, 
follistatin has been shown to have inhibitory effects on various other molecules of the BMP family 
(Fainsod, Deissler et al. 1997; Otsuka, Moore et al. 2001; Amthor, Christ et al. 2002). 
The Isolated Trauma group was selected to understand the influence of trauma on the temporal 
dynamics of growth factors. The Polytrauma Group additionally helped to understand the influence 
of further injuries and fractures, compared to controls. The Head Injury Group provided 
supplementary information, on the additional effects of traumatic brain injury on multiply injured 
patients (Polytrauma Group). Finally, the Healthy Control group was aged and sex matched to all 3 
trauma groups, to provide baseline (pre-trauma) levels of these growth factors. 
My main finding from this analysis was the suppression of anabolic growth factors (PDGF-AA, 
angiogenin) initially by day 1 compared to control group of patients and upregulated in the 
inhibitory growth factor (follistatin). This effect was observed to be greater in the more severely 
injured group (Head Injury and Polytrauma). In other words, the more severe the trauma, the more 
pronounced the suppression/upregulation.  
There have been other studies published on the dynamics of growth factors following fractures, 
these studies were limited to patients with single fractures only (Weiss, Zimmermann et al. 2009; 
Pountos, Georgouli et al. 2013) . However, to my best knowledge, my study is the first to compare 
the effects of the growth factor across trauma groups with different severity (Isolated Trauma versus 
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Polytrauma Groups) as well as the additional effect of the presence of traumatic brain injury (Head 
Injury Group). 
I then attempted to understand the mechanism or reason behind the initial suppressions of these 
growth factors, which appeared to worsen with increasing trauma severity. One possible factor 
explored was the effect of intravenous fluid dilution, as patients admitted following trauma often 
receive intravenous fluid as part of their resuscitation. Moreover, patients with multiple injuries 
(hence Polytrauma/Head Injury groups) often require higher volume of fluid resuscitations. Although 
I found a significantly higher volume of intravenous fluid transfusion in Polytrauma/Head Injury 
patients compared to Isolated Trauma, when analysed against the levels of all 4 growth factors, I 
failed to find any significant associations between volumes of fluid transfusion to concentration of 
growth factors. 
Hence, I believe that the observed initial suppression of anabolic growth factors is genuine 
suppression. Firstly, as described above, no correlations with fluid dilutions were found. Secondly, 
identical/matched samples from these patients were observed to have an upregulation of follistatin, 
with both suppression (PDGF-AA, angiogenin) and upregulation (follistatin) trends returning towards 
baseline (Healthy Control) levels by 1 week post trauma. Thirdly, the in vivo half-lives of the 
molecules measured are relatively short [PDGF-AA (2 minutes) (Cianciolo, Stefoni et al. 1999), 
follistatin (4 minutes) (Kogure, Zhang et al. 1996), TGF-β2 (2 minutes) (Kaminska, Wesolowska et al. 
2005), angiogenin (12 hours) (Hatzi, Bassaglia et al. 2000)]. This implies that the concentrations of 
these growth factors detected represented what was being actively synthesised and released into 
the peripheral circulation at that moment in time. The mechanisms behind this observed dynamics 
remain to be explored. 
 
8.2. Growth Factor and Inflammatory Response 
My next step to try to address the observed growth factor dynamics was based on the observations 
that the degree of trauma severity (Isolated versus Polytrauma/Head Injury) exerted differential 
influence on the levels of these growth factors. Previous studies have reported on the association 
between the severity of trauma and levels of inflammatory response cytokines in peripheral 
circulation (Giannoudis, Harwood et al. 2008; Giannoudis, Mallina et al. 2010).  Therefore, the 
differences in growth factor dynamics were explored in relation to degree of inflammatory response. 
To my knowledge, this association has not been previously explored.  
I selected parameters available from routine hospital laboratory investigations that were known to 
be reflective of inflammatory state (white cell count, C-reactive protein, platelets).  Overall, no 
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correlations were found between the inflammatory states of the patients (as represented by levels 
of white cell count, C-reactive protein, platelets). The exception was the incidental finding of 
correlation between levels of platelets and PDGF-AA. This was not surprising, given that the alpha-
granules of platelets were a major storage site of cytokines including PDGF-AA (McNicol and Israels 
2008). 
As the analysis of biochemical parameters representing inflammatory state of the patients did not 
address the observed differences between trauma groups, I then analysed the dynamics of growth 
factors against clinical presence of inflammation. Systemic Inflammatory Response Syndrome (SIRS) 
is a recognized clinical phenomenon representing a severe degree of inflammatory response. 
Patients in all groups were divided into either the ones who fulfilled criteria for SIRS against those 
that did not. Similarly, no significant differences were found in the growth factor levels over time 
when compared to the presence or absence of SIRS. 
Finally, I explored the potential translational significance to clinical practice of my growth factor 
dynamics observations. I correlated the levels of growth factors into patients who had normal 
healing response compared to patients who had delayed or fracture non-union. It appeared that 
levels of follistatin non-union group showed an increasing trend in the first 3 days post injury, 
compared to a decreasing trend in the normal healing group. However, the differences between 
levels on matched time points between these 2 groups of patients in isolation did not reach 
statistical significance overall. Therefore application of the concept of increasing follistatin trends in 
the first 3 days post trauma as a predictive stratification of fracture non-union may be possible. 
However, if the trends when applied to future patients were less noticeable, then interpretation 
(into high or low risk of fracture non-union) can be tricky. 
Thus far, interpretation of TGF-β2 dynamics has been fraught with difficulty, due to the high inter-
individual variations in levels both in trauma as well as healthy control patients.  Yet, when analysed 
against patients with normal versus “non-union” fracture healing, a clear and significant difference 
emerged. Patients who developed fracture non-union had consistently low levels of TGF-β2 in the 
first week following injury, and this difference was statistically significant. Bearing in mind the high 
inter-individual difference in baseline (non-trauma) levels, I would speculate that it is the patients 
who have inherently low levels of TGF-β2, who then continued to express low levels following 
trauma, and eventually developing fracture non-union. A different isoform of this molecule (TGF-β1) 
have also similarly been reported to be depressed in patients with fracture non-union, but only 
detectable at week 4 post injury (Zimmermann, Henle et al. 2005). Therefore, TGF-β2 would be a 
better candidate molecule for application as an early predictive tool of fracture non-union. Ideally, I 
would like to measure the levels of TGF-β2 in patients pre- and post-fracture and confirms their 
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correlation with fracture non-union. However, this would require mobilisation of significant 
resources on a large (national) scale basis in order to obtain pre-fracture blood samples, then 
matching with a very small proportion or patients who eventually sustained a fracture, and fracture 
non-union. Similar efforts have been carried out for the investigation of bone turnover markers as 
predictors of fracture risk in the elderly with some success (Ivaska, Gerdhem et al. 2010). 
To conclude, the degree of inflammatory response (biochemical and clinical) does not correlate with 
growth factor dynamics, despite differences observed between patients with different trauma 
severity.  TGF-β2 may be a candidate molecule for early prediction of fracture non-union. 
  
8.3. MSCs and Trauma 
Thus far, I have explored the relationship between circulating growth factors and trauma. I have 
shown that the levels of growth factors following trauma is dynamic and changes over time.  
Following fracture, MSCs play a central role in the fracture healing process, as it is the progenitor 
cells that will differentiate amongst others to osteoblast, which is responsible for bone formation(De 
Bari, Dell'Accio et al. 2008). Additionally, MSCs have been shown to respond to different cytokines in 
vitro, including inflammatory cytokines (Crop, Baan et al. 2010; Herrmann, Weil et al. 2011), and 
growth factors (Pountos, Georgouli et al. 2010). This in vitro relationship has never been explored in 
humans in vivo. Therefore, I wanted to assess the systemic effect that trauma (and circulating 
growth factors) exerts on MSCs. 
 For this analysis, I obtained samples from patients’ iliac crest bone marrow (ICBM) as well as 
peripheral blood. ICBM aspirate can be easily obtained, and is well described as a source of 
osteoprogenitor cells and bone graft material (Hernigou, Poignard et al. 2005). Animal models have 
shown that following injury, MSCs may be released into the peripheral circulation, and homing in to 
the fracture site (Shirley, Marsh et al. 2005; Yoon, Park et al. 2010). Therefore, I wanted to assess for 
the presence and levels of MSCs in peripheral blood following trauma. 
The classical method of colony forming fibroblast unit (CFU-F) was used for the purpose of MSC 
enumeration. I carried out two different previously published techniques in parallel, Direct plating 
(Galotto, Berisso et al. 1999) and Mononuclear Cell (MNC) Plating (Castro-Malaspina, Gay et al. 
1980). Overall, I did not find one technique to be superior to the other. Hence the Direct Plating 
method appeared favourable as it is technically simpler, and therefore less opportunity for technical 
errors to occur. However, the Direct plating method involved the additional presence of bone 
marrow constituents (cells, serum) compared to MNC Plating method, and may influence MSC 
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culture in vitro. This was clearly shown by the lack of association between matched PDGF-AA and 
MSC enumeration by the Direct Plating method, compared to MNC Plating method. 
No MSC were found in peripheral blood samples following trauma, implying that MSCs are not 
mobilized into the peripheral circulation. Rather, the source of MSCs on the fracture healing site is 
locally derived (from surrounding bone marrow for example). 
I found that ICBM MSCs is not static, and changes dynamically over time, and this were proven by 
both Direct and MNC Plating methods. However, the trend of upregulation or downregulation in 
MSC numbers over time appeared variable, and was independent of trauma severity. Additionally, 
the presence of SIRS did not exert any influence on this trend. Similarly, fracture healing outcome 
was also not associated with any early systemic trends in ICBM MSC numbers.  
 Given the above findings, I then sought to analyse whether the trends in MSC dynamics could be 
linked to the dynamics of circulating growth factors. To my knowledge, this is the first study to 
demonstrate that ICBM MSC numbers is influenced by changes in levels of PDGF and platelets. 
Therapeutically, this could lead to potential application of platelets transfusion to boost MSC 
numbers prior to ICBM harvest. 
However, as MSCs are not mobilized into the peripheral circulation, the changes in MSC numbers 
observed could either be due to increased proliferation or local migration within the trabecular bone 
niche.  To address this, I would inoculate identical batches of MSC in vitro with patient serum 
(known previously measured quantities of PDGFs), and observed the proliferative effect on MSCs. I 
could also set up migration assays with similar inoculation of the same patient serum, and compare 
the effect on MSC migration versus MSC proliferation. I would be keen to test the hypothesis that 
platelet transfusion could cause a systemic stimulation of bone marrow MSCs, initially with an 
animal model, and if proven true, potentially escalate towards human clinical trials. 
 
8.4. Summary 
In summary, this thesis showed that trauma severity directly influences the dynamics of growth 
factors in the peripheral circulation following injury. However, trauma severity does not influence 
the dynamics of bone marrow MSCs. Instead, it is shown to be associated by changes in levels of 
platelet/PDGF-AA/BB. Finally, trauma does not result in mobilization of MSCs into the peripheral 
circulation.  
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10. Appendix 
10.1. Growth factor dynamics following trauma 
 
Table 10.1-1 Inter-individual variations in PDGF-AA (pg/ml) 
 DONOR ID Day 0 Day 1 Day 3 Day 5 Day 7 Day 14 
H
EA
D
 IN
JU
R
Y 
BH1  1152.2 1365.1 1929.6 1860.2 1968.3 
BH3  1107.4 1509.7 2748.5 2398.6 2854.3 
BH4 852.7 621.4     
BH6 2081.1 1322.8 2038.2 2868.6 2852.3 2983.2 
BH8  1164.8 1248.0 1485.4 1798.9 2667.5 
BH9  697.9 859.6 1315.5 1751.1 2997.6 
BH10 466.1 729.9 1455.7 2114.3 2681.6 4120.5 
BH11 1038.0 763.7 68.9 3014.0 3285.0 2942.2 
BH13  1464.3 1882.6 2954.1 3324.4 9228.0 
BH16  2113.4 2761.6 4553.5  10133.2 
BH17 1371.5 1892.0 1215.4 3008.5 5625.9 8258.8 
BH18 2133.3 2544.6 3713.2 1077.4 5107.4 6173.9 
BH20 3491.2 2338.0 4259.2 3882.7 5642.8  
BH21 2491.9 2453.2 2656.6 3830.1 2887.0  
MEAN 1740.7 1454.7 1925.7 2675.6 3267.9 4938.9 
SD 995.8 689.1 1159.9 1054.9 1428.4 2974.9 
CV (%) 57.2 47.4 60.2 39.4 43.7 60.2 
IS
O
LA
TE
D
 T
R
A
U
M
A
 
BP3 3526.9 1805.3 3078.5  5316.2 8129.7 
BP7 2130.5 2236.5 3876.8 3291.0 3916.8  
BP9 3732.7 2920.6 2692.9 3219.7 3693.3 2466.1 
BP8 3008.6 1642.8 2357.0    
BP10 1709.6 2206.7 2911.4 3262.4 4447.4  
JM8 3353.1 1988.7 2920.6 3836.9 5104.3  
JM12 2999.3 2198.2 2833.5 3439.7 3334.0  
JM16 2792.5 1424.2 2797.0 2331.1 4768.4  
BP11 4491.5 3609.2 5507.6 5414.7 6164.9 6313.4 
BP13 3652.7 3018.8 4289.5 3795.0 4462.5  
BP14 4892.3 4056.7 6152.0 4791.1 6805.5  
BP17 3673.4 2938.9   3688.7  
BP23 4186.3 4316.4 3876.6    
BP22 4657.4 2971.1 4122.2 5126.0 4102.2  
BP24 3571.8 2480.5 3393.4 4657.4 5144.0  
MEAN 3491.9 2654.3 3629.2 3924.1 4688.3 5636.4 
SD 884.0 859.4 1105.6 953.3 1013.1 2891.9 
CV (%) 25.3 32.4 30.5 24.3 21.6 51.3 
P
O
LY
TR
A
U
M
A
 
NT1 822.4 2038.5 154.0 160.5   
DL 329.2 1977.5 3883.5 832.6   
BP2 6096.1 2756.9 2838.2  4357.5 5183.8 
BP4 2535.6 1452.4 1848.4 4196.0 4303.5  
BP6 2905.6 3051.6 3289.3 3852.1 5400.8  
JM2 849.8 997.3 1831.4 2896.0 5510.2  
BP15 3194.4 2726.5 2706.7 4124.4 6365.3  
BP16 1963.0 2391.6 3485.2 4720.1 6197.1 10046.2 
BP12  1486.1 1670.9 2681.9 3545.6 8382.7 
BP18 4167.4 2656.6 4540.8 4732.1   
BP19 2829.7 1598.8 2205.5 3873.4 3612.4 1686.0 
BP20 4170.7 3053.5 4424.2 3878.5 5303.6 7390.6 
BP27 2608.3 1840.7 2475.4 4145.0 5598.5 1515.3 
BP28 2269.1 2113.5 3003.0 2339.1 3755.1  
BP31 1593.0 1004.2 1183.5 2020.8 2135.5  
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MEAN 2595.3 2076.4 2636.0 3175.2 4673.8 5700.8 
SD 1533.2 685.3 1206.8 1415.9 1264.4 3545.0 
CV (%) 59.1 33.0 45.8 44.6 27.1 62.2 
 
Table 10.1-2 Inter-individual variations in Angiogenin (pg/ml) 
 DONOR ID Day 0 Day 1 Day 3 Day 5 Day 7 Day 14 
H
EA
D
 IN
JU
R
Y 
BH1  293396.4 527543.0 465445.6 491441.3 548302.3 
BH3  371712.5 432621.8 424407.5 358168.0 478831.7 
BH4 238786.6 304346.1     
BH6 372118.7 429036.3 553018 451943.7 443424.0 261546.8 
BH8  328711.9 410598.6 441088.4 500405.3 136835.6 
BH9  465445.6 398353.8 341966.7 512274.3 608554.7 
BH10 309180.8 295693.1 406852.8 387846.1 238242.6 160944.1 
BH11 136521.0 208118.2 289960.0 338194.3 408724.6 387230.2 
BH13  229098.1 115324.4 144349.3 82789.72 130022.0 
BH16  122670.0 123478.8 118975.6  62201.8 
BH17 611544.5 517253.4 380322.7 527549.7 558278.9 504201.3 
BH18 364986.5 351665.0 551418.1 605056.2 476843.1 533596.5 
BH20 488198.3 574348.1 663867.4 569395.8 584287.3  
BH21 356672.2 473544.7 529468.9 545786.1 600033.9  
MEAN 359751.1 354645.7 414063.7 412461.9 437909.4 346569.7 
SD 144967.9 126622.7 162699.2 149214.4 150524.7 200433.9 
CV (%) 40.3 35.7 39.3 36.2 34.4 57.8 
IS
O
LA
TE
D
 T
R
A
U
M
A
 
BP3 440661.2 420373.4 464456.2  612692.0 561676.4 
BP7 378766.9 363934.7 389190.6 370365.2 381906.5  
BP9 525806.4 488742.3 479710.1 400957.9 472848.1 386756.6 
BP8 379249.3 365122.2 383843.6    
BP10 334517.5 289207.6 395302.1 457421.7 387486.1  
JM8 261991.0 222207.2 362985.9 239055.6 266173.5  
JM12 377321.4 312319.1 363460.2 336126.1 325838.6  
JM16 429202.9 299685.9 424400.8 343982.3 397536.3  
BP11 539652.1 537339.5 634060.0 537628.3 393963.3 508161.3 
BP13 551850.8 556230.7 464109.0 448022.6 510429.0  
BP14 555353.8 414080.1 492667.3 464657.8 503636.5  
BP17 304752.9 351665.0   385104.2  
BP23 350796.1 495569.9 540657.4    
BP22 594189.4 401158.7 563419.6 706850.6 504264.1  
BP24 501276.2 259352.3 367424.1 365852.8 315473.8  
MEAN 435025.9 385132.6 451834.8 424629.2 419796.3 485531.4 
SD 103791.4 101365.4 83953.3 123035.1 95985.5 89628.8 
CV (%) 23.9 26.3 18.6 29.0 22.9 18.5 
P
O
LY
TR
A
U
M
A
 
NT1 472345.4 391735.4 424429.4 374775.7   
DL 329158.3 419255.2 297973.4 378740.4   
BP2 408724.1 336248.0 311456.8  332459.6 404387.5 
BP4 410514.8 243408.4 315152.4 406426 356889.2  
BP6 355433.9 396272.5 373540.0 350358.4 219742.5  
JM2 310765.7 378988.8 354222.9 331987.2 348432.1  
BP15 378789.2 430532.9 429464.6 491827.0 159695.5  
BP16 142332.3 137655.0 147430.6 106331.9 159695.5 128641.5 
BP12  266945.8 378661.7 277697.4 390905.1 366304.0 
BP18 297874.0 277289.6 408220.1 429398.8   
BP19 320754.3 371586.7 292690.8 351013.3 275456.6 288356 
BP20 388966.5 409976.1 428270.7 372377.0 369447.6 332935.9 
BP27 251576.9 253364.3 538276.6 423790.2 344307.8 357138.8 
BP28 357584.0 506508.8 364955.9 458854.9 324274  
BP31 381437.7 341891.7 394242.3 584483.5 509006.8  
MEAN 343304.1 344110.6 363932.5 381290.1 315859.4 312960.6 
SD 80015.9 93454.8 87507.8 109207.3 99706.3 98116.3 
CV (%) 23.3 27.2 24.0 28.6 31.6 31.4 
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Table 10.1-3 Inter-individual variations in Follistatin (pg/ml) 
 DONOR ID Day 0 Day 1 Day 3 Day 5 Day 7 Day 14 
H
EA
D
 IN
JU
R
Y 
BH1  3219.1 1372.0 907.8 955.7 1025.1 
BH3  2426.9 4654.0 5782.3 2598.0 1570.4 
BH4 4226.7 4281.7     
BH6 925.3 1465.0 2086.4 855.4 1295.4 771.9 
BH8  3159.0 4872.4 2933.8 820.3 661.1 
BH9  3558.4 1954.2 2271.5 1498.8 1150.1 
BH10 2279.7 2994.3 2703.5 2369.7 2748.0 1507.2 
BH11 2974.1 2123.5 2008.0 4438.7 683.3 960.1 
BH13  945.9 2516.4 1288.9 1729.0 1417.9 
BH16  4809.3 12605.7 9027.7  2025.6 
BH17 2588.5 2356.1 1107.4 1447.6 862.3 768.6 
BH18 5073.7 4722.6 11186.9 5257.8 4344.7 846.7 
BH20 1544.4 1479.0 2988.5 1281.8 1758.8  
BH21 2240.5 2903.0 2278.1 2032.6 1781.7  
MEAN 2731.6 2888.8 4025.6 3068.9 1756.3 1155.0 
SD 1358.5 1193.1 3672.5 2420.7 1050.5 425.9 
CV (%) 49.7 41.3 91.2 78.9 59.8 36.9 
IS
O
LA
TE
D
 T
R
A
U
M
A
 
BP3 1892.7 2745.1 4679.8  1216.7 3801.1 
BP7 1533.1 2209.4 5417.5 3516.6 2281.8  
BP9 1837.3 1159.1 1351.3 3572.9 5681.9 5062.5 
BP8 2112.1 2415.6 1594.8    
BP10 1632.5 2521.6 2340.3 1690.6 1621.5  
JM8 4224.1 5707.5 8172.2 6910.3 2570.6  
JM12 1848.4 2062.5 1431.5 1364.2 1138.4  
JM16 2132.9 3436.1 1875.9 1343.0 1132.0  
BP11 1829.0 5569.1 1742.6 2002.5 1957.4 2320.2 
BP13 2951.5 1228.4 2477.0 4018.1 2872.0  
BP14 1656.6 1353.4 1457.1 1160.0 1247.1  
BP17 1892.2 3199.8   1785.6  
BP23 1926.4 992.8 1363.2    
BP22 2388.7 1937.6 1922.4 1886.9 2479.8  
BP24 1393.2 4071.5 3332.5 1897.0 1530.8  
MEAN 2083.4 2707.3 2797.0 2669.3 2116.6 3727.9 
SD 700.8 1477.4 1997.7 1723.1 1220.1 1372.6 
CV (%) 33.6 54.6 71.4 64.6 57.6 36.8 
P
O
LY
TR
A
U
M
A
 
NT1 2222.7 2954.5 1785.5 3894.8   
DL 1012.3 810.2 688.5 793.5   
BP2 1453.1 1966.9 1168.6  884.4 1394.5 
BP4 1335.8 1467.8 2357.7 3619.5 2143.2  
BP6 6238.9 2557.6 925.4 1634.7 1063.1  
JM2 2824.7 3057.5 3523.5 1766.3 1203.8  
BP15 1634.3 2212.9 4368.3 1272.0 1707.5  
BP16 5701.0 2499.9 2477.0 2463.9 1736.2 1899.5 
BP12  5203.7 3262.6 2161.2 1126.1 870.5 
BP18 2627.1 2161.2 1598.1 1336.0   
BP19 2619.6 3598.2 2630.8 2319.6 2244.2 2511.1 
BP20 2651.6 2671.9 3820.4 1091.6 1286.0 3543.9 
BP27 5508.7 4312.3 2565.7 3342.6 2312.8 4583.1 
BP28 2277.3 3070.5 2105.1 5093.7 2989.8  
BP31 2682.0 2307.7 1973.2 9602.3 2277.3  
MEAN 2913.5 2723.5 2350.0 2885.1 1747.9 2467.1 
SD 1678.3 1081.2 1064.3 2290.4 650.7 1390.0 
CV (%) 57.6 39.7 45.3 79.4 37.2 56.3 
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Table 10.1-4 Inter-individual variations in TGF-β2 (pg/ml) 
 DONOR ID Day 0 Day 1 Day 3 Day 5 Day 7 Day 14 
H
EA
D
 IN
JU
R
Y 
BH1  488.7 341.6 361.4 359.9 313.4 
BH3  430.8 346.1 543.6 681.1 587.8 
BH4 529.7 536.7     
BH6 467.0 548.9 473.6 636.6 589.6 470.3 
BH8  526.3 600.3 370.6 463.6 642.2 
BH9  500.6 526.3 671.8 766.9 668.0 
BH10 631.2 623.9 485.3 492.1 460.3 411.5 
BH11 434.1 562.9 857.9 633.0 651.4 490.4 
BH13  220.8 395.4 453.9 285.4 355.2 
BH16  315.8 281.4 279.4  299.5 
BH17 271.5 318.3 362.1 295.5 662.5 262.1 
BH18 232.9 197.5 197.5 192.2 216.9 271.1 
BH20 197.5 194.0 202.7 187.0 201.0  
BH21 238.3 211.5 211.5 190.5 188.7  
MEAN 375.3 405.5 406.3 408.3 460.6 433.8 
SD 161.5 156.1 186.0 176.9 208.4 148.9 
CV (%) 43.0 38.5 45.8 43.3 45.2 34.3 
IS
O
LA
TE
D
 T
R
A
U
M
A
 
BP3 198.1 513.4 581.4  541.0 297.1 
BP7 441.6 268.7 385.7 249.4 2386.7  
BP9 1390.0 689.2 556.7 585.0 295.6 798.7 
BP8 174.5 1057.9 975.2    
BP10 868.4 630.1 599.3 381.0 622.8  
JM8 267.6 3119.2 759.7 915.2 998.3  
JM12 602.9 886.7 345.2 1563.9 1439.4  
JM16 1771.9 606.5 2623.1 830.3 279.4  
BP11 315.0 207.6 356.9 215.0 457.7 293.9 
BP13 281.0 209.1 222.4 154.3 276.3  
BP14 184.6 217.9 213.5 183.2 212.0  
BP17 222.2 202.7   166.3  
BP23 256.5 231.2 213.3    
BP22 1441.2 2912.9 1249.0 1714.0 2183.6  
BP24 2829.5 2220.3 1981.0 1736.4 5072.9  
MEAN 749.7 931.6 790.2 775.2 1148.6 463.2 
SD 779.5 994.2 717.6 629.9 1394.0 290.6 
CV (%) 104.0 106.7 90.8 81.3 121.4 62.7 
P
O
LY
TR
A
U
M
A
 
NT1 344.9 215.1 198.1 238.1   
DL 348.9 301.6 234.2 322.0   
BP2 285.4 271.4 285.4  218.9 281.4 
BP4 279.4 249.8 338.5 259.6 299.5  
BP6 263.5 222.7 263.5 419.2 218.9  
JM2 380.5 303.6 561.2 271.4 261.5  
BP15 179.0 191.7 184.6 170.6 270.0  
BP16 203.3 203.3 210.6 166.5 196.0 254.3 
BP12  240.1 195.7 190.5 202.7 265.6 
BP18 194.0 180.0 171.4 185.2   
BP19 278.4 213.3 194.0 234.7 216.9 199.2 
BP20 4946.1 4603.8 10908.4 5125.6 4235.2 825.0 
BP27 3180.2 2106.3 1097.2 890.5 848.1 3118.9 
BP28 1740.1 1862.6 2106.3 1557.4 1301.9  
BP31 3507.3 2564.1 2187.2 1877.4 967.4  
MEAN 1152.2 915.3 1275.8 850.6 769.8 824.1 
SD 1572.0 1302.1 2749.8 1345.8 1153.3 1147.8 
CV (%) 136.4 142.3 215.5 158.2 149.8 139.3 
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Table 10.1-5 Influence of trauma groups on PDGF-AA levels (Mann-Whitney U, p-value) 
A
d
m
is
si
o
n
  Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p<0.05 p=0.20 p<0.05 
Isolated Trauma p<0.05 N/A p=0.03 p=0.10 
Polytrauma p=0.20 p=0.03 N/A p=0.02 
Control p<0.05 p=0.10 p=0.02 N/A 
      
D
ay
 1
 
 Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p<0.05 p<0.05 p<0.05 
Isolated Trauma p<0.05 N/A p=0.09 p<0.05 
Polytrauma p<0.05 p=0.09 N/A p<0.05 
Control p<0.05 p<0.05 p<0.05 N/A 
      
D
ay
 3
 
 Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p<0.05 p=0.09 p<0.05 
Isolated Trauma p<0.05 N/A p=0.06 p=0.21 
Polytrauma p=0.09 p=0.06 N/A p<0.05 
Control p<0.05 p=0.21 p<0.05 N/A 
      
D
ay
 5
 
 Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p<0.05 p=0.23 p<0.05 
Isolated Trauma p<0.05 N/A p=0.38 p=0.57 
Polytrauma p=0.23 p=0.38 N/A p=0.15 
Control p<0.05 p=0.57 p=0.15 N/A 
      
D
ay
 7
 
 Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p<0.05 p<0.05 p=0.06 
Isolated Trauma p<0.05 N/A p=0.83 p=0.33 
Polytrauma p<0.05 p=0.83 N/A p=0.18 
Control p=0.06 p=0.33 p=0.18 N/A 
      
D
ay
 1
4
 
 Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p=0.94 p=0.92 p=0.73 
Isolated Trauma p=0.94 N/A p=1.0 p=0.41 
Polytrauma p=0.92 p=1.0 N/A p=0.41 
Control p=0.73 p=0.41 p=0.41 N/A 
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Table 10.1-6 Influence of trauma groups on ANG levels (Mann-Whitney U, p-value) 
A
d
m
is
si
o
n
  Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p=0.16 p=0.95 p=0.18 
Isolated Trauma p=0.16 N/A p<0.05 p=0.98 
Polytrauma p=0.95 p<0.05 N/A p<0.05 
Control p=0.18 p=0.98 p<0.05 N/A 
      
D
ay
 1
 
 Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p=0.53 p=0.90 p=0.19 
Isolated Trauma p=0.53 N/A p=0.37 p=0.36 
Polytrauma p=0.90 p=0.37 N/A p<0.05 
Control p=0.19 p=0.36 p<0.05 N/A 
      
D
ay
 3
 
 Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p=0.88 p=0.16 p=0.87 
Isolated Trauma p=0.88 N/A p<0.05 p=0.66 
Polytrauma p=0.16 p<0.05 N/A p=0.05 
Control p=0.87 p=0.66 p=0.05 N/A 
      
D
ay
 5
 
 Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p=0.79 p=0.29 p=0.92 
Isolated Trauma p=0.79 N/A p=0.62 p=0.62 
Polytrauma p=0.29 p=0.62 N/A p=0.17 
Control p=0.92 p=0.62 p=0.17 N/A 
      
D
ay
 7
 
 Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p=0.38 p<0.05 p=0.26 
Isolated Trauma p=0.38 N/A p<0.05 p=0.76 
Polytrauma p<0.05 p<0.05 N/A p<0.05 
Control p=0.26 p=0.76 p<0.05 N/A 
      
D
ay
 1
4
 
 Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p=0.31 p=0.55 p=0.79 
Isolated Trauma p=0.31 N/A p<0.05 p=0.31 
Polytrauma p=0.55 p<0.05 N/A p<0.05 
Control p=0.79 p=0.31 p<0.05 N/A 
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Table 10.1-7 Influence of trauma groups on Follistatin levels (Mann-Whitney U, p-value) 
A
d
m
is
si
o
n
  Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p=0.14 p=0.84 p=0.07 
Isolated Trauma p=0.14 N/A p=0.15 p=0.53 
Polytrauma p=0.84 p=0.15 N/A p<0.05 
Control p=0.07 p=0.53 p<0.05 N/A 
      
D
ay
 1
 
 Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p=0.49 p=0.66 p<0.05 
Isolated Trauma p=0.49 N/A p=0.66 p=0.06 
Polytrauma p=0.66 p=0.66 N/A p<0.05 
Control p<0.05 p=0.06 p<0.05 N/A 
      
D
ay
 3
 
 Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p=0.24 p=0.30 p<0.05 
Isolated Trauma p=0.24 N/A p=0.88 p=0.21 
Polytrauma p=0.30 p=0.88 N/A p=0.20 
Control p<0.05 p=0.21 p=0.20 N/A 
      
D
ay
 5
 
 Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p=0.89 p=0.92 p=0.15 
Isolated Trauma p=0.89 N/A p=0.96 p=0.31 
Polytrauma p=0.92 p=0.96 N/A p=0.15 
Control p=0.15 p=0.31 p=0.15 N/A 
      
D
ay
 7
 
 Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p=0.33 p=0.69 p=0.67 
Isolated Trauma p=0.33 N/A p=0.42 p=0.33 
Polytrauma p=0.69 p=0.42 N/A p=0.43 
Control p=0.67 p=0.33 p=0.43 N/A 
      
D
ay
 1
4
 
 Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p<0.05 p<0.05 p=0.14 
Isolated Trauma p<0.05 N/A p=0.20 p<0.05 
Polytrauma p<0.05 p=0.20 N/A p=0.41 
Control p=0.14 p<0.05 p=0.41 N/A 
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Table 10.1-8 Influence of trauma groups on TGF-β2 levels (Mann-Whitney U, p-value) 
A
d
m
is
si
o
n
  Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p=0.61 p=0.79 p<0.05 
Isolated Trauma p=0.61 N/A p=0.76 p=0.10 
Polytrauma p=0.79 p=0.76 N/A p=0.09 
Control p<0.05 p=0.10 p=0.09 N/A 
      
D
ay
 1
 
 Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p=0.16 p=0.46 p<0.05 
Isolated Trauma p=0.16 N/A p=0.37 p=0.25 
Polytrauma p=0.46 p=0.37 N/A p<0.05 
Control p<0.05 p=0.25 p<0.05 N/A 
      
D
ay
 3
 
 Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p=0.11 p=0.42 p<0.05 
Isolated Trauma p=0.11 N/A p=0.13 p=0.21 
Polytrauma p=0.42 p=0.13 N/A p<0.05 
Control p<0.05 p=0.21 p<0.05 N/A 
      
D
ay
 5
 
 Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p=0.34 p=0.51 p<0.05 
Isolated Trauma p=0.34 N/A p=0.55 p=0.24 
Polytrauma p=0.51 p=0.55 N/A p<0.05 
Control p<0.05 p=0.24 p<0.05 N/A 
      
D
ay
 7
 
 Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p=0.45 p=0.89 p=0.07 
Isolated Trauma p=0.45 N/A p=0.19 p=0.40 
Polytrauma p=0.89 p=0.19 N/A p<0.05 
Control p=0.07 p=0.40 p<0.05 N/A 
      
D
ay
 1
4
 
 Head Injury Isolated Trauma Polytrauma Control 
Head Injury N/A p=0.82 p=0.42 p<0.05 
Isolated Trauma p=0.82 N/A p=0.44 p=0.17 
Polytrauma p=0.42 p=0.44 N/A p=0.10 
Control p<0.05 p=0.17 p=0.10 N/A 
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10.2. Growth factor dynamics and inflammatory response 
10.2.1. Summary of R and p-values between Growth Factors and 
Hospital Parameters 
 
Table 10.2-1 Summary R and p-values of relationship between CRP and Growth Factors 
Growth Factor Trauma Group R value p-value 
PDGF-AA 
Head Injury -0.04 0.80 
Polytrauma -0.19 0.24 
Isolated Trauma -0.45 0.14 
Combined -0.11 0.27 
Angiogenin 
Head Injury -0.03 0.85 
Polytrauma +0.02 0.98 
Isolated Trauma -0.58 0.05 
Combined -0.13 0.18 
Follistatin 
Head Injury +0.54 <0.01 
Polytrauma +0.58 0.29 
Isolated Trauma -0.13 0.68 
Combined +0.36 <0.01 
TGF-β2 
Head Injury +0.07 0.59 
Polytrauma +0.14 0.41 
Isolated Trauma +0.17 0.60 
Combined +0.13 0.19 
 
 
Table 10.2-2 Summary R and p-values of relationship between WCC and Growth Factors 
Growth Factor Trauma Group R value p-value 
PDGF-AA 
Head Injury +0.27 0.02 
Polytrauma +0.10 0.02 
Isolated Trauma +0.10 0.45 
Combined +0.20 0.01 
Angiogenin 
Head Injury +0.02 0.88 
Polytrauma +0.02 0.90 
Isolated Trauma +0.18 0.32 
Combined +0.07 0.39 
Follistatin 
Head Injury -0.14 0.26 
Polytrauma +0.04 0.73 
Isolated Trauma -0.28 0.13 
Combined -0.09 0.24 
TGF-β2 
Head Injury -0.06 0.61 
Polytrauma +0.23 0.07 
Isolated Trauma +0.19 0.30 
Combined +0.21 0.01 
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Table 10.2-3 Summary R and p-values of relationship between Platelets and Growth Factors 
Growth Factor Trauma Group R value p-value 
PDGF-AA 
Head Injury +0.69 <0.01 
Polytrauma +0.55 <0.01 
Isolated Trauma +0.85 <0.01 
Combined +0.61 <0.01 
Angiogenin 
Head Injury -0.06 0.63 
Polytrauma -0.11 0.39 
Isolated Trauma +0.38 0.03 
Combined -0.02 0.78 
Follistatin 
Head Injury -0.31 <0.01 
Polytrauma -0.08 0.54 
Isolated Trauma -0.01 0.94 
Combined -0.20 0.01 
TGF-β2 
Head Injury +0.52 <0.01 
Polytrauma +0.14 0.27 
Isolated Trauma +0.04 0.81 
Combined +0.32 <0.01 
 
10.2.2. Growth Factor and Clinical complications (SIRS Score) 
Table 10.2-4 Summary SIRS score (Head Injury Group).  
SIRS? Patient ID Admission Day 1 Day 3 Day 5 Day 7 Day 14 
Yes BH1 2 1 1 2 1 1 
Yes BH3 1 0 2 0 1 0 
No BH6 1 0 1 0 0 0 
Yes BH8 2 2 0 2 2 1 
Yes BH9 1 0 0 0 0 2 
Yes BH11 2 3 1 1 2 2 
No BH13 1 1 1 1 1 1 
No BH16 0 1 0 1 1 1 
No BH17 1 0 1 1 1 1 
Yes BH18 2 0 0 0 3 1 
Yes BH20 1 0 1 2 1 
 
Yes BH21 2 0 1 2 2 
 
SIRS is present when score is ≥2 
 
Table 10.2-5 Summary SIRS score (Polytrauma Group).  
SIRS? Patient ID Admission Day 1 Day 3 Day 5 Day 7 Day 14 
Yes NT1 1 2 1 0 1 4 
Yes DL 0 2 1 0 0 0 
Yes BP2 2 0 0 2 3 2 
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Yes BP4 0 1 3 2 1 2 
Yes BP6 1 0 1 3 2 2 
Yes BP15 2 1 0 0 0 
 
Yes BP16 0 1 0 0 3 2 
No BP12 0 1 1 1 1 1 
Yes BP18 2 1 1 1 
  
No BP19 1 0 0 0 1 1 
Yes BP20 2 1 0 3 2 1 
No BP27 1 1 0 0 0 
 
No BP28 0 0 0 1 1 
 
Yes BP31 2 1 0 0 
  
SIRS is present when score is ≥2 
 
Table 10.2-6 Summary SIRS score (Isolated Trauma Group).  
SIRS? Patient ID Admission Day 1 Day 3 Day 5 Day 7 Day 14 
No BP3 1 1 1 1 1 0 
No BP7 1 0 0 0 0 
 
Yes BP9 2 1 0 0 0 1 
No BP10 0 0 0 0 0 0 
No BP11 0 0 0 0 0 0 
No BP13 1 0 0 0 0 
 
No BP14 1 0 0 0 0 
 
No BP17 1 0 0 0 0 
 
Yes BP23 2 2 0 
   
No BP22 1 0 0 0 1 
 
Yes BP24 2 1 1 1 3 
 
SIRS is present when score is ≥2 
 
Table 10.2-7 Comparison of time and group matched PDGF-AA levels between patient who developed SIRS and patients 
who did not.  
Trauma Group Time point p-value 
Head Injury 
Admission 0.36 
Day 1 0.50 
Day 3 0.73 
Day 5 0.23 
Day 7 0.31 
Day 14 0.03 
Polytrauma 
Admission 0.87 
Day 1 0.16 
Day 3 0.32 
Day 5 0.76 
Day 7 0.26 
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Day14 0.28 
Isolated Trauma 
Admission 0.84 
Day 1 0.68 
Day 3 0.14 
Day 5 0.32 
Day 7 0.60 
Day 14 0.22 
Mann-Whitney test, p-value<0.05 is statistically significant 
 
Table 10.2-8 Comparison of time and group matched angiogenin levels between patient who developed SIRS and 
patients who did not.  
Trauma Group Time point p-value 
Head Injury 
Admission 0.12 
Day 1 0.64 
Day 3 0.17 
Day 5 0.28 
Day 7 0.52 
Day14 0.09 
Polytrauma 
Admission 0.18 
Day 1 0.89 
Day 3 1.00 
Day 5 0.76 
Day 7 0.71 
Day 14 0.83 
Isolated Trauma 
Admission 0.68 
Day 1 1.00 
Day 3 0.73 
Day 5 0.10 
Day 7 0.30 
Day 14 0.22 
Mann-Whitney test, p-value<0.05 is statistically significant 
 
Table 10.2-9 Comparison of time and group matched follistatin levels between patient who developed SIRS and patients 
who did not.  
Trauma Group Time point p-value 
Head Injury 
Admission 0.36 
Day 1 0.31 
Day 3 0.87 
Day 5 0.50 
Day 7 0.54 
Day 14 0.83 
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Polytrauma 
Admission 0.61 
Day 1 <0.01 
Day 3 0.16 
Day 5 0.36 
Day 7 0.13 
Day 14 0.83 
Isolated Trauma 
Admission 0.68 
Day 1 0.31 
Day 3 0.21 
Day 5 0.51 
Day 7 0.60 
Day 14 0.22 
Mann-Whitney test, p-value<0.05 is statistically significant 
 
Table 10.2-10 Comparison of time and group matched TGF-β2 levels between patient who developed SIRS and patients 
who did not.  
Trauma Group Time point p-value 
Head Injury 
Admission 0.17 
Day 1 1.00 
Day 3 0.73 
Day 5 0.73 
Day 7 0.68 
Day 14 0.14 
Polytrauma 
Admission 0.40 
Day 1 0.57 
Day 3 1.00 
Day 5 0.76 
Day 7 0.85 
Day 14 0.83 
Isolated Trauma 
Admission 0.22 
Day 1 0.22 
Day 3 0.91 
Day 5 0.10 
Day 7 0.43 
Day 14 0.22 
Mann-Whitney test, p-value<0.05 is statistically significant 
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10.2.3. Growth Factor and Fracture Healing 
Table 10.2-11 Rate of fracture healing 
Trauma 
Group 
Patient 
ID 
Fracture 
location 
Weeks to heal Revision surgery 
Head Injury BH1 Distal radius 8 n/a 
Head Injury BH9 Femur 18 n/a 
Head Injury BH11 Distal radius 10 n/a 
Head Injury BH17 Femur 8 n/a 
Polytrauma BP2 Pelvic 18 n/a 
Polytrauma BP4 Tibia 49 n/a 
Polytrauma BP6 Femur 7 n/a 
Polytrauma BP15 Ulna 38 
Revision surgery with 
iliac crest  bone graft 
Polytrauma BP16 Pelvic 10 n/a 
Polytrauma BP12 Femur 19 n/a 
Polytrauma BP18 Ulna 46 
Revision surgery 
exchange plate 
Polytrauma BP19 Pelvic 10 n/a 
Polytrauma BP20 Femur 13 n/a 
Polytrauma BP27 Tibia 20 n/a 
Polytrauma BP28 
Tibia 
plateau 
14 n/a 
Isolated 
Trauma 
BP3 Tibia 34 n/a 
Isolated 
Trauma 
BP7 Tibia 28 
Exchange nail for 
delayed union 
Isolated 
Trauma 
BP9 Tibia 10 n/a 
Isolated 
Trauma 
BP8 Tibia 
n/a (Excluded as recruited to 
drug trial post discharge) 
n/a 
Isolated 
Trauma 
BP10 Ankle 21 n/a 
Isolated 
Trauma 
BP11 Tibia 11 n/a 
Isolated 
Trauma 
BP13 Tibia 84 
Revision surgery with 
iliac crest  bone graft 
Isolated 
Trauma 
BP14 Tibia 14 n/a 
Isolated 
Trauma 
BP17 Ankle 9 n/a 
Isolated 
Trauma 
BP23 Femur 8 n/a 
Isolated 
Trauma 
BP22 Femur 7 n/a 
Isolated 
Trauma 
BP24 Femur 16 n/a 
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Table 10.2-12 Comparative analysis of growth factor dynamics between patients with normal healing versus delayed 
healing. Statistical significance is p<0.05, Mann-Whitney. 
Growth Factor Time point p-value 
PDGF-AA 
Admission 0.40 
Day 1 0.46 
Day 3 0.56 
Day 5 0.67 
Day 7 1.00 
Day 14 0.51 
Angiogenin 
Admission 0.57 
Day 1 0.81 
Day 3 0.62 
Day 5 0.75 
Day 7 0.92 
Day 14 0.28 
Follistatin 
Admission 0.40 
Day 1 0.19 
Day 3 0.03 
Day 5 0.34 
Day 7 0.29 
Day 14 0.51 
TGF-β2 
Admission 0.16 
Day 1 <0.05 
Day 3 0.08 
Day 5 <0.05 
Day 7 0.60 
Day 14 0.83 
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10.3. Mesenchymal Stem Cell (MSC) and Trauma 
 
Table 10.3-1 Matched sample values for CFU-F count and areas for both MNC and Direct Plating Methods 
GROUP PT ID 
CFU-F 
MNC/dish 
Total Area 
MNC / dish 
(cm
2
) 
Average colony 
size MNC (cm
2
) 
CFU-F 
Direct/dish 
Total Area 
Direct / dish 
(cm
2
) 
Average colony 
size Direct (cm
2
) 
P
O
LY
TR
A
U
M
A
 
BT010 
Day 0 17.33 4.76 0.27 40.33 21.30 0.53 
BT010 
Day 2 1.00 3.33 3.33 68.00 31.96 0.47 
BT010 
Day 22 25.33 15.15 0.60 88.00 52.33 0.59 
BT015 
Day 0 19.00 12.35 0.65 16.67 9.83 0.59 
BT015 
Day 2 8.67 3.97 0.46 23.33 5.64 0.24 
BT016 
Day 0 19.33 10.53 0.54 57.67 17.22 0.30 
BT016 
Day 4 89.33 25.84 0.29 122.00 27.07 0.22 
BT016 
Day 25 203.67 64.96 0.32 83.33 28.12 0.34 
BT017 
Day 0 11.67 13.82 1.18 12.33 7.61 0.62 
BT017 
Day 32 121.33 49.16 0.41 68.00 40.02 0.59 
BT018 
Day 0 53.67 14.80 0.28 51.00 25.52 0.50 
BT018 
Day 5 123.33 66.96 0.54 98.00 63.97 0.65 
BT019 
Day 0 179.33 62.54 0.35 184.67 65.05 0.35 
BT019 
Day 15 76.67 32.04 0.42 166.67 71.80 0.43 
BT020 
Day 0 67.33 9.17 0.14 140.33 45.96 0.33 
BT020 
Day 2 46.33 8.22 0.18 139.00 47.58 0.34 
BT021 
Day 0 100.00 35.04 0.35 85.67 31.94 0.37 
BT021 
Day 4 35.67 24.22 0.68 19.67 22.97 1.17 
BT021 
Day 12 25.67 6.90 0.27 76.67 37.90 0.49 
BT025 
Day 0 64.67 4.90 0.08 131.67 47.27 0.36 
BT025 
Day 2 110.67 29.78 0.27 148.33 24.95 0.17 
BT025 
Day 4 76.50 8.72 0.11 128.67 58.88 0.46 
BT027 
Day 0 32.33 3.16 0.10 42.00 3.96 0.09 
BT027 
Day 5 63.67 30.13 0.47 88.00 35.52 0.40 
BT028 
Day 0 20.33 30.41 1.50 48.00 61.92 1.29 
BT028 
Day 2 50.00 49.12 0.98 57.67 55.38 0.96 
BT028 
Day 5 50.33 41.72 0.83 38.00 46.45 1.22 
BT029 
Day 0 11.33 24.94 2.20 14.33 7.02 0.49 
BT029 
Day 3 1.67 3.06 1.83 20.00 26.65 1.33 
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BT031 
Day 0 27.00 27.50 1.02 64.33 17.10 0.27 
BT031 
Day 3 19.33 8.26 0.43 26.00 23.08 0.89 
BT031 
Day 11 22.67 14.26 0.63 93.67 35.78 0.38 
BT033 
Day 0 18.33 44.59 2.43 33.67 33.31 0.99 
BT033 
Day 2 7.67 6.07 0.79 8.00 19.41 2.43 
BT033 
Day 8 32.00 24.23 0.76 16.00 11.69 0.73 
BT034 
Day 0 42.00 20.82 0.50 58.67 14.20 0.24 
BT034 
Day 8 37.33 13.40 0.36 48.00 23.63 0.49 
BT034 
Day 12 75.00 57.09 0.76 59.33 31.49 0.53 
IS
O
LA
TE
D
 T
R
A
U
M
A
 
BT006 
Day 0 0.33 0.00 0.00 1.33 3.85 2.89 
BT006 
Day 3 3.00 2.02 0.67 4.67 12.09 2.59 
BT007 
Day 0 52.00 3.37 0.06 140.33 66.37 0.47 
BT007 
Day 3 43.00 1.01 0.02 141.00 49.08 0.35 
BT008 
Day 0 38.00 19.31 0.51 62.33 34.25 0.55 
BT008 
Day 8 90.67 26.61 0.29 123.67 29.80 0.24 
BT009 
Day 0 48.67 11.38 0.23 64.33 34.11 0.53 
BT009 
Day 12 165.00 28.69 0.17 90.33 38.44 0.43 
BT009 
Day 16 146.67 35.45 0.24 41.67 8.62 0.21 
BT011 
Day 0 17.00 6.53 0.38 54.00 16.78 0.31 
BT011 
Day 9 21.00 8.30 0.40 31.67 7.05 0.22 
BT013 
Day 0 3.33 6.05 1.82 2.00 0.21 0.11 
BT013 
Day 3 48.00 9.30 0.19 36.67 21.21 0.58 
BT014 
Day 0 54.33 24.63 0.45 47.33 14.19 0.30 
BT014 
Day 7 39.67 14.23 0.36 37.67 18.00 0.48 
CONTROL 
BT023 50.00 5.40 0.11 101.00 4.39 0.04 
BT024 43.67 1.10 0.03 12.67 15.65 1.24 
BT026 28.00 3.37 0.12 40.67 6.45 0.16 
 
 
 
 
